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Résumé 
Contexte Autant dans une population schizophrène que non schizophrène, l’abus de substance a 
pour conséquence la manifestation de symptômes psychiatriques et neurologiques. Dans les 
présentes études cas-témoins, nous avons examiné les différences initiales ainsi que les 
changements suite au traitement de 12 semaines à la quetiapine au niveau de la sévérité de la 
toxicomanie et des symptômes psychiatriques et neurologiques chez 3 groupes distincts. Ces 3 
groupes sont: des patients schizophrènes avec une toxicomanie (double diagnostic: DD), des 
patients schizophrènes sans toxicomanie concomittante (SCZ) et finalement, des toxicomanes 
non schizophrènes (SUD). Parallèlement, afin de nous aider à interpréter nos résultats, nous 
avons mené deux revues systématiques: la première regardait l’effet d’antipsychotiques dans le 
traitement de troubles d’abus/dépendance chez des personnes atteintes ou non de psychoses, la 
deuxième comparait l’efficacité de la quetiapine et sa relation dose-réponse parmi différents 
désordres psychiatriques. Méthodes Pour nos études cas-témoins, l’ensemble des symptômes 
psychiatriques et neurologiques ont été évalués via l’Échelle du syndrome positif et négatif 
(PANSS), l’Échelle de dépression de Calgary, l’Échelle des symptômes extrapyramidaux 
(ESRS) ainsi qu’avec l’Échelle d’akathisie de Barnes. Résultats À la suite du traitement de 12 
semaines avec la quetiapine, les groupes SCZ et DD recevaient des doses de quetiapine 
significativement plus élevées (moyenne=554 et 478mg par jour, respectivement) par rapport au 
groupe SUD (moyenne = 150 mg par jour). Aussi, nous avons observé chez ces mêmes patients 
SUD une plus importante baisse du montant d’argent dépensé par semaine en alcool et autres 
drogues, ainsi qu’une nette amélioration de la sévérité de la toxicomanie comparativement aux 
patients DD. Par conséquent, à la fin de l’essai de 12 semaines, il n’y avait pas de différence 
significative dans l’argent dépensé en alcool et drogues entre les deux groupes de toxicomanes 
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or, les patients DD présentait, comme au point de départ, un score de toxicomanie plus sévère 
que les SUD. Étonnamment, aux points initial et final de l’étude, le groupe DD souffrait de plus 
de symptômes parkinsoniens et de dépression que le groupe SCZ. Par ailleurs, nous avons trouvé 
qu’initiallement, les patients SUD présentaient significativement plus d’akathisie, mais qu’en 
cours de traitement, cette akathisie reliée à l’abus/dépendance de cannabis s’est nettement 
améliorée en comparaison aux patients SCZ. Enfin, les patients SUD ont bénéficié d’une plus 
grande diminution de leurs symptômes positifs que les 2 groupes atteints de schizophrénie. 
Conclusions Bref, l’ensemble de nos résultats fait montre d’une vulnérabilité accentuée par les 
effets négatifs de l’alcool et autres drogues dans une population de patients schizophrènes. 
Également, ces résultats suggèrent que l’abus de substance en combinaison avec les états de 
manque miment certains symptômes retrouvés en schizophrénie. De futures études seront 
nécessaires afin de déterminer le rôle spécifique qu’a joué la quetiapine dans ces améliorations. 
 
Mots clefs: Quétiapine, Schizophrenie, Toxicomanie, Symptoms extrapiramidales, 
Antipsychotique. 
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Résumé en Anglais 
Background Psychiatric and neurological symptoms are consequences of substance abuse in 
schizophrenia and non-schizophrenia patients. The present case-control studies examined 
differences in substance abuse/dependence, and psychiatric symptoms and neurological 
symptoms in substance abusers with [dual diagnosis (DD) group] and without schizophrenia 
[substance use disorder (SUD) group] and in non-abusing schizophrenia patients (SCZ group) –
undergoing 12-week treatment with quetiapine. Furthermore, two systematic reviews were 
conducted in order help explain our results. The first examined the usefulness of antipsychotics 
for the treatment of substance abuse/dependence in psychosis and non-psychosis patients. The 
second examined the dose-response and comparative efficacy of quetiapine across psychiatric 
disorders. Methods Psychiatric symptoms and neurological symptoms were evaluated with the 
Positive and Negative Syndrome Scale, the Calgary Depression Scale for Schizophrenia, the 
Extrapyramidal Symptoms Rating Scale, and the Barnes Akathisia Rating Scale. Results DD and 
SCZ patients were receiving significantly higher doses of quetiapine (mean=554 and 478mg per 
day, respectively), relative to SUD patients (mean=150mg per day). We found that SUD patients 
showed greater improvement in weekly dollars spent on alcohol and drugs and SUD severity, 
compared to DD patients. At endpoint, there was no significant difference in dollars spent, but 
DD patients still had a higher mean SUD severity. Interestingly, DD patients had significantly 
higher parkinsonism and depression than SCZ patients at baseline and endpoint. On the other 
hand, we found that SUD patients had significantly more akathisia at baseline, improved more 
than SCZ patients, and this was related to cannabis abuse/dependence. Finally, SUD patients 
improved more in Positive and Negative Syndrome Scale positive scores than DD and SCZ 
patients. Conclusions Taken together, our results provide evidence for increased vulnerability to 
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the adverse effects of alcohol and drugs in schizophrenia patients. They also suggest that 
substance abuse/withdrawal may mimic some symptoms of schizophrenia. Future studies will 
need to determine the role quetiapine played in these improvements. 
 
Key words: Quetiapine, Schizophrenia, Substance use disorder, Extrapyramidal symptoms, 
Antipsychotic 
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The lifetime prevalence of substance abuse/dependence in schizophrenia approaches 50% 
(Regier et al. 1990). Psychiatric and extrapyramidal (neurological) symptoms are 
consequences of substance abuse in schizophrenia and non-schizophrenia patients. The 
present case-control studies examined differences in substance abuse/dependence, and 
psychiatric and extrapyramidal symptoms in substance abusers with [dual diagnosis (DD) 
group] and without schizophrenia [substance use disorder (SUD) group] and in non-abusing 
schizophrenia patients (SCZ group) – undergoing 12-week treatment with quetiapine. 
Furthermore, two systematic reviews were conducted in order help explain our results. The 
first examined the usefulness of antipsychotics for the treatment of substance 
abuse/dependence in psychosis and non-psychosis patients. The second examined the dose-
response and comparative efficacy of quetiapine across psychiatric disorders. Here, I will 
describe these reports and present additional data focusing on the SUD-alone group, and 
personality traits at baseline in the three groups. The data will be preceded by a general 
background on schizophrenia, antipsychotics, substance abuse/dependence, extrapyramidal 
symptoms, and the schizophrenia/SUD comorbidity.  
 
Schizophrenia  
1.1.1 Historical perspectives 
Originally termed ‘dementia praecox’ (premature dementia), schizophrenia was first 
identified as a discrete illness by Dr. Emile Kraepelin in 1887 (Kyziridi, 2005). Kraepelin 
characterized the disorder as part of a process of incurable cognitive deterioration. The term 
‘schizo (split) `phrenia (mind)’ was coined by Eugene Bleuler in 1907 – intending it to refer 
to a separation between perception, memory, thinking, and personality. Bleuler believed that 
Kraepelin`s definition was misleading because many schizophrenia patients did not exhibit a 
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pattern of progressive decline, and there was even partial or near-complete recovery in some 
cases (Kyziridi, 2005).  
Bleuler was the first to classify schizophrenia symptoms as being `positive` (e.g. 
hallucinations, delusions) or `negative` (e.g. amotivation, blunted affect, asociality; Waters 
and Badcock, 2010). Another important characterization of schizophrenia symptoms was 
made by Kurt Schneider in 1959. He proposed the existence of core features or `first-rank` 
symptoms. These symptoms included third person auditory verbal hallucinations, loud 
(audible) thoughts (i.e. patients report that their own thoughts seem so loud that someone 
nearby could hear them), delusions of control (i.e. actions, intentions, and/or feelings are 
experienced to be under the control of some other force), and thought broadcasting (i.e. 
thoughts are believed to be accessible to others), insertion (i.e. thoughts are experienced as not 
being the patients’ own) and withdrawal (i.e. thoughts experienced as actively extracted by 
others; Waters and Badcock, 2010). Together, these early characterizations greatly 
contributed to the notion of schizophrenia that we have today. Many of these early ideas (e.g. 
characteristic symptoms, positive/negative symptoms) have been carried forward in the latest 
version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; APA, 1994).  
 
1.1.2 Pharmacological hypotheses 
There are at least four pharmacological hypotheses regarding the pathophysiology of 
psychosis: the serotonergic, cannabinoidergic, glutamatergic, and dopaminergic hypotheses. 
Serotonin was the first neurotransmitter to be implicated in the pathophysiology of psychosis 
(for review, see Pararelli et al. 2011). This was related to the discovery of the 
psychotomimetic effects of lysergic acid diethylamide (LSD), which acts as an agonist with 
high affinity for serotonergic 5-HT1-7 receptors (excluding 5-HT3) and lower affinity for 
dopaminergic D1-D5 recepors (Woolley and Shaw, 1954; Porter et al. 1999; Nichols et al. 
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2002). Early studies revealed some similarities between schizophrenia and LSD-psychosis. 
For example, a comparison between 30 LSD-psychosis and 10 paranoid schizophrenia 
patients found that the former experienced more elation, disturbance in time sense, feeling of 
loss of control, body image changes, and somatic symptoms; however, suspiciousness was 
equal among the two groups (Langs and Barr, 1968). There is also evidence among 15 LSD-
psychosis and 116 schizophrenia patients that the former reported significantly more visual 
illusions and hallucinations, but less auditory hallucinations. By contrast, some delusions 
were less common in patients with LSD-psychosis, possibly because of the frequency of 
insight into the abnormal nature of their perceptual symptoms (Hays and Tilley, 1973).  
Administration of LSD to schizophrenia patients has been shown to produce 
aggravation of psychotic symptoms (Cholden et al. 1955). Because the effects of LSD are 
blocked by 5-HT2A antagonists, it could be expected that these agents would have 
antipsychotic properties (Marek and Aghajanian, 1996). However, this has not entirely been 
the case. For instance, Meltzer et al. (2004) showed that haloperidol produced highly 
significant reductions in Brief Psychiatric Rating Scale (BPRS) and Positive and Negative 
Syndrome Scale (PANSS) total scores (p<0.001), whereas the 5-HT2A/2C antagonist, 
SR46349B, produced barely significant reductions on these scales (p=0.04). Interestingly, 
analysis of subscales revealed that SR46349B did not produce significant reductions on the 
BPRS psychosis cluster score or the PANSS positive subscales, but it did produce significant 
improvements on the PANSS general (p=0.03) and PANSS negative (p=0.04) subscales. 
However, the greatest improvement with SR46349B versus placebo occurred on the Calgary 
Depression Scale for Schizophrenia (CDSS; p=0.009), suggesting that the benefit of 
SR46349B was of an antidepressant – rather than an antipsychotic – nature (Meltzer et al. 
2004). These data coincide with the fact that drug development of the 5-HT2A antagonist, 
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M10090, was stopped due to lack of efficacy versus established treatments schizophrenia (De 
Paulis, 2001).  
The endogenous cannabinoid receptor system acts through retrograde transport as a 
functional autoreceptor for many neurotransmitter systems, including dopamine, opioids and 
gamma-aminobutyric acid (GABA; Meyer and Quenzer, 2005). Activation of cannabinoid 
type-1 receptors by tetrahydrocannabinol (THC) is associated with feelings of 
euphoria/mania, paranoia and hallucinations. For instance, there is evidence that cannabis-
induced psychosis patients had significantly more hypomania and agitation at baseline and 
less affective flattening, incoherent speech, auditory hallucinations and hysteria, relative to 
paranoid schizophrenia patients, and many of these symptoms diminished after the individuals 
ceased cannabis use (Rottanburg et al. 1982). Surprisingly, both groups were equally given a 
diagnosis of paranoid schizophrenia at hospital admission. There is also evidence that 
cannabis-psychosis patients performed significantly better on tests of content of thought, 
forms of thought, and short-term memory, compared to bipolar mania and schizophrenia 
patients, whereas schizophrenia patients exhibited significantly more auditory hallucinations, 
relative to the other two groups (Imade and Ebie, 1991). Altogether, these studies indicate that 
cannabis psychosis and schizophrenia share a propensity towards paranoid thoughts and 
behaviours. Despite this association, however, Meltzer et al. (2004) did not find a significant 
difference between the CB1 antagonist, SR141716, and placebo for positive or negative 
symptoms in schizophrenia.  
Glutamate is the major excitatory neurotransmitter in the brain. Antagonism of 
ionotropic glutamate N-Methyl-D-aspartate (NMDA) receptors by drugs such as ketamine 
and phencyclidine produces neurological effects such as ataxia, drowsiness, and stupor, and at 
high doses, a lucid dream state (i.e. 'k-hole'; Muetzelfeldt et al. 2008). Due to the similarities 
between NMDA-antagonist intoxication and some symptoms of schizophrenia (e.g. 
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hallucinations, depersonalization, blunted affect, poverty of speech), it has been proposed that 
glutamate may play a role in schizophrenia psychopathology (Bubenikova-Valesova et al. 
2008). In addition to their effects the NMDA receptor, both ketamine and phencyclidine 
display high affinity for D2 receptors and moderate affinity for 5-HT2 receptors, and the latter 
also binds to the dopamine transporter (Schiffer et al. 2003; Kapur and Seeman, 2001, 2002). 
Administration of ketamine to schizophrenia patients produced significant worsening of 
schizophrenia symptoms (as measured by BPRS total), which was mostly accounted for by 
changes in positive symptoms. Additionally, the ketamine-induced psychotic symptoms were 
similar to the patients` symptoms during active episodes of the illness (Lahti et al. 1995). 
These symptoms were partially, but not completely attenuated by concomitant treatment with 
haloperidol. Likewise, another study found haloperidol to significantly reduce symptoms of 
acute intoxication induced by ketamine (Giannini et al. 2000). These findings suggest that 
pro-dopaminergic activity is partially responsible for the aggravations in positive symptoms 
observed in ketamine-treated schizophrenia patients.  
On the other hand, ketamine is not known to produce significant amounts of paranoia 
in normal subjects, and reports of ketamine-induced psychosis are rare. In the case of 
phencyclidine, there is evidence that – among 100 subjects with toxic psychosis – only 22 
percent evidenced paranoid ideas, 12 percent depression, 5 percent fear/anxiety, and 3 percent 
suicidal ideation (McCarron et al. 1981). The low amount of schizophrenia symptoms in this 
phencyclidine sample were confirmed by a key comparison between cocaine- and 
phencyclidine-induced psychosis patients. The authors found that cocaine-induced psychosis 
predominantly included suspiciousness (17 of 22 patients), whereas phencyclidine-induced 
psychosis predominantly included perception of physical strength (12 of 22 patients) and 
divine spiritual experiences (6 of 22 patients). Furthermore, they found that patients taking 
phencyclidine would not report suspiciousness, but instead would report fear that bad things 
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might befall them, and fear of losing control or a sense of imminent dissolution of the self 
(Rosse et al. 1994).  
The original as well as the most recent version of the dopaminergic hypothesis of 
schizophrenia posits that psychotic symptoms are caused by hyperactivity of the mesolimbic 
dopamine system (for review, see Howes and Kapur, 2009). The original hypothesis stemmed 
from the discovery in 1952 that chlorpromazine, a dopamine D2 antagonist, was effective at 
treating positive symptoms in schizophrenia patients (Turner, 2007). To this day, 
antipsychotics remain the sole indicated treatment for the disorder. The case of pro-
dopaminergic agents also favours this interpretation. Indeed, a review of classic studies found 
that the majority of patients exhibited an exacerbation of psychotic symptoms following acute 
treatment with amphetamine, whereas only 25% of controls exhibited such symptoms 
(Lieberman et al. 1987). Similarly, Laurelle (1998) reported that 47% of 34 schizophrenia 
patients who were challenged with amphetamine were classified as ‘worseners’, 41% were 
classified as ‘no change’, and 12% as ‘improvers’, in relation to PANSS positive symptoms. 
Compared with the no change, or the improver patients, the worsener patients displayed a 
significantly greater displacement of [123I]IBZM, suggesting enhanced striatal dopamine 
release. These studies provide evidence for dopaminergic hyperactivity in schizophrenia 
patients via increased presynaptic dopamine release. They also show that the dopaminergic 
hypothesis is the only model that can show significant changes in both directions in response 
to pharmacological challenge (i.e. improvement with antagonists and worsening with 
agonists). Finally, the data imply that NMDA antagonists do not share the same propensity to 
induce paranoia as serotonergic agonists (hallucinogens), cannabinoids, and psychostimulants. 
It may be that the latter agents produce paranoia through activation of common pathway(s) 
that are also affected in schizophrenia.  
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1.1.3 Symptomatology 
Schizophrenia is the most disabling mental disorder, according to the global burden of disease 
study (Eaton et al. 2008). Schizophrenia patients suffer from positive, negative, and 
depressive symptoms (Tirupati et al. 2006; Villalta-Gil et al. 2006; Levine and Rabinowitz, 
2007). The first decade of illness in schizophrenia is often characterized by repeated episodes 
of psychosis with varying levels of remission between episodes and increased disability 
following each episode (Tandon et al. 2009; Wyatt, 1991). Moreover, the bulk of functional 
deterioration tends to occur in the first five years after onset of schizophrenia, following 
which the illness typically progresses into a stable phase, wherein positive symptoms are 
decreased and negative predominate (Tandon et al. 2009).  
Positive symptoms refer to symptoms that the majority of the population does not 
experience, but which are present in psychosis patients. They involve distortions of reality, 
including hallucinations (potentially in all five sensory modalities) and delusions (Tandon et 
al. 2009). To characterize the nature of hallucinations and delusions in schizophrenia, 
Mitchell and Vierkant (1991) conducted a study among 100 involuntarily hospitalized, 
paranoid schizophrenia patients. They found that auditory, visual, and tactile hallucinations 
were reported by 36, 7, and 3 patients, respectively. Command and non-command 
hallucinations were reported by 20 and 9 patients, respectively and they were often bizarre 
and threatening in nature. In addition, 49 patients reported delusions of persecution, 12 
reported identity delusions, 9 reported possession delusions, 4 reported grandiose delusions 
and 4 reported Capgras Syndrome delusions (Mitchell and Vierkant, 1991). Another study by 
Mitchell and Vierkant (1989) examined delusions and hallucinations reported in the social 
histories of 150 schizophrenia patients admitted to a Texas hospital during the 1930s and of 
150 patients admitted during the 1980s. Interestingly, the authors found that patients who 
were admitted during the 1930s exhibited the material deprivation and personal powerlessness 
9 
 
of the great depression in delusions of great wealth and hallucinations of positive ‘special 
powers’. By contrast, patients in the 1980s exhibited an increased frequency of threatening 
hallucinations such visions of blood, snakes, and dead people of animals and command 
hallucinations to hurt, to kill, or to do ‘perverse things’. These phenomena, according to the 
authors, suggest that the subcultural milieu of the 1980s had become more dangerous 
(Mitchell and Vierkant, 1989). Taken together, these data provide insight into the nature of 
hallucinations and delusions in schizophrenia patients and their association to the context in 
which they occur.  
Negative symptoms consist of emotional, social and/or motivational deficits (Erhart et 
al., 2006; Stahl and Buckley, 2007). A recent study examining the factor structure of the Scale 
for the Assessment of Negative Symptoms (SANS) revealed a four-item structure consisting 
of affective flattening (e.g. paucity of expressive gestures, unchanging facial expression), 
alogia (e.g. poverty of content of speech, blocking), avolition-apathy (e.g. physical anergia, 
impersistence at work or school) and anhedonia-asociality (e.g. lack of relationships with 
friends and peers and lack of recreational interests and activities) (Rabany et al. 2011). In 
addition to negative symptoms, schizophrenia patients may exhibit depressive symptoms such 
as hopelessness, self-depreciation, guilty ideas of reference, morning depression and early 
wakening (Majadas et al. 2011).  Interestingly, in the Rabany et al. (2011) study, the SANS 
total score showed a small negative correlation (r= –0.184; p=0.05) with Calgary Depressive 
Scale for Schizophrenia (CDSS) total score, supporting the notion that negative and 
depressive symptoms are separate constructs (despite a similarly sounding nomenclature). The 
occurrence of both negative and depressive symptoms has been termed the “emotion paradox” 
of schizophrenia, suggesting a disjunction between expression, perception and experience of 
emotion (Aleman and Kahn, 2005). For instance, there is evidence that patients with negative 
symptoms were less expressive than those without after viewing emotional films; however, 
10 
 
the former patients did not report experiencing less emotion to the films (Earnst and Kring, 
1999). Consequently, it has been suggested that negative and depressive symptoms can co-
exist in schizophrenia because levels of emotional experience may increase with the latter, 
whereas the ability to perceive emotional cues may diminish with the former (Aleman and 
Kahn, 2005). 
 
1.1.4 Treatment 
Antipsychotics attenuate positive symptoms in schizophrenia, and help improve outcomes, 
especially in the early stages of illness (Wyatt, 1991). For example, a pivotal study by May 
(1968) revealed that treatment with antipsychotics increased the rate of release from the 
hospital, reduced the length of hospital stay, and decreased the need for sedatives in newly 
admitted first-episode psychosis (FEP) patients, relative to psychotherapy or milieu therapy. 
Another study by Crow et al. (1986) showed that 46% of 120 FEP patients maintained on 
antipsychotics relapsed within two years, compared to 62% of patients on placebo and the 
chance of subsequent psychotic relapse was significantly increased in patients with a longer 
duration of untreated psychosis.  
Apart from antipsychotics, there are a number of treatments that can partially improve 
outcomes among schizophrenia patients. In the May (1968) study, electroconvulsive therapy 
(ECT) was nearly as effective as neuroleptics for decreasing the duration of inpatient stay 
among schizophrenia patients. However, a more recent study revealed that the benefit from 
ECT was evident at 8 weeks, but it did not remain at the 6-month follow-up (Abraham and 
Kulhara, 1987). Similarly, while early data found that psychotherapy was ineffective with or 
without antipsychotics, more recent evidence has suggested that psychotherapy may 
significantly improve outcomes when paired with antipsychotics, particularly long-acting 
injectables (May, 1968; Hogarty et al. 1979; for review, see Zhornitsky and Stip, 2012). For 
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its part, repetitive transcranial magnetic stimulation has shown some promise as a treatment 
for positive and negative symptoms in schizophrenia, but results have been inconsistent (Lai 
et al. 2010; Barr et al. 2011). Unfortunately, however, none of these alternative treatments 
have come close to providing the same efficacy as antipsychotics for schizophrenia.  
 
1.2 Antipsychotics 
1.2.1 Typical vs. atypical 
Following the discovery in 1952 that chlorpromazine has antipsychotic properties, there was 
finally a pharmacological treatment for schizophrenia; however, chlorpromazine and other 
`typical` antipsychotic drugs produced disturbing extrapyramidal or neurological side-effects 
such as parkinsonism, akathisia, dystonia and dyskinesia (Taylor, 2007). This was due to their 
potent antagonism of D2 receptors located in the nigrostriatal dopamine system – a pathway 
that is heavily implicated in the capacity for voluntary movement (Tisch et al. 2004). 
However, new ‘atypical’ molecules would soon be developed that displayed lower affinity for 
D2 receptors and did not produced large amounts of extrapyramidal symptoms.   
The first widely used atypical antipsychotic was thioridazine (Boissier et al. 1959; 
Costall and Naylor, 1975). It is considered atypical because it produces an antipsychotic effect 
without a high propensity for inducing extrapyramidal symptoms. Thioridazine has a low-to-
moderate affinity for D1 and D2/D3 receptors, coupled with significant affinity for 5-HT2A, 5-
HT2C, 5-HT6, 5-HT7, α-1 adrenergic and histamine-H1 receptors (Roth et al. 2004). Sulpiride 
was the second atypical antipsychotic to be developed (Carrère, 1968). It has low-to-moderate 
affinity for D2/D3 receptors and preferential binding to pre- (D2Short) versus post-synaptic D2 
receptors (D2Long; Pani and Gessa, 2002). Loxapine and clozapine were the next atypical 
antipsychotics to be marketed (Bishop and Gallant 1970; de Maio, 1972). Loxapine displays 
low-to-moderate affinity for D1 and D2/D3 receptors and significant affinity for 5-HT2A, 5-
12 
 
HT2C, 5-HT6, 5-HT7, α1-2, and H1 receptors (Kroeze et al. 2002). Clozapine displays low-to-
moderate affinity for D1 and D2/D3 receptors and significant affinity for 5-HT2A, 5-HT2C, 5-
HT6, 5-HT7, α1-2, M1, M2, M3, M4, M5 cholinergic, and H1 receptors (Bolden, 1992; Roth et al. 
2004). Subsequently, at least two other ‘first-generation’ atypical antipsychotics would 
follow: tiapride and melperone (Legrain, 1976; Kretzschmar et al. 1976). The former is a 
selective D2/D3 antagonist with a binding profile similar to sulpiride, and the latter displays 
low affinity for D2/D3, coupled with significant affinity for 5-HT2A, and α1-2 receptors 
(Richelson and Souder, 2000; Burstein et al. 2005).  
In the 1990s, companies developed new ‘second-generation’ drugs with a low 
propensity to produce extrapyramidal symptoms, beginning with amisulpride, and followed 
by risperidone, olanzapine, quetiapine, and ziprasidone (Mann et al. 1984; Janssen et al. 1988; 
Moore et al. 1992; Saller and Salama, 1993; Bench et al. 1993). Amisulpride shares with 
sulpiride and tiapride a selective affinity for D2/D3 receptors, and a preference for presynaptic 
D2 receptors. Broadly speaking, the clinical and receptor-binding profile of olanzapine is 
similar to clozapine, the profile of quetiapine is similar to melperone, and the profiles of 
ziprasidone and risperidone are similar to thioridazine and loxapine (Richelson and Souder, 
2000; Roth et al. 2004). Due to their marked affinity for serotonergic receptors, some of these 
atypical antipsychotics are also effective treatments for depression (for review, see Zhornitsky 
et al. 2011a, Pani and Gessa, 2002). In the case of sulpiride, tiapride and amisulpride, their 
preferential affinity for pre- over post-synaptic D2 receptors at low doses leads to increased 
dopamine synthesis and turnover in dopamine terminal areas, thereby producing an 
antidepressant effect (Härnryd et al. 1984). Finally, their high affinity for noradrenergic 
receptors explains the anxiolytic/sedative properties associated with some atypical 
antipsychotics (Roth et al. 2004).  
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1.2.2 Side-effects 
The broad spectrum of action of many atypical antipsychotics suggests that they should be 
associated with multiple side-effects. Antipsychotics with a moderate-to-high affinity for the 
D2 receptor induce extrapyramidal and secondary negative symptoms, particularly when 
occupancy of striatal D2 receptors reaches above 80% (Bobes et al. 2010; Uchida et al. 2011). 
In addition, due to their affinity for α-1 receptors, many antipsychotics produce sedation, 
orthostatic hypotension, and syncope. Furthermore, some atypical antipsychotics such as 
clozapine and olanzapine are associated with a high rate of metabolic disorders, possibly due 
to their antagonism of muscarinic M3 receptors, which regulate insulin secretion from 
pancreatic islets (Gautam et al. 2010; Kong et al. 2010). Antagonism of muscarinic receptors 
is also believed to be responsible for symptoms of dry mouth, blurred vision, constipation, 
and confusion associated with these agents (Kozumplik et al. 2010). However, these 
properties also lead to a low rate of extrapyramidal symptoms, relative to D2 affinity, because 
muscarinic M4 receptors possess a regulatory effect on dopaminergic neurotransmission 
(Bymaster et al. 2003). Finally, prolactin elevation is a concern following treatment with 
typical antipsychotics and some substituted benzamides (amisulpride, but not tiapride and 
sulpiride) due to their selectivity/high affinity for D2 receptors and preferential blockade of 
presynaptic D2 receptors located on the anterior pituitary – a region that regulates prolactin 
secretion (Apud et al. 1987; Petty, 1999). 
 
1.3 Substance abuse/dependence 
Substance abuse is a term that that refers to pathological use of a medication or alcohol/illicit 
drugs that leads to significant impairment or distress and results in a failure to fulfill major 
role obligations at work, school or home; recurrent substance use in situations that are 
physically hazardous; recurrent substance-related legal trouble; and continued substance 
14 
 
abuse despite having substance-related social or interpersonal problems (APA, 1994). 
Substance abuse is more likely to be diagnosed in individuals that just began taking 
alcohol/drugs and it is often an early symptom of substance dependence.  
 In contrast to substance abuse, the DSM-IV definition of substance dependence relates 
more closely to the process of drug addiction (APA, 1994). For instance, one item requires the 
individual to exhibit tolerance as defined by a need for markedly increased amounts of the 
substance in order to achieve desired effect and diminished effectiveness with continued use. 
Another item requires the individual to exhibit symptoms of withdrawal and the need for 
more of the same substance to relieve or avoid withdrawal symptoms. Other items that may 
lead to a diagnosis of substance dependence include a persistent unsuccessful desire to reduce 
substance use and a habit of taking the substance in larger amounts or over a longer period 
than intended, and spending a great deal of time on activities necessary to obtain the 
substance, to use the substance and to recover from its effects (APA, 1994). The content of 
these items show that the DSM-IV definition of substance dependence is centred on processes 
surrounding alcohol/drug addiction (e.g. tolerance, withdrawal), whereas the definition of 
substance abuse is centered on substance-associated personal and societal harm. Interestingly, 
tolerance and withdrawal are no longer considered to be core features of substance 
dependence, although they remain part of its definition. New theories focus much more on 
loss of control, compulsive use and relapse. 
 
1.3.1 Pharmacological mechanisms  
All major drugs of abuse including psychostimulants, opiates, cannabis and alcohol are 
believed to produce their rewarding effects by increasing striatal dopamine levels (Meyer and 
Quenzer, 2005; Wise and Rompre, 1989). Cocaine produces its psychoactive effects by 
blocking the dopamine reuptake transporter, leading to large increases of dopamine in the 
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synaptic cleft, and at the affected synapses (Ritz et al. 1990). Amphetamine and 
methamphetamine produce their effects by being uptaken by monoaminergic transporters 
(mainly dopamine at low doses), wherein they provoke neurotransmitter release from the 
synaptic vesicles into the cytoplasm, and cause the transporters to function in a reverse 
direction to release neurotransmitters from the cytoplasm into the extracellular fluid (Ritz and 
Kuhar, 1989). In rats, amphetamine and cocaine elicit a locomotor response when injected 
directly into the ventral tegmental area (VTA) or nucleus accumbens (Chen and Reith, 1994; 
Meyer and Quenzer, 2005). Moreover, 6-hydroxydopamine (6-OHDA) lesions of these 
regions attenuate the locomotor-stimulating and reinforcing properties of systemically 
administered amphetamine and cocaine (Kelly et al. 1975; Koob et al. 1981; Roberts and 
Koob, 1982). During withdrawal, amphetamine and cocaine produce significant reductions in 
extracellular dopamine concentration in the ventral striatum, which can be observed 
behaviourally via increased thresholds to rewarding brain stimulation (Rossetti et al. 1992; 
Zhornitsky et al. 2010; Stoker and Markou, 2011).  
Opiates such as heroin and morphine activate the endogenous opioid system, which 
plays a pivotal role in analgesia, reward, and body perception/sensory integration. These 
agents are agonists of μ, δ and κ-opioid receptors; however, they are more selective for the 
first subtype (Spetea et al. 2004). Both the μ and δ-receptor subtypes are believed to tonically 
inhibit dopamine. Activation of these sites increases VTA cell firing and dopamine release in 
the nucleus accumbens by inhibiting the (inhibitory) GABA cells found in VTA (Meyer and 
Quenzer, 2005). By contrast, activation of κ-opioid receptors exerts the opposite effect on the 
mesolimbic dopaminergic system. Specifically, higher doses of the psychotomimetic κ-
agonist, salvinorin A, were found to significantly reduce dopamine levels in the caudate and 
putamen – an effect that was completely blocked by administration of the κ-antagonist, nor-
binaltorphimine (Zhang et al. 2005). Here, the authors also found that the same doses of 
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salvinorin A caused conditioned place aversion and decreased locomotor activity, suggesting 
decreased reward system activity. On the other hand, there is evidence that nor-
binaltorphimine potentiated decreases in dopamine release, conditioned-place aversion, and 
overt signs associated with morphine withdrawal (Spanagel et al. 1994).  
Cannabis produces its psychoactive effects activating endogenous cannabinoid-type 1 
(CB1) receptors (Demuth and Molleman, 2006). Endocannabinoids are synthesized and 
released in response to depolarization of the postsynaptic cell due to influx of calcium. After 
they are released, these substances cross the synaptic cleft, activate presynaptic CB1 receptors, 
and block calcium-mediated neurotransmitter release from the terminal (Demuth and 
Molleman, 2006). Cannabinoids produce their rewarding effects primarily by indirectly 
stimulating the dopamine and opioid neurotransmitter systems. Indeed, studies have shown 
that cannabinoids stimulate firing of dopamine neurons in the VTA and increase dopamine 
release in the nucleus accumbens (French et al. 1997; Sperlágh et al. 2009). Furthermore, 
there is evidence that that CB1 antagonist, SR141716A, reduced self-administration of heroin 
in rats or mice and naltrexone, reduced THC self-administration in squirrel monkeys 
(Chaperon et al. 1998; Justinova et al. 2004). During withdrawal, there is evidence that THC 
produced reductions in dopamine cell activity and somatic symptoms, which were alleviated 
when rats were given more of the molecule (Diana et al. 1998).  
Alcohol exerts its effects via a number of neurotransmitter pathways. Alcohol inhibits 
glutamate neurotransmission by reducing its effectiveness at NMDA receptors and reducing 
its release in a number of brain regions (Lovinger et al. 1989). During alcohol withdrawal, 
glutamate release is increased dramatically, leading to central nervous system (CNS) 
hyperexcitability, and potentially seizures. In addition, alcohol produces its psychoactive 
action by activating GABA receptors – an effect that is not surprising since alcohol shows 
cross-tolerance and cross-dependence with other GABA-receptor agonists such as 
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benzodiazepines and barbiturates (Allan et al. 1992; Toki et al. 1996). Indeed, there is 
evidence that manipulations that increase and decrease GABA also enhance and attenuate 
alcohol`s behavioral effects, respectively (Grobin et al. 1998). In addition to GABA, alcohol 
activates the opioidergic system, which plays a crucial role in the body’s ability to relieve 
pain, and whose stimulation reverses the tonic inhibition that these receptors have on 
dopamine neurons, thereby leading to dopamine release (Meyer and Quenzer, 2005). 
Interestingly, alcohol consumption is attenuated in animals after administration of moderate 
and high doses of morphine, suggesting that the morphine displaces the alcohol from opioid 
receptors, thereby reducing its rewarding effects (Herz, 1997). Furthermore, alcohol augments 
the firing rate of dopaminergic neurons in the VTA and increases the amount of dopamine 
released into the nucleus accumbens (Tateno and Robinson, 2011). Finally, there is evidence 
that animals will self-administer alcohol directly into the VTA, and infusion of D2 antagonists 
into the nucleus accumbens has been shown to reduce alcohol self-administration 
(Czachowski et al. 2001; Rodd-Henricks et al. 2000). 
 
1.3.2 Treatment 
Pharmacotherapies targeting the GABAergic system have been shown to be useful for the 
treatment of substance abuse/dependence. Benzodiazepines have long been used for the 
treatment of alcohol withdrawal due their ability to reduce withdrawal-induced seizures, and 
their ability to act as a substitution therapy in order to wean individuals off of alcohol 
(Koutsky and Sleten, 1963). However, these agents have a high addiction potential 
themselves, thus limiting their use among the substance use disorder population (Lalive et al. 
2011). Indeed, there is evidence that while 15mg of diazepam reduced alcohol associations 
active problem drinkers, a lower dose (5mg) significantly increased the salience of alcohol 
18 
 
associations (Zack et al. 2006). In a similar vein, diazepam was found to significantly increase 
consumption of de-alcoholised beer among problem drinkers (Poulos and Zack, 2004). 
Medications targeting the endogenous opioid system have had success in the treatment 
of opiate and alcohol abuse/dependence. For example, substitution therapy with oral 
methadone, a partial µ-opioid receptor agonist, has proven useful because of its ability to 
minimize withdrawal symptoms and wean patients off heroin (Mattick et al. 2009). 
Alternatively, naltrexone, a non-selective opioid-receptor antagonist, has been shown to 
reduce heavy drinking versus placebo in 19 of 27 (70%) clinical trials, presumably by 
attenuating the rewarding effects of alcohol (Pettinanti et al. 2006). However, the same study 
also found that only 9 of 25 (36%) trials found that naltrexone, was superior to placebo in 
improvement abstinence or ‘any drinking’. 
Studies suggest that targeting serotonergic and/or noradrenergic systems may help 
attenuate the effects of alcohol/drug intoxication and withdrawal. For instance, the dual 
serotonin and norepinephrine reuptake inhibitor, venlafaxine, significantly decreased the acute 
subjective effects of cocaine by 10-20% (Foltin et al. 2003). There is also evidence that the 
non-selective α-1/β-adrenergic receptor antagonist, carvedilol, attenuated increases in blood 
pressure and heart-rate induced by crack cocaine and decreased self-administration among 
users of crack cocaine (Sofuoglu et al. 2000). Additionally, the 5-HT2A and 5-HT2C 
antagonist, mirtazapine, attenuated withdrawal symptoms in amphetamine-dependant subjects 
(Shoptaw et al. 2009), and the beta-adrenergic antagonist, propanolol, decreased cocaine use 
in a subset of individuals with a high withdrawal severity (Kampman et al. 2001). Similarly, 
there is evidence that trazodone – a α-1 receptor antagonist – reduced symptoms of alcohol 
withdrawal and improved sleep quality post-detoxification (Karam-Hage and Brower, 2003; 
Borras et al. 2006). These preliminary findings attest to the potential of serotonergic and 
noradrenergic manipulation for the treatment of substance abuse/dependence. 
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Dopaminergic agents are intriguing targets for the treatment of SUDs because they 
directly target the mesolimbic dopamine system. Substitution therapy with dopamine agonists 
is one approach; however, they have addictive potential themselves. Experimental studies 
have found that sustained-release amphetamine reduced cocaine-associated subjective effects 
and drug-liking, and reduced breakpoint for cocaine self-administration among dependant 
individuals (Greenwald et al. 2010; Rush et al. 2010). There is also evidence that sustained-
release amphetamine decreased the subjective and physiological effects of intranasal 
methamphetamine (Rush et al. 2011). Similarly, bupropion (a weak dopamine transporter 
inhibitor) reduced subjective effects and craving in methamphetamine-dependant individuals 
(Newton et al. 2006). Altogether, these data suggest that agonist substitution may be mildly 
effective for the treatment of SUDs. 
 
1.3.2.1 Why treat with antipsychotics? 
Another approach to pharmacotherapy of substance abuse/dependence is to block the 
rewarding effects of substances of abuse with atypical antipsychotics. In addition, many 
atypical antipsychotics possess significant anxiolytic and antidepressant efficacy due to 
antagonism of multiple serotonergic and noradrenergic receptor subtypes, suggesting that they 
may have the added benefit of alleviation of withdrawal, without the addictive potential of 
benzodiazepines and dopaminergic agonists (Roth et al. 2004). Animal models of reward have 
demonstrated that antipsychotics reverse cocaine-, amphetamine-, and morphine-induced 
decreases in threshold for rewarding brain stimulation and block the establishment of a 
conditioned place preference to alcohol, amphetamine, and cocaine (Yokel and Wise, 1976; 
Barrett et al. 1980; Winsauer et al. 2008; Arolfo and McMillen, 2000; Walker and Ettenberg, 
2007). There is also evidence that antipsychotic agents block drug- and cue-induced 
reinstatement of responding on the drug-associated lever during self-administration of 
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cocaine, amphetamine, and heroin, and prevent the ability of amphetamine and heroin to 
reinstate operant runway behaviour (Ettenberg, 1990; Ettenberg et al. 1996; Gál and 
Gyertyán, 2006; Feltenstein et al. 2007). 
Early studies in chronic alcoholics revealed that melperone was effective at reducing 
depression, tension, paranoia, craving and insomnia (Carlsson and Gullberg, 1978, Carlsson et 
al. 1979). Around the same time, tiapride began to gain interest for the treatment of alcohol 
withdrawal syndrome, particularly due to its ability to attenuate delirium tremens (Parent et al. 
1978). More recently, quetiapine was found to reduce subjective intoxication, craving and 
sedation during alcohol administration, and alcohol cue-exposure (Ray et al. 2011). Similarly, 
there is evidence that clozapine decreased pleasant (i.e. expected ‘high’, ‘rush’) and 
unpleasant (paranoia and nervousness) responses to intranasal cocaine (Farren et al. 2000). As 
a whole, these experimental and short-term studies indicate that atypical antipsychotics may 
have promise for the treatment of SUDs via a reduction of intoxication or alleviation of 
craving and withdrawal. 
 
1.4 Extrapyramidal symptoms 
Extrapyramidal symptoms refer to antipsychotic-induced disorders of movement. They 
include parkinsonism (e.g. resting tremor, bradykinesia), dyskinesia (e.g. involuntary 
movements of the body and face), dystonia (e.g. muscular contractions) and akathisia (e.g. 
subjective and objective restlessness). Parkinsonism is considered to be a hypokinetic 
disorder, whereas dyskinesia, dystonia, and akathisia are considered to be hyperkinetic 
disorders. Furthermore, extrapyramidal symptoms may be acute or tardive: the former may be 
transient, while the latter appears during long-term treatment (often after several years), and 
may be irreversible even after antipsychotics are discontinued (especially after treatment with 
typicals; Tarsy et al. 2011). 
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1.4.1 Neurobiology 
Extrapyramidal symptoms are believed to occur because of antagonism of dopaminergic 
receptors in the basal ganglia (Feinberg and Snyder, 1975). The basal ganglia refer to several 
nuclei in the mesencephalon and diencephalon. They include the globus pallidus, striatum 
(putamen & caudate nucleus), subthalamic nucleus and substantia nigra (divided into pars 
compacta and pars reticulata). The basal ganglia form a network with the cortex and thalamus, 
and together, they regulate processes such as movement, cognition, and emotion. The striatum 
is the central input structure in this network and it receives numerous afferent connections 
from the cortex, thalamus, and substantia nigra pars compacta. The main output structures 
include the globus pallidus and substantia nigra pars reticulata, which project to the thalamus 
and brainstem (Tisch et al. 2004). The majority of neurons in the basal ganglia (~96%) are 
medium spiny neurons, which are inhibitory GABAergic neurons (Stolerman, 2010). In the 
basal ganglia neural network there are two major pathways (i.e. types of medium spiny 
neurons). Neurons in the ‘direct’, pathway facilitate the initiation and execution of voluntary 
movement and express mainly D1 and presynaptic muscarinic M4 receptors (Bymaster et al. 
2003). Neurons in the ‘indirect’ pathway prevent unwanted motor commands from competing 
with voluntary movement and express mainly D2 receptors. The role of dopamine is to keep 
the two pathways balanced and neurologically normal individuals are able to switch between 
the two pathways in a continuous, uninterrupted fashion. However, dysfunction of the direct 
and indirect pathways results in hypo- and hyperkinesia, respectively (Onla-or and Winstein, 
2001). 
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Figure 1: Direct and indirect pathways of movement 
 
Adapted from http://neuroscience.uth.tmc.edu/s3/chapter04.html 
 
1.4.1.1 Parkinsonism 
Drug-induced parkinsonism typically develops following several days to weeks of 
antipsychotic therapy due to blockade of dopaminergic receptors in the nigrostriatal pathway. 
The syndrome is characterized by poverty of movement (akinesia), slowness of movement 
(bradykinesia), rigidity, and resting tremor (frequency = 3-6Hz; Mattay and Casey, 2003). In 
monkeys, both D1 and D2 receptor antagonists have been evidenced to produce parkinsonism 
without tolerance, but the syndrome is more likely to develop with following treatment with 
the former (Lawrence et al. 1991; Casey, 1995). In schizophrenia, Kapur et al. (1995) showed 
that risperidone produced significant levels of parkinsonism when occupancy of striatal D2 
receptors reached above ~75%. Recently, a pooled analysis of 12 studies revealed a similar 
rate cut-off point of 78% D2 occupancy for extrapyramidal symptoms as a whole (Uchida et 
al. 2011). It is likely that these overall estimates mainly reflect parkinsonism because 
akathisia, dyskinesia, and dystonia are rarer, and they show a weaker relationship to D2 
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occupancy in positron-emission tomography (PET) studies (Kapur et al. 1995; Uchida et al. 
2009).  
Parkinsonism in schizophrenia can be treated by administration of anticholinergic 
drugs. Anticholinergics such as atropine and benztropine are believed to produce their 
antiparkinsonian effects via antagonism of M4 receptors (Langmead et al. 2008). High levels 
of M4 receptors are found in the striatum, cerebellum, and cerebral cortex, and on neurons in 
the ‘direct’ pathway. Interestingly, there is evidence that haloperidol-induced catalepsy was 
attenuated following treatment with scopolamine (an anticholinergic) in normal mice, but not 
in M4 knockout mice (Karasawa et al. 2003). Similarly, Betz et al. (2007) showed that 
tropicamide (a moderately selective M4 antagonist) suppressed the tremulous jaw movements 
(an animal model of parkinsonism) induced by the antipsychotic pimozide, and the muscarinic 
agonist pilocarpin. Moreover, tropicamide was equally as potent as atropine (a less selective 
anticholinergic) at reversing the effects of pilocarpin, but it was more potent at reversing the 
effects of pimozide, suggesting that M4 antagonism was the moderating factor (Betz et al. 
2007).  
 
1.4.1.2 Dyskinesia 
Tardive dyskinesia is a potentially irreversible syndrome characterized by abnormal 
involuntary orofacial and limb/trunk movements that normally emerge after long-term 
antipsychotic treatment (Gardos et al. 1987). Alternatively, pro-dopaminergic drugs (e.g. 
cocaine, amphetamine, L-DOPA) can induce dyskinesias (usually termed choreiform 
movements) during the acute and withdrawal phases, and especially after treatment with 
antipsychotics. The original hypothesis put forth to explain dyskinesia suggested that 
chemical denervation by antipsychotics led to striatal dopaminergic hyperactivity via 
upregulation and supersensitivty of the remaining dopamine receptors (Klawans and 
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Rubovitz, 1972). In support of this view, there is evidence that monkeys that underwent 
dopaminergic denervation (91-97%) of the basal ganglia with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) exhibited significantly increased binding to D2, but not D1 
receptors in this region (Graham et al. 1990). There is also evidence that oral dyskinesia 
induced by D2 antagonists in monkeys was significantly reduced following treatment with the 
partial dopamine agonist, SDZ HAC-911 (Peacock and Gerlach, 1993). On the other hand, 
chronic treatment of monkeys with low or high doses of D1 antagonists has been shown to 
induce mild acute dyskinesia, but there are no reports of tardive dyskinesia following 
treatment with these agents (Gerlach and Hansen, 1993; Lublin et al. 1994). Similarly, greater 
improvement in tardive dyskinesia was witnessed in the combined D1 and D2 antagonist 
treatment group, relative to monkeys who were treated with D2 antagonists-alone (Peacock et 
al. 1999a,b). These findings imply that D1 antagonism is a favourable property for 
antipsychotics to have when tardive dyskinesia is a concern. 
 Tardive dyskinesia is often exacerbated in schizophrenia patients following a 
reduction in dosages, suggesting that it may be a state of antipsychotic-withdrawal (Anand 
and Dewan, 1996; Tranter and Healy, 1998). In support, we recently showed that in patients 
who were switched to ziprasidone, abrupt discontinuation of typical antipsychotics resulted in 
elevated rates of dyskinesia, relative to patients who were slowly withdrawn from medication 
(Stip et al. 2010). We also found that patients, who were abruptly discontinued exhibited 
significantly less improvement on the BPRS, compared those who were slowly withdrawn. 
These data corroborate reports of an association between tardive dyskinesia and antipsychotic 
withdrawal-induced supersensitivity psychosis in the literature (Chouinard, 1991; Roy-
Desruisseaux et al. 2011; Fallon and Dursun, 2011). In a similar vein, acute dyskinesia may 
be exacerbated by antipsychotic treatment – as illustrated by the case of a psychostimulant-
naïve 7-year old boy who recently stopped taking risperidone and developed twitching 
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movements of his hands and feet, mouth movements, tongue protrusion, shoulder shrugging, 
and aggressive behaviour following initiation of methylphenidate (a dopamine transporter 
inhibitor; Hollis and Thompson, 2007).  
Several pharmacological agents have been tried as treatment for tardive dyskinesia, 
including pro-dopaminergic drugs, dopamine depleting agents, and anticholinergics. 
However, none of these treatments has yielded consistently beneficial results and some may 
aggravate the syndrome. Consequently, once tardive dyskinesia becomes manifest it is 
important to reduce the risk of worsening symptoms by employing the lowest effective dose, 
switching to an atypical antipsychotic, or eventually discontinuing the medication, if possible 
(Mattay and Casey, 2003).  
 
1.4.1.3 Dystonia 
Dystonia is a hyperkinetic disorder of the basal ganglia that features prolonged muscle spasms 
(0.5-5 seconds) in agonist and antagonist muscles (Richter and Loscher, 1998). Dystonia can 
be classified in a number of different ways. Focal dystonia involves contractions of a specific 
body part, whereas generalized dystonia involves contractions of the entire body. Dystonia 
can be primary (i.e. characterized by lack of aetiology) or secondary (e.g. due to disease, 
lesions, and antipsychotics). Dystonia can be acute or tardive; the latter involves sustained 
abnormal postures and may persist for months or years after discontinuation of antipsychotic 
drugs (Mattay and Casey, 2003). Imaging studies have revealed that dystonia is often 
observed in stroke patients with lesions of the putamen, globus pallidus and thalamus (Mink, 
1996). Additionally, there is evidence of decreased D2-binding in the putamen of individuals 
with primary dystonia (Perlmutter et al. 1997). On the other hand, secondary dystonia is often 
the consequence of concomitant administration of psychostimulants and typical 
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antipsychotics, possibly due to dopaminergic supersensitivity (van Harten; et al. 1998; Evans 
et al. 2001).  
In monkeys, studies show that D1 antagonists produce dystonia when administered at 
high doses, as well as at low doses following pretreatment with D2 antagonists; however, 
tolerance to this effect develops after a few days of treatment (Kistrup and Gerlash, 1987; for 
review, see Gerlach et al. 1996). Significantly, Peacock et al. (1999a) showed that tolerance to 
dystonia occurred during combined treatment with D1 and D2 antagonists in monkeys 
pretreated with D2 antagonists; however, the tolerance disappeared when the former were 
discontinued and monkeys continued to receive the latter. Likewise, there is evidence that 
both SCH23390 (a selective D1 antagonist) and raclopride (a selective D2/D3 antagonist) 
induced identical levels of dystonia and this effect was completely reversed by administration 
of biperiden (an anticholinergic) and LY171555 (a selective D2 agonist; Kistrup and Gerlach, 
1987). These studies indicate that antipsychotics that block D1 (in addition to M4) receptors 
may be preferred for individuals with a history of drug-induced dystonia. 
 
1.4.1.4 Akathisia 
Akathisia is the subjective feeling of restlessness, coupled with the presence of objective 
restlessness. Akathisia is described by patients as feeling uptight, anxious, and unable to relax, 
and it is associated with suicidal behaviour in schizophrenia (Barnes, 1989). Acute akathisia 
typically begins within hours to days following the onset of antipsychotic treatment. By 
contrast, tardive akathisia is differentiated by its persistence for months or years after 
discontinuation of antipsychotic therapy. Objective signs of akathisia include pacing, crossing 
and uncrossing the legs, rocking back and forth, and lifting the feet as if marching in place. 
Akathisia is often misdiagnosed as psychotic agitation, leading to an escalation of 
antipsychotic dose and aggravation of the initial symptoms (Mattay and Casey, 2003).  
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The pathophysiology is of akathisia is unclear; however, a number of 
neurotransmitters, including dopamine, serotonin, noradrenaline, acetylcholine and GABA 
have been implicated. This has stemmed from observations that akathisia is treated with beta-
adrenergic blockers, anticholinergics, and benzodiazepines, and induced/aggravated by 
dopaminergic antagonists and serotonin transporter blockers (Sachdev and Brüne, 2000). 
Using PET, Farde (1992) demonstrated that akathisia, in response to D1 and D2 antagonism, 
was clinically indistinguishable between schizophrenia patients and healthy controls, and it 
occurred at similar levels of SCH-23390 and raclopride binding in basal ganglia (40-73%). 
The regions of basal ganglia may not be the only structures implicated in the pathophysiology 
of akathisia, however. For instance, case reports have evidenced reduced metabolic activity in 
the thalamus and cerebellum of a patient with antipsychotic-induced akathisia, and lesions of 
the prefrontal cortex in a patient with akathisia resulting from a traumatic brain injury (Silver 
and Yablon, 1996; Landgrebe et al. 2006). Unfortunately, however, experimental studies on 
this topic are rare and will need to be addressed by future research.  
 
1.5 Schizophrenia and SUDs 
Schizophrenia is associated with a nearly 50% lifetime prevalence of SUDs (excluding 
nicotine; Regier et al. 1990). In absolute numbers, patients who suffer from schizophrenia use 
alcohol and cannabis more frequently than cocaine. However, in relative numbers, cocaine 
abuse/dependence in schizophrenia is associated with the highest risk (odds ratio = 13), 
compared to the general population (Regier et al. 1990). Compared to non-abusing patients, 
dual diagnosis schizophrenia patients (DD) are more frequently hospitalized, non-compliant 
with treatment, suicidal, impulsive and violent, homeless and unemployed, and they have 
more legal and health problems (Mueser et al. 1998; Negrete, 2003). Moreover, there is 
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evidence that DD patients have more psychiatric and neurological symptoms, relative to non-
abusing patients (Potvin et al. 2006a; Maat et al. 2008).  
 
1.5.1 Psychiatric effects 
Studies suggest that substance abuse is a major risk factor for the development of depression 
among the general public (Lynskey et al. 2004; Falck et al. 2006). In schizophrenia, a recent 
meta-analysis of 3283 patients revealed that DD patients experience more severe depressive 
symptoms compared to non-abusing patients (Potvin et al. 2007). In addition, substances of 
abuse can induce transient psychosis and anxiety that may be indistinguishable from 
schizophrenia and anxiety/panic disorders (Mauri et al. 2007; Lapworth et al. 2009). In the 
more serious case of psychosis, individuals may be diagnosed as having substance-induced 
psychotic disorder according to the DSM-IV if they include prominent delusions or 
hallucinations coupled with a lack of insight (Mathias et al. 2008).  
Alcohol produces a range of effects depending on dose, including euphoria, anxiety, 
depression, psychotic reactions, stupor, and coma (West and Gossop, 1994; Jordaan et al. 
2009). A recent comparison between alcohol-induced psychotic disorder and schizophrenia 
revealed that the former had significantly higher levels of depressive and anxiety symptoms, 
fewer negative and disorganized symptoms, better insight and judgment, and less functional 
impairment compared with patients with schizophrenia (Jordaan et al. 2009). In 
schizophrenia, there is evidence that patients with baseline paranoia or hallucinations reported 
an increase in these symptoms after drinking. Alcohol-abusing schizophrenia patients were 
also significantly more likely than those without schizophrenia to cite relief of depression and 
problems or worries as a reason for alcohol use (Pristach and Smith, 1996). Overall, there is 
evidence that alcoholism is associated with greater non-compliance, relapse, homelessness, 
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physical illness, suicidal behaviour, violence and hospital readmission in schizophrenia 
(Drake et al. 1989; Batki et al. 2009; Gerding et al. 1999; Rasanen et al. 1998).  
THC intoxication is associated with feelings of euphoria/mania, anxiety and 
paranoia/hallucinations (D’Souza et al. 2004). In schizophrenia, an important experimental 
study demonstrated that THC transiently exacerbated a range of positive and negative 
symptoms (D’Souza et al. 2005). The positive symptoms induced in these patients were 
similar to their typical symptoms; the exacerbations were brief, modest, and occurred even 
though subjects were clinically stable, medication responsive and treated with therapeutic 
doses of antipsychotics. Analysis of negative symptoms revealed that patients were more 
blunted, less talkative, less spontaneous, and more internally preoccupied (D’Souza et al. 
2005). With regards to long-term consequences of cannabis use, a 10-year follow-up study by 
Foti et al. (2010) revealed that lifetime cannabis use was associated with earlier onset of 
psychosis and increased positive symptoms, even after controlling for potential confounding 
variables. By contrast, there is evidence that the prevalence of suicidal attempts was increased 
in schizophrenia patients without cannabis use and they spent more time in hospital (Makkos 
et al. 2011). Similarly, a recent study of first-episode patients revealed that cannabis abusers 
had a significantly shorter duration of untreated psychosis and less negative symptoms, 
compared to non-abusing patients (Burns et al. 2010). As a whole, these findings may be 
reconciled if we assume that some cannabis abusers may represent a different (e.g. younger, 
male, lower illness severity) subpopulation of schizophrenia patients.  
Cocaine use is associated with psychiatric symptoms in non-psychosis individuals that 
can be similar to those seen in schizophrenia (Caton et al. 2000; Mauri et al. 2007). Recently, 
a retrospective study of 674 cocaine users admitted to the emergency room found that 
psychiatric symptoms were the most frequent complaints (60.9%) associated with dependant 
and non-dependant cocaine use. Of these, the most common were anxiety (31.5%), agitation 
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(26.1%), paranoia (16.8%), psychosis (12.2%), depression (4.2%) and hallucinations (3.6%; 
Pavarin et al. 2011). In more severely dependent individuals – including those that use 
intravenous and smoked (crack) cocaine – psychotic symptomatology may be observed in 
nearly 90% of patients (Brady et al. 1991; Smith et al. 2009). In schizophrenia, research 
suggests that patients who abuse cocaine may have more hallucinations and 
depression/anxiety (Lysaker et al. 1994; Serper et al. 1995, 1999). There is also evidence that 
schizophrenia patients with a history of cocaine abuse/dependence are more depressed, 
relative to their non-abusing counterparts (Sevy et al. 1990). Similarly, a comparison between 
cocaine dependant patients with and without schizophrenia revealed that schizophrenia 
patients reported having significantly more energy, craving, depression and feeling worse and 
these differences were stable at the 72-hours follow-up (Carol et al. 2001). Taken together, the 
aforementioned studies show that alcohol, cannabis, and cocaine may induce schizophrenia-
like psychiatric symptoms in non-psychosis individuals and aggravate these symptoms in 
schizophrenia patients.  
 
1.5.2 Extrapyramidal effects 
Alcohol and drugs of abuse may induce extrapyramidal symptoms in psychosis and non-
psychosis patients. Alcohol acutely alters the functioning of the basal ganglia, and its long-
term use produces anatomic and physiological changes in the striatum (Wang et al. 2000; 
Martinez et al. 2005; Sullivan et al. 2005). Among non-psychosis individuals, alcohol abuse 
was shown to produce enhanced body sway and action tremor during acute and protracted 
withdrawal (Bauer et al. 1993; Sullivan et al. 2010). Among schizophrenia patients, alcohol 
abuse was found to be related to more severe orofacial dyskinesia and akathisia (Duke et al. 
1994). Moreover, there is evidence that inhalation of THC reduced raclopride binding in the 
ventral striatum and the precommissural dorsal putamen, suggesting an increase in dopamine 
31 
 
release (Bossong et al. 2009). In schizophrenia, current cannabis use and intravenous THC 
aggravated the presence of tardive dyskinesia, which is consistent with the dopaminergic 
supersensitivity hypothesis (Zaretsky et al. 1993; D’Souza et al. 2005). Alternatively, there is 
evidence that cannabis smoking may serve as a protective factor against the development of 
dyskinesia (Niehaus et al. 2008). Further research is needed to confirm these findings.   
Long-term abuse of cocaine and amphetamine is associated with significant reduction 
in dopamine D2 receptor availability in the striatum that may last for months after 
detoxification, similar to the striatal dopaminergic deficit observed in Parkinson’s disease 
(Volkow et al. 2004). Studies in non-psychosis individuals have shown that cocaine abuse 
may produce extrapyramidal symptoms, including rigidity and Parkinsonian resting tremor—
a symptom that has been shown to last as long as 12 weeks into abstinence (Bauer et al. 1993, 
1996). Among schizophrenia patients, studies have revealed that cocaine use is a major risk 
factor for dystonia, parkinsonism, dyskinesia, and akathisia (Potvin et al. 2006a; Maat et al. 
2008). Overall, a recent meta-analysis of studies investigating the effects of substance abuse 
on extrapyramidal symptoms in patients dually diagnosed with schizophrenia and SUDs 
revealed that these patients had more severe extrapyramidal symptoms, relative to non-
abusing schizophrenia patients; an effect that was most prominent in dually diagnosed cocaine 
abusers (Potvin et al. 2009). 
 
1.6  Hypotheses and research objectives 
In the following sections, I will examine the results of the present trial which compared SUD 
outcomes as well as psychiatric and extrapyramidal (neurological) symptoms in substance 
abusers with and without schizophrenia, and in non-abusing schizophrenia patients at 
baseline, and after 12-weeks of treatment with quetiapine. This antipsychotic was chosen 
because it has previously been shown to improve substance use outcomes and psychiatric 
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symptoms in psychosis and non-psychosis patients (Potvin et al. 2004, 2006; Pinkofsky et al. 
2005; Martinotti et al. 2008), while also producing little or no extrapyramidal symptoms 
(Weiden, 2007). Because this was a naturalistic study, the prescribed dose of quetiapine was 
determined by the treating physician. 
The goal of this project was improve our understanding of the complex relationships 
between substance abuse and schizophrenia. It was also expected to help elucidate the clinical 
consequences of substance abuse in schizophrenia patients as well as their potential treatment 
by pharmacological means. Our hypothesis was that quetiapine treatment would result in 
improvements in substance abuse and clinical variables (psychiatric and neurological 
symptoms) across the groups. We also expected that improvements in substance use outcomes 
would be less pronounced in DD patients, relative to non-psychosis substance abusers (SUD 
arm). We made this hypothesis because of evidence that DD patients have a hard time quitting 
alcohol and/or drugs (Ziedonis et al. 2005). In order to contextualize the present study, I will 
present our supplementary data on outcomes in the SUD arm and on between the three groups 
at baseline. Moreover, I will examine findings from our systematic review on antipsychotics 
for the treatment of SUDs in patients with and without comorbid psychosis. We conducted 
this review to understand the impact of psychosis-status and substance-type on SUD 
outcomes – the latter issue being specifically important because of the inclusion of 
polysubstance abusers in the present trial. Second, I will examine findings from our 
systematic review on the dose-response and comparative efficacy and tolerability of 
quetiapine across psychiatric disorders. We conducted this review to understand the impact of 
quetiapine-dose on different psychiatric symptoms such as anxiety, depression, and psychosis 
and to understand the potential implications of the differences in prescribed quetiapine dose 
among the three groups in the present study.  
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2.1 Abstract 
Background Extrapyramidal symptoms (EPS) such as parkinsonism, dystonia, dyskinesia, 
and akathisia are conditions of impaired motor function which are associated with chronic 
antipsychotic treatment in schizophrenia. In addition, EPS are often exacerbated by 
psychoactive substance (PAS) abuse, which is frequently observed in this population. Few 
studies, however, have investigated the contribution of PAS abuse on EPS in PAS-abusers 
without comorbid psychosis. Methods The present study compared the occurrence of EPS in 
outpatient schizophrenia patients with (DD group; n=36) and without PAS abuse (SCZ group; 
n=41) as well as in non-schizophrenia PAS abusers undergoing detoxification (SUD group; 
n=38). Psychiatric symptoms were measured using the Positive and Negative Syndrome Scale 
and the Calgary Depression Scale for Schizophrenia. Extrapyramidal symptoms were 
evaluated with the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Scale. 
SUD diagnoses were complemented with urine drug screenings. Results We found that DD 
patients exhibited significantly more parkinsonian symptoms than SCZ patients and SUD 
individuals. Our sub-analyses revealed that cocaine and alcohol abuse/dependence was 
responsible for the increase in parkinsonism in DD patients. Additionally, we found that SUD 
individuals exhibited significantly more akathisia than the other two groups. In these latter 
individuals, sub-analyses revealed that alcohol and cannabis abuse/dependence was 
responsible for the increase in akathisia. Conclusion Our results suggest that PAS abuse is a 
contributor to EPS in individuals with and without schizophrenia.  
Key words schizophrenia – substance use disorders – extrapyramidal symptoms – 
antipsychotics  
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2.2 Introduction 
Schizophrenia is the most disabling psychiatric disorder, according to the Global Burden of 
Disease (GBD) study.1 A major factor that contributes to occupational and social dysfunction 
in schizophrenia is poor treatment compliance.2 Studies have shown that approximately two 
thirds of schizophrenia patients are only partially compliant or completely noncompliant with 
the medication they are prescribed, thereby greatly increasing the chances of psychotic 
relapse, rehospitalization and suicide.2-4 Interestingly, a study by Garcia-Cabeza et al.5 found 
that differences in negative subjective response to antipsychotic drugs and poor treatment 
compliance were strongly related to the presence of extrapyramidal symptoms (EPS) such as 
akathisia (subjective and observed restlessness), dystonia (muscular cramps), parkinsonism 
(resting tremor, bradykinesia, and rigidity) and tardive dyskinesia (repetitive and involuntary 
movements).6,7 Although these symptoms may have disparate pathophysiologies, they have 
been found to occur during high levels of striatal dopamine D2 receptor occupancy by 
antipsychotics, which was also associated with worse subjective experience and increased 
substance abuse.8,9,10,11 
The problem of antipsychotic-induced EPS is further compounded by the fact that 
schizophrenia is associated with a nearly 50% lifetime prevalence of substance use disorders 
(SUDs).12 An aggravation of EPS via administration of antipsychotics and/or some 
psychoactive substances (PAS) such as alcohol, cocaine, amphetamine and cannabis is 
conceivable because these compounds have effects on the basal ganglia – a group of 
subcortical nuclei which are vital for voluntarily movement.6 Cocaine and amphetamine 
stimulate striatal dopaminergic neurotransmission by blocking and reversing the dopamine 
transporter, respectively.13 However, their long-term abuse is associated with significant 
reduction in dopamine D2 receptor availability in the striatum that may last for months after 
detoxification,14 similar to the striatal dopaminergic deficit observed in Parkinson's disease.6 
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Studies in non-psychosis individuals have shown that cocaine abuse may produce 
extrapyramidal symptoms, including rigidity15 and parkinsonian resting tremor – a symptom 
that has been shown to last as long as 12 weeks into abstinence.16,17 Conversely, there is 
evidence that prior regular use of amphetamines is common in patients with Parkinson’s 
disease.18 In schizophrenia patients, studies have revealed that cocaine use is a major risk 
factor for dystonia, parkinsonism, dyskinesia and akathisia.19,20,21,22 
Alcohol acutely alters the functioning of the basal ganglia,23 and its long-term use 
produces anatomic and physiological changes in the striatum.24,25 In non-psychosis 
individuals, alcohol abuse was shown to produce enhanced body sway and essential tremor 
during acute and protracted withdrawal.16,26 In schizophrenia patients, alcohol abuse was 
found to be related to more severe orofacial dyskinesia and akathisia.27 
As for cannabis, there is evidence that inhalation of delta-9-tetrahydrocannabinol 
(THC) – the main psychoactive constituent of cannabis – reduced raclopride binding in the 
ventral striatum and the precommissural dorsal putamen, suggesting an increase in dopamine 
release.28 In schizophrenia patients, current cannabis use29 and intravenous THC30 aggravated 
the presence of tardive dyskinesia. On the other hand, there is evidence that cannabis smoking 
may serve as a protective factor against the development of dyskinesia.31 Altogether, our 
recent meta-analysis of studies investigating the effects of PAS abuse on EPS in patients 
dually diagnosed with schizophrenia and an SUD revealed that these patients had more severe 
EPS relative to non-PAS abusing schizophrenia patients; an effect that was most prominent in 
dually diagnosed cocaine abusers.32 Unfortunately, one of the major problems with the studies 
conducted thus far has been the lack of a non-psychosis drug abuser group, thereby preventing 
researchers from elucidating the respective contributions of antipsychotics and drugs of abuse 
on EPS in schizophrenia. For this purpose, the present study is the first of its kind to 
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investigate EPS and PAS abuse in all three groups (i.e. dually-diagnosed schizophrenia 
patients, non-PAS abusing schizophrenia patients and non-psychosis PAS abusers). 
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2.3 Methods 
Participants 
Three groups of participants were recruited, namely: (i) patients with schizophrenia-spectrum 
disorders (schizophrenia, schizo-affective disorder, schizophreniform disorder); (ii) non-
psychosis patients with SUDs in detoxification; and (iii) schizophrenia patients with comorbid 
SUDs. Psychiatric and SUD diagnoses were all based on DSM-IV criteria. Most SUD 
diagnoses were complemented with urine drug screenings (91% of patients). All participants 
signed a detailed consent form. The study was approved by the local ethics committee. 
 Patients in the dual-diagnosis schizophrenia group (DD; n=36) had one or more of the 
following substance use disorders (abuse or dependence): alcohol (n=19), cannabis (n=22), 
psychostimulants (cocaine and amphetamines) (n=11), hallucinogens (n=1) and phencyclidine 
(n=1), including 14 patients with poly-substance abuse/dependence. Substance 
abuse/dependence diagnoses were complemented with urine drug screenings. Patients were 
treated with one or more of the following antipsychotic: clozapine (n=1), olanzapine (n=22), 
risperidone (n=7), quetiapine (n=2), ziprasidone (1), haloperidol (n=4), flupenthixol (n=1) and 
other typical antipsychotics (n=6). 
 Non-PAS abusing schizophrenia patients (SCZ; n=41) were treated with one or more 
of the following antipsychotics: clozapine (n=7), olanzapine (n=9), risperidone (n=8), 
quetiapine (n=9), haloperidol (n=4), flupenthixol (n=2), and other typical antipsychotics 
(n=7). 
 As for non-psychosis substance-abusing patients (SUD; n=38), they had one or more 
of the following substance use disorders (abuse or dependence): (i) alcohol (n=25), cannabis 
(n=18), cocaine (n=12), amphetamines (n=4), opiates (n=2), and benzodiazepines (n=1) – 
including 16 individuals with poly-substance abuse/dependence. Substance abuse/dependence 
diagnoses were complemented with urine drug screenings. No patient in the SUD group had a 
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history of antipsychotic treatment at the moment of testing. There were 3 cases of substance-
induced psychosis in the SUD group; however, a reexamination of patients after 3 months 
revealed no cases of schizophrenia.  
 
Clinical assessments 
Psychiatric symptoms were measured using the Positive and Negative Syndrome Scale 
(PANSS)33 and the Calgary Depression Scale for Schizophrenia (CDSS).34 We chose the 
CDSS because it has previously been shown to exhibit little overlap with negative symptoms 
and EPS in schizophrenia35,36 and because it is less likely to over-estimate depressive 
symptoms in dual-diagnosis schizophrenia, compared to other scales, as shown previously by 
our group.37 For its’ part, the PANSS has previously been used to measure positive symptoms 
in various psychiatric disorders,38 including cases of drug-induced psychosis.39 EPS were 
evaluated with the Extrapyramidal Symptoms Rating Scale (ESRS).40 The ESRS provides a 
score for the patients’ subjective appraisal of his symptoms, objective scores for 
parkinsonism, dystonia and dyskinesia. Akathisia was evaluated with the Barnes Akathisia 
Scale.41 EPS were assessed by a well-trained physician (TP) with a unique expertise in 
psychiatry, neurology and addiction medicine. The screening of EPS was performed to 
distinguish EPS from symptoms resembling EPS. A particular effort was made to distinguish 
akathisia from pseudoakathisia; the latter being characterized by observed fidgety, restless 
movements without the subjective compulsion to move.42 Likewise, a particular effort was 
made to distinguish parkinsonian resting tremor from essential tremor, commonly associated 
with alcohol withdrawal.43 Finally, an experienced team of clinicians verified that DD patients 
were not intoxicated at the moment of clinical assessments. 
 
Statistical analyses 
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Differences in EPS and psychiatric symptoms between the DD, SCZ and SUD groups were 
analyzed using one-way analyses of variance (ANOVA) with group as the independent 
variable. Multiple comparisons were performed and p-values were adjusted using a 
Bonferroni correction. The potential influence of confounding factors was analyzed with 
analyses of covariance (ANCOVA). Dichotomous variables were evaluated using Pearson’s 
Chi-square test. The level of significance was set at p<0.05. Statistical analyses were 
performed using the Statistical Package for Social Sciences (version 14). 
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2.4 Results 
Extrapyramidal symptoms  
Between-group differences were found for parkinsonism, dyskinesia, and akathisia. Multiple 
comparisons revealed that DD (mean = 9.2 [13.5]) exhibited significantly more parkinsonism 
than SCZ patients (mean = 3.2 [3.9]; F= 4.711; p= 0.011). Dyskinesia was significantly higher 
in SCZ patients (mean = 1.6 [3.3]) than in SUD individuals (mean = 0.3 [1.0]; F= 3.755; p= 
0.026). Akathisia was significantly higher in SUD individuals (mean = 1.4 [1.2]) than in SCZ 
patients (mean = 0.6 [1.2]; F= 4.321; p= 0.016). No between-group differences were found for 
subjective extrapyramidal symptoms. 
Because we found that DD patients exhibited significantly more parkinsonism than 
SCZ patients, we performed sub-analyses to parcel out the contribution of specific PAS to 
these results. Sub-analyses revealed that the increase in parkinsonism in DD patients was 
related to alcohol (n=19) (F= 11.884; p= 0.001) and psychostimulants (n=11) (F= 14.618; p= 
0.0001). Because we found that SUD individuals exhibited significantly more akathisia than 
SCZ patients, we performed sub-analyses to parcel out the contribution of specific PAS to 
these results. Sub-analyses revealed that the increase in akathisia was related to alcohol 
(n=25) (F= 4.187; p= 0.047) and cannabis (n=18) (F= 13.604; p=0.001). 
 
Psychiatric symptoms 
Between-group differences were found for PANSS positive, negative and total scores as well 
as for CDSS scores. Multiple comparisons revealed that DD patients had significantly higher 
PANSS positive scores (mean = 18.8 [4.8]) than SUD individuals (mean = 15.4 [5.2]; F= 
4.498; p= 0.013). Both DD (mean = 16.4 [4.3]) and SCZ patients (mean = 18.7 [4.9]) had 
significantly higher PANSS negative scores than SUD individuals (mean = 13.6 [4.7]; 
F=10.966; p= 0.0001). PANSS total scores were significantly higher in DD patients (mean = 
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79.2 [10.3]) than in SUD individuals (mean = 69.5 [15.5]; F= 4.726; p= 0.011). CDSS scores 
were significantly higher in DD (mean = 7.2 [4.8]) and SUD individuals (mean = 6.7 [4.4]) 
SCZ patients (mean = 3.5 [3.8]; F= 8.440; p= 0.0001). No significant difference was found in 
PANSS general scores. 
 
Socio-demographic variables 
Between-group differences were found for age and number of hospitalizations. Multiple 
comparisons revealed that DD patients were significantly younger (mean [SD] = 31.4 [10.4]) 
than SCZ (mean = 37.8 [10.8]) and SUD individuals (mean = 37.9 [12.4]; F= 4.261; p= 
0.016). DD patients (mean = 2.9 [3.0]) also had significantly fewer hospitalizations than SCZ 
patients (5.1 [4.8], respectively; t= -2.245; p= 0.028). SUD individuals spent on average 
significantly more dollars on PAS (mean = 795.6$ [1748.6]) than DD patients (mean = $82.3 
[62.3]; F= 5.978; p= 0.017). DD and SCZ patients were outpatients, while SUD individuals 
were undergoing detoxification at an addiction treatment centre. The groups did not differ in 
terms of sex, ethnicity, psychiatric diagnosis, chlorpromazine equivalents, or anticholinergics 
(Table 1).  
In order to control for potential confounding factors that may have contributed to our 
results, ANCOVAs were performed on significant socio-demographic variables (age and 
number of hospitalizations). The between-group differences in dyskinesia disappeared after 
using hospitalizations as a covariate (p=0.086). All other previously significant differences in 
EPS remained significant (all p<0.05).  
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2.5 Discussion 
The present cross-sectional study is the first of its kind to examine EPS in dually-diagnosed 
schizophrenia patients, in non-PAS abusing schizophrenia patients and in non-psychosis PAS 
abusers.  Analysis of EPS – our primary outcome measure – revealed that DD patients 
displayed significantly more parkinsonism compared to SCZ patients, while SUD individuals 
displayed significantly more akathisia than SCZ patients. In terms of parkinsonism, sub-
analyses on specific PAS revealed that cocaine and alcohol abuse/dependence was 
significantly related to the severity of parkinsonian symptoms in DD patients. Consistent with 
our findings, previous studies in DD patients have shown cocaine use to be a major risk factor 
for parkinsonian symptoms. For example, Potvin et al.21 found that compared to abstinent 
patients, DD patients displayed greater parkinsonism, which was significantly associated with 
cocaine use. Likewise, Maat et al.22 demonstrated recent cocaine use to be significantly 
associated with the severity of parkinsonism in schizophrenia patients. For its part, alcohol 
was shown to produce parkinsonian-like symptoms in non-psychosis individuals during acute 
and protracted withdrawal.16,26 Here, we report increased parkinsonian symptoms in alcohol 
abusing DD patients, relative to SCZ patients. Together, these data suggest that there is a 
compounding effect on parkinsonism as a result of alcohol and/or cocaine abuse and 
antipsychotic treatment in DD patients. It is also interesting that SUD individuals displayed 
significant amounts of parkinsonism, suggesting that PAS abuse and treatment with 
antipsychotics do not differ in their liability to produce parkinsonian symptoms – at least in 
the short-term. 
In SUD individuals, we found significantly more akathisia relative to SCZ patients. 
Sub-analyses revealed that these symptoms were significantly related to alcohol and cannabis 
abuse/dependence. Previous studies in non-psychosis individuals have found alcohol 
withdrawal to be associated with the presence of restlessness44 and psychomotor unrest.45 In 
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addition to alcohol, our sub-analyses revealed that cannabis abuse was significantly associated 
with the presence of akathisia in SUD individuals. While not commonly associated with 
withdrawal symptoms in popular culture, heavy cannabis use has been shown to induce 
restlessness46 and physical tension/agitation during withdrawal; symptoms which may last as 
long as 28 days.47 Although the aforementioned studies did not distinguish between akathisia 
and pseudoakathisia, the present study did not score patients as having akathisia unless they 
complained of subjective restlessness, in addition to exhibiting observed, restless 
movements.42 Consequently, our results confirm the presence of moderate amounts of ‘true’ 
akathisia in alcohol and cannabis withdrawal and suggest that this symptom may be more 
severe – at least transiently – than akathisia resulting from antipsychotic treatment (mostly 
atypicals, here). 
Although counterintuitive, the finding that our SUD sample had more akathisia than 
our DD sample may be explained by the fact that the former individuals were undergoing 
detoxification, while the latter were active users. Moreover, DD patients in the present study 
spent significantly less money on PAS; a result that coincides with evidence that even 
infrequent use of small amounts of PAS can cause clinically relevant problems in individuals 
with schizophrenia48 – possibly due to sensitization of their reward system.49 
While previous studies have found abuse of PAS to be significantly associated with 
dyskinesia in DD patients21,22,50, this was not found in the present study. Interestingly, it was 
our SCZ patients that exhibited the most severe dyskinesia. One explanation for these findings 
is that our SCZ sample was significantly older than our DD sample, and consequently, these 
patients are expected to have been treated with antipsychotics for longer periods of time. 
Indeed, after controlling for the number of hospitalizations (an indirect measure of duration of 
antipsychotic treatment), the differences in dyskinesia disappeared.  
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No between-group differences were found for dystonia. This is consistent with the 
results of our meta-analysis which found a non-significant effect size for dystonia.32 It must 
also be considered that there was a low incidence of dystonia in our overall sample. In SUD 
individuals, there is evidence of dystonic reactions following concomitant administration of 
intravenous cocaine and high doses of the neuroleptic flupenthixol.51 In the present study, 
however, the majority of schizophrenia patients (DD and SCZ groups) were treated with 
atypical antipsychotics, some of which bind more loosely to dopamine-D2 receptors52; 
whereas SUD individuals were not undergoing antipsychotic treatment. Also noteworthy, 
both DD and SUD individuals were abusing mixed PAS, not stimulants specifically. 
Analysis of between-group differences in schizophrenia symptoms revealed that DD 
patients exhibited the highest PANSS positive and total scores of the three groups. These 
results are consistent with previous studies showing that PAS-abusing schizophrenia patients 
are at a greater risk for psychotic relapse than abstinent patients.32,53 Interestingly, the level of 
positive symptoms did not differ between SUD and SCZ patients. As such, this result 
confirms previous reports showing that psychotic reactions are common in patients with 
substance abuse/dependence.54 On the other hand, despite the high PANSS positive scores in 
SUD subjects in the present study, only 3 out of 40 subjects in the SUD group responded to a 
diagnosis of substance-induced psychotic disorder. This may be explained by the fact that 
insight was still present in most SUD subjects, even when experiencing symptoms such as 
paranoia. In addition, it must be considered that the PANSS is not a diagnostic tool. While the 
strength of the PANSS is its reliability and its low risk of creating type II errors, the scale may 
lack specificity.33 As for negative symptoms, the present study found that both DD and SCZ 
patients had significant amounts of negative symptoms, compared to SUD individuals – 
symptoms which may be resistant to antipsychotic treatment.55 These results suggest that, 
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unlike positive symptoms, negative symptoms may be more unique to schizophrenia rather 
than arising due to PAS abuse.56  
Finally, our results revealed that depression scores were significantly higher in DD 
and SUD individuals than in SCZ patients. Consistent with these results, previous studies 
found that DD patients have more depressive symptoms.37,57,58 In a similar vein, there is 
evidence that mood disorders and SUDs are often comorbid with each other, suggesting that 
individuals may abuse PAS in order to relieve depressive symptoms or that PAS abuse may 
lead to the development and/or exacerbation of these symptoms.59 Thus, our results add 
further support for a significant association between depression and abuse of PAS, both in 
psychosis and non-psychosis patients. Our results suggest that depressive symptoms are more 
strongly associated substance abuse than to schizophrenia – at least transiently. Assuredly, 
these results will need to be replicated by other groups. 
 
Limitations 
The present study has limitations. First, our DD and SUD samples differed in that the former 
were active PAS abusers, while the latter were undergoing detoxification. Additionally, the 
aforementioned groups differed in the amount of money spent on PAS, suggesting a different 
degree of abuse in these samples. The latter confound may be unavoidable, however, because 
schizophrenia only minimal quantities of PAS can cause clinically relevant changes in 
schizophrenia patients.48 Moreover, although the increased frequency of parkinsonism in the 
DD group could be due to the presence of more clozapine-treated patients in the SCZ group, 
only 4 out of 7 patients were taking clozapine as their sole antipsychotic in the SCZ group; the 
other 3 patients were administered clozapine in combination with another antipsychotic. 
Finally, the lack of follow-up of the present study prevents us from revealing the temporal 
relationship of PAS-induced EPS and whether they are transient or stable in time.  
48 
 
Conclusion 
Despite its limitations, the present study is the first of its kind to cross-sectionally examine 
EPS in the three groups (DD, SCZ and SUD). Indeed, all of the studies to date investigating 
the effects of antipsychotics and PAS on EPS in schizophrenia have lacked a group of 
antipsychotic-free non-psychosis PAS-abusers. Moreover, the present study contains a 
relatively large sample size (n=115) coupled with a careful clinical evaluation, paying 
particular attention to measuring EPS and not merely symptoms resembling EPS. We found 
that DD patients exhibit significantly more parkinsonian symptoms than SCZ patients and 
non-psychosis PAS abusers. Our sub-analyses revealed that cocaine and alcohol 
abuse/dependence was responsible for the increase in parkinsonism in DD patients. By 
contrast, we found that non-psychosis PAS abusers exhibit significantly more akathisia than 
the other two groups. In these latter individuals, sub-analyses revealed that alcohol and 
cannabis abuse/dependence was responsible for the increase in akathisia. In sum, our results 
demonstrate that PAS abuse is a contributor to EPS in individuals with and without 
schizophrenia. Future research should include a follow-up in order to elucidate the temporal 
relationship of PAS-induced EPS and to determine whether these symptoms are transient or 
stable through time. 
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3.1 Abstract 
Neurological and psychiatric symptoms are consequences of substance abuse in schizophrenia 
and non-schizophrenia patients. The present case–control study examined changes in substance 
abuse/dependence, and neurological and psychiatric symptoms in substance abusers with [dual 
diagnosis (DD) group, n=26] and without schizophrenia [substance use disorder (SUD) group, 
n=24] and in non-abusing schizophrenia patients (SCZ group, n=23) undergoing 12-week 
treatment with the atypical antipsychotic, quetiapine. Neurological and psychiatric symptoms 
were evaluated with the Positive and Negative Syndrome Scale, the Calgary Depression Scale 
for Schizophrenia, the Extrapyramidal Symptoms Rating Scale, and the Barnes Akathisia Rating 
Scale. At endpoint, DD and SCZ patients were receiving significantly higher doses of quetiapine 
(mean=554 and 478mg/day, respectively), relative to SUD patients (mean=150mg/day). We 
found that SUD patients showed greater improvement in weekly dollars spent on alcohol and 
drugs and SUD severity, compared to DD patients. At endpoint, there was no significant 
difference in dollars spent, but DD patients still had a higher mean SUD severity. Interestingly, 
DD patients had significantly higher parkinsonism and depression than SCZ patients at baseline 
and endpoint. On the other hand, we found that SUD patients had significantly more akathisia at 
baseline, improved more than SCZ patients, and this was related to cannabis abuse/dependence. 
Finally, SUD patients improved more in Positive and Negative Syndrome Scale positive scores 
than DD and SCZ patients. Taken together, our results provide evidence for increased 
vulnerability to the adverse effects of alcohol and drugs in schizophrenia patients. They also 
suggest that substance abuse/withdrawal may mimic some symptoms of schizophrenia. Future 
studies will need to determine the role quetiapine played in these improvements. 
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3.2 Introduction 
Schizophrenia is the most disabling psychiatric disorder, according to the Global Burden of 
Disease study (Eaton et al., 2008). Important contributors to disability in schizophrenia are 
psychiatric (e.g., positive, negative, and depressive symptoms) and neurological symptoms (e.g., 
parkinsonism, dyskinesia, and akathisia; Patterson et al., 1998; Villalta-Gil et al., 2006; Aubin et 
al., 2009). Compounding these problems is the nearly 50% lifetime prevalence of substance use 
disorder (SUD) associated with schizophrenia (Regier et al., 1990). In non-psychotic individuals, 
substance use is associated with neurological and psychiatric symptoms (Mauri et al., 2007; 
Zhornitsky et al., 2010a). In schizophrenia patients, substance use has a negative impact on the 
course of the pathology. Compared to non-abusing patients, dual diagnosis (DD) schizophrenia 
patients are more frequently hospitalized, non-compliant with treatment, suicidal, impulsive and 
violent, homeless and unemployed, and they have more legal and health problems (Mueser et al., 
1998; Negrete, 2003). Similarly, there is evidence that DD patients have more neurological and 
psychiatric symptoms than non-abusing schizophrenia patients (Bersani et al., 2005; Potvin et al., 
2007, 2009; Harrison et al., 2008). 
Current evidence suggests that atypical antipsychotic treatment is associated with 
improvements in psychiatric symptoms in schizophrenia (Lieberman et al., 2005; Lee et al., 
2009; Nakamura et al., 2009). Due to these benefits, as well as their low propensity to induce 
neurological symptoms, atypical antipsychotics are increasingly being tried as treatments for 
substance abuse in psychotic and non-psychotic patients (for review, see Zhornitsky et al., 
2010b). Indeed, previous studies in single- and DD patients suggest that atypical antipsychotics 
may lead to improvements in alcohol use disorder (Littrell et al., 2001; Martinotti et al., 2007, 
2009). Some studies have also found atypical antipsychotics to improve cannabis use disorder in 
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DD patients (Green et al., 2003; van Nimwegen et al., 2008). However, irrespective of their 
efficacy for actually relieving substance abuse, we know very little about the effects of atypical 
antipsychotics on neurological and psychiatric symptoms when prescribed to substance abusers 
with or without comorbid psychosis. This is an important area of study because any residual 
symptoms and deficits may act as negative reinforcers to maintain the cycle of addiction (Koob 
and Le Moal, 2001), and may impair their social functioning and quality of life (Addington and 
Addington, 1997; Lahmek et al., 2009). 
The present study examined substance use outcomes and neurological and psychiatric 
symptoms in substance abusers with and without schizophrenia and in non-abusing 
schizophrenia patients undergoing a 12-week treatment with the atypical antipsychotic 
quetiapine. This antipsychotic was chosen because it has previously been shown to improve 
substance use outcomes in psychotic and non-psychotic patients (Potvin et al., 2006a; Kampman 
et al., 2007; Martinotti et al., 2008; Rizkallah et al., 2010) and is an effective monotherapy for 
anxiety and depressive disorders (for review, see Zhornitsky et al., 2011), while also producing 
little or no neurological symptoms (Weiden, 2007). Importantly, this is the first study of its kind 
to trace the evolution of neurological and psychiatric symptoms in all three groups of patients 
undergoing a homogenous antipsychotic treatment. This study is complementary to earlier 
studies by Potvin et al. (2006a) and Rizkallah et al. (2010), which reported substance abuse and 
clinical outcomes for DD patients and non-schizophrenia substance abusers.  
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3.3 Methods 
Participants 
Three groups of participants were recruited, namely: (i) substance-abusing patients with 
schizophrenia-spectrum disorders (schizophrenia, schizoaffective disorder, schizophreniform 
disorder; DD group); (ii) non-psychotic substance abusers in detoxification (SUD group); and 
(iii) schizophrenia patients without comorbid substance abuse (SCZ group). Psychiatric and SUD 
diagnoses were by well-trained psychiatrists (Lahcen Aït Bentaleb, Olivier Lipp, and Emmanuel 
Stip) and physicians (Jean-Pierre Chiasson), and were all based on DSM-IV criteria. SUD 
diagnoses were complemented with urine drug screenings. In the SUD group, there were two 
diagnoses of borderline personality disorder and two diagnoses of substance-induced psychotic 
disorder (DSM-IV). All participants signed a detailed consent form. The study was approved by 
the local ethics committee. 
For all three groups, exclusion criteria were: (i) patients already on clozapine or 
quetiapine; (ii) patients hospitalized in a psychiatric unit; (iii) pregnancy; (iv) female subjects of 
childbearing potential or inadequate contraception; and (v) clinically meaningful unstable, renal, 
hepatic, cardiovascular, respiratory, cerebrovascular, or other serious, progressive physical 
disease. For the DD and SCZ groups, patients were excluded if their total score on the Positive 
and Negative Syndrome Scale (PANSS; Kay et al., 1987) was lower than 65. Adjuvant 
medications were allowed in all three groups. 
 
Clinical assessments 
Neurological symptoms were evaluated with the Extrapyramidal Symptoms Rating Scale (ESRS; 
Chouinard et al., 1980). Akathisia was evaluated with the Barnes Akathisia Scale (BAS; Barnes, 
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1989). Psychiatric symptoms were measured using the PANSS and the Calgary Depression Scale 
for Schizophrenia (CDSS; Addington et al., 1993). For more information on clinical assessments, 
refer to Potvin et al. (2006a). 
 
SUD assessments 
Quantities of substances used in the last week were also registered, using the TimeLine Follow-
Back (TLFB) procedure (Sobell and Sobell, 1992). Quantities used were noted for all substances. 
Amount spent on substances was calculated based on the value market in Quebec province 
(Canada). To complement our evaluation of SUDs, urine screenings were performed on weeks 0 
and 12, for cannabinoids, opiates, and psychostimulants. SUD severity was also evaluated using 
an adapted eight-item scale, based on DSM-IV criteria of substance dependence. Two trained 
students and a trained nurse scored [from 0 (no problem) to 5 (severe problem)] the patient's 
SUD severity on the following items: (1) loss of control; (2) time spent on PAS; (3) impact of 
SUDs on social life; (4) impact of SUDs on daily occupations; (5) physical impact of SUDs; (6) 
psychiatric impact of SUDs; (7) impact of SUDs on compliance; and (8) ability to enjoy 
pleasures other than substance use. For more information on SUD assessments, refer to Potvin et 
al. (2006a) and Rizkallah et al. (2010). 
 
Statistical analyses 
Baseline and endpoint differences between the DD, SCZ, and SUD groups were analyzed using 
one-way analyses of variance (ANOVA) with group as the independent variable. Changes in 
substance abuse, neurological and psychiatric symptoms were analyzed using mixed ANOVA 
with group as the independent variable and time as the repeated measure. Multiple comparisons 
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were performed using the Bonferroni correction. The influence of potential confounds on 
improvements in neurological and psychiatric symptoms were analyzed using analyses of 
covariance (ANCOVA). Dichotomous variables were evaluated using Pearson's Chi-square test. 
The level of significance was set at p<0.05. Last-observation carried forward (LOCF) was used. 
Statistical analyses were performed using the Predictive Analytics SoftWare (PASW; version 
18).  
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3.4 Results 
Participants 
Thirty-one DD patients were prescribed quetiapine; of these, two were lost-to-follow-up and 
three dropped out due to side-effects (Figure 1.). Twenty-five SCZ patients were prescribed 
quetiapine; of these, two were lost-to-follow-up. Thirty-three SUD patients were prescribed 
quetiapine; of these, two were lost-to-follow-up, two dropped out due to side-effects, three 
dropped out due to relapse, and clinical data was missing for two patients. Therefore, LOCF 
analysis was available for 26, 23, and 24 patients in the DD, SCZ, and SUD group, respectively. 
 
Sociodemographic variables 
Significant differences were found for age (F=5.5, p=0.006), gender (χ2=7.1, p=0.03), and 
quetiapine dose (F=22.1, p=0.0001) between the three groups (Table 1.). By contrast, no 
significant differences were found between the groups in ethnicity, psychiatric diagnosis, type of 
substance(s) used, number of hospitalizations, and baseline antipsychotic.  
 
Substance use outcomes 
Additionally, SUD patients had significantly higher SUD severity than DD patients at baseline 
(F=11.3, p=0.002), but DD patients had significantly higher SUD severity at endpoint (F=14.7, 
p<0.001; Table 2). Moreover, SUD patients spent significantly more dollars per week on alcohol 
and drugs at baseline (F=11.1, p=0.002), but there was no significant difference between the 
groups at endpoint. There was also a significant main effect of time for SUD severity (F=106.4, 
p<0.001) and dollars per week (F=21.5, p<0.001). Finally, SUD patients improved significantly 
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more than DD patients in SUD severity (F=41.7, p<0.001) and dollars per week (F=16, 
p<0.001).  
 
Neurological symptoms 
Dual diagnosis patients had significantly more parkinsonism than SCZ patients at baseline 
(F=3.6, p=0.03) and significantly more than SUD patients at endpoint (F=4.2, p=0.02; Table 3). 
In addition, SUD patients had significantly higher akathisia scores than SCZ patients at baseline 
(F=3.1, p=0.05), but not at endpoint. No significant differences were observed for dyskinesia at 
baseline or endpoint. Dystonia was not present in significant numbers in our sample (data not 
shown). Repeated measures analysis revealed that there was a main effect of time for 
parkinsonism (F=9.5, p=0.003) and akathisia (F=6.9, p=0.01), but not dyskinesia. Changes in 
parkinsonism and dyskinesia did not differ significantly between the groups. Akathisia improved 
significantly more from baseline to endpoint in SUD relative to DD and SCZ patients (F=5.3, 
p=0.02). The between-group differences in improvements in akathisia were no longer significant 
when changes in SUD outcomes were considered as covariates (p=n.s). Sub-analyses of drug-
specific effects revealed that improvements in akathisia in SUD patients were particular to 
cannabis abusers (F=7.2, p=0.01). They also revealed that improvements in parkinsonism in DD 
patients were particular to stimulant abusers (F=5.3, p=0.03).  
 
Psychiatric symptoms 
At baseline (F=13.7, p<0.001) and endpoint, DD and SCZ patients had significantly higher 
PANSS negative scores compared to SUD patients (F=23.6, p<0.001; Table 4). In addition, 
depression scores were significantly higher in DD compared to SCZ patients at baseline (F=3.2, 
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p=0.05). Moreover, they were significantly higher in DD compared to SCZ and SUD patients at 
endpoint (F=5.7, p=0.005). No differences were observed in PANSS positive scores at baseline; 
however, PANSS positive symptoms were significantly higher in DD and SCZ patients at 
endpoint (F=16.9, p<0.001). Repeated measures analysis revealed that was a significant main 
effect of time for PANSS positive (F=38, p<0.001) and negative symptoms (F=28.7, p<0.001) as 
well as depression (F=36.6, p<0.001; Table 4). Changes in negative and depressive symptoms 
did not differ significantly between the groups (Table 4). However, PANSS positive symptoms 
improved significantly more in SUD patients from baseline to endpoint, compared to DD and 
SCZ patients (F=5.3, p=0.007). There was no effect of age, gender, and dose when these 
variables were entered into the ANCOVA model. However, the finding of a greater improvement 
in positive symptoms in SUD patients disappeared after changes in SUD severity in time were 
considered as a covariate (p=n.s).  
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3.5 Discussion 
The present study aimed to examine changes in substance use, as well as neurological symptoms 
and psychiatric symptoms in substance abusers with and without schizophrenia and in non-
abusing schizophrenia patients undergoing 12-week treatment with quetiapine We found that 
SUD patients had a higher mean SUD severity, spent significantly more dollars weekly on 
alcohol and drugs at baseline and showed greater improvement in these variables, compared to 
DD patients. Nevertheless, at endpoint, there was no significant difference in dollars spent, but 
DD patients still had a higher mean SUD severity. Interestingly, DD patients had significantly 
higher parkinsonism and depression than SCZ patients at baseline and endpoint. On the other 
hand, we found that SUD patients had significantly more akathisia at baseline, improved more 
than SCZ patients and this was related to cannabis abuse/dependence. Finally, there were no 
significant differences in PANSS positive scores between the groups; however, SUD patients 
improved more and the differences were significant at endpoint. 
In the present study, we found that SUD patients improved more in terms of SUD 
outcomes than DD patients. One explanation for this result could be that SUD patients had a 
significantly higher SUD severity at baseline, leading to the greater improvement. In addition, 
our SUD group began the study in detoxification, whereas our DD group were active users, 
suggesting that it was easier for the former patients to quit alcohol and/or drugs. Alternatively, 
these results suggest that it may be more difficult for schizophrenia patients to reduce or quit 
their substance use (Ziedonis et al., 2005). Importantly, DD patients still had a higher mean SUD 
severity than SUD patients at endpoint, despite spending similar amounts on alcohol and drugs. 
This finding is consistent with reports that substance abuse can have negative consequences on 
schizophrenia patients even when they use small amounts, infrequently (Ziedonis et al., 2005). It 
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is also consistent with evidence of increased dopaminergic sensitivity in schizophrenia. Indeed, 
PET studies have reported increased D2/D3 occupancy in schizophrenia patients in response to 
amphetamine challenge, relative to healthy controls (Laruelle et al., 1996; Abi-Dargham et al., 
1998). 
In terms of EPS, we found that DD patients had elevated parkinsonism at baseline, 
relative to SCZ and SUD patients, despite using significantly smaller quantities of alcohol and/or 
drugs. At endpoint, DD patients still had elevated parkinsonism relative to the other two groups, 
although they were taking similar amounts of these substances relative to SUD patients. 
Interestingly, a subanalysis revealed that improvements in parkinsonism were only significant in 
abusers of psychostimulants in the DD group. Obviously, the increase in parkinsonism in DD 
patients, relative to SUD patients, may be attributed to the fact that schizophrenia patients 
concomitantly take antipsychotics, which may interact with psychostimulants to increase 
parkinsonism (Potvin et al., 2006b; Maat et al., 2008). Indeed – when given acutely – cocaine 
and amphetamine stimulate striatal dopaminergic neurotransmission by blocking and reversing 
the dopamine transporter, respectively. However, their long-term abuse is associated with 
significant reduction in dopamine D2 receptor availability in the striatum that may last for 
months after detoxification, similar to the striatal dopaminergic deficit observed in Parkinson's 
disease (Volkow et al., 2004). Taken together, these results suggest that schizophrenia patients 
are more vulnerable to develop parkinsonism than SUD patients, even when taking small 
amounts of psychostimulants. 
An unexpected result of the present study is the elevated akathisia at baseline in SUD 
patients. Intriguingly, a subanalysis revealed that the improvements in akathisia were found in 
cannabis abusers, which is consistent with reports of restlessness and physical tension/agitation 
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among patients undergoing cannabis withdrawal (Kouri and Pope, 2000; Budney et al., 2003). 
Moreover, we found that akathisia improved significantly more in SUD patients, relative to SCZ 
patients, which is consistent with previous accounts of cannabinoid withdrawal. Overall, these 
results suggest that the endogenous cannabinoid system plays a role in the manifestation of 
akathisia, which may be related to its role in motor behavior (El Manira and Kyriakatos, 2010). 
Analysis of psychiatric symptoms revealed that DD and SCZ patients had significantly 
more negative symptoms, relative to SUD patients at baseline and endpoint. This is consistent 
with evidence suggesting that negative symptoms are relatively unique to schizophrenia 
(Zhornitsky et al., 2010a). By contrast, we found that depressive symptoms were nearly twice as 
high in DD and over one and a half times higher in SUD compared to SCZ patients. This finding 
is in line with research showing that substance abuse is a risk factor for the development of 
depression (Lynskey et al., 2004; Falck et al., 2006; Pozzi et al., 2008) as well as with a meta-
analysis of 3283 patients showing that addicted schizophrenia patients experience more severe 
depressive symptoms compared to non-abusing patients (Potvin et al., 2007). At study endpoint, 
depression scores were persistently elevated in DD patients. Taken together, these results are 
consistent with increased vulnerability in schizophrenia patients in response to drugs of abuse. 
Finally, at baseline – but not at endpoint – we found that all three groups had equally significant 
levels of positive symptoms, which is consistent with observations of elevated positive 
symptoms in non-schizophrenia substance abusers (Mauri et al., 2007; Lapworth et al., 2009). 
Interestingly, however, despite their high levels of positive symptoms, only two SUD patients 
responded to substance-induced psychosis criteria (SIPD; DSM-IV). Since the DSM-IV notes 
that a patient must have persistent delusions or hallucinations coupled with a lack of insight to be 
diagnosed with SIPD, we examined in more detail which PANSS positive items were most 
71 
 
 
 
elevated at baseline in our SUD group. We found that the most elevated items (mean score ≈3) 
were hostility, excitement and paranoia/suspiciousness; symptoms which may manifest during 
post-intoxication or withdrawal but do not signify the presence of SIPD, according to the DSM-
IV (Unnithan and Cutting, 1992; West and Gossop, 1994; Rosenthal et al., 1998; Mathias et al., 
2008). Moreover, the fact that positive symptoms showed greater improvement in SUD patients, 
relative to DD and SCZ patients, is likely linked to their greater improvement in substance abuse 
outcomes. Taken together, our findings suggest that paranoia is not a symptom which reliably 
distinguishes between schizophrenia and SUD patients, when the latter individuals are 
undergoing withdrawal. 
Improvements in neurologic and psychiatric symptoms did not differ between DD and 
SCZ patients, meaning that DD patients can improve in time as much as SCZ patients, as long as 
they significantly decrease their drug consumption – a finding that is consistent with previous 
reports (Conley et al., 1998; Swartz et al., 2008). Thus, it is not necessarily true that DD patients 
are doomed to have a worse prognosis than SCZ patients (Mueser et al., 1998; Negrete, 2003); 
rather, our results suggest that similar rates of improvements in psychiatric symptoms can be 
expected when DD patients diminish their substance use. However, in DD patients who maintain 
their substance use, this could prove otherwise. Indeed, there is evidence from non-
pharmacological studies that psychotic patients who maintain their substance use have more 
severe depression, more positive symptoms, poorer functional outcome, and greater rates of 
relapse at 1 year follow-up, relative to non-users and those who maintain abstinence (Turkington 
et al., 2009). 
The present study contains both strengths and limitations. Importantly, this is the first 
study of its kind to trace the evolution of substance abuse, neurological and psychiatric 
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symptoms in DD, SCZ, and SUD patients undergoing a homogenous antipsychotic treatment. 
However, this pilot study was not powered to detect complex interactions between 
sociodemographic, psychiatric, neurologic, and SUD variables. The study is also limited because 
the design does not permit us to deduce whether or not quetiapine played a significant role in the 
improvements in psychiatric symptoms in SUD patients. Interestingly, there is evidence to 
suggest that low-dose quetiapine is a highly effective anxiolytic and antidepressant and may 
possess mild antipsychotic activity as well (Fabre et al., 1995; Arvanitis and Miller, 1997; Cutler 
et al., 2009; Bandelow et al., 2010; see Zhornitsky et al., 2011 for review). However, we entered 
dose into the ANCOVA model and it showed no significant effect for any of our results. Other 
potential confounds such as age and gender also did not affect our results. By contrast, SUD 
severity was a significant factor in the ANCOVA models and is likely related to the fact that our 
SUD patients were recruited when they entered into detoxification, whereas our DD patients 
were active users. Thus, differences in changes in neurological and psychiatric symptoms 
between SUD patients and the other two groups seem to be intoxication/withdrawal-related 
phenomena. Future studies should take more frequent measurements (e.g., every 3 weeks) of 
psychiatric symptoms and EPS, in order to better elucidate the temporal relationship in 
improvements of these variables. The contribution of quetiapine in the psychiatric and 
neurologic symptoms reported here will also need to be elucidated. 
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Figure 1. Participant disposition  
 
ITT, intention-to-treat; LOCF, last-observation carried forward; DD, dual diagnosis group; SCZ, non-
abusing schizophrenia group; SUD, non-schizophrenia substance abuser group. 
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Table 1: Sociodemographic variables 
Variable (mean, SD) 
 
Statistics (multiple 
comparisons)* 
Age (years) 
           DD 
           SCZ 
           SUD 
 
30.5 (9.5) 
40.6 (12.4) 
37.5 (11) 
 
F=5.5; p=0.006 (SCZ > DD) 
Gender  
           DD 
           SCZ 
           SUD 
         
24 Male: 2 Female 
15Male: 8 Female  
15Male: 9 Female  
 
χ²=7.1, p=0.03 
Ethnicity 
          DD 
          SCZ 
          SUD 
 
24 Caucasian: 2 other 
20 Caucasian: 3 other 
20 Caucasian: 4 other 
 
χ²=1, p=0.6 
Quetiapine dose (mg/d) 
          DD 
          SCZ 
          SUD 
 
553.9 (254.9) 
478.3 (272) 
150 (117.7) 
 
F=22.1; p=0.0001 (DD & 
SCZ > SUD) 
Hospitalizations 
         DD 
         SCZ 
         SUD 
 
2.8 (3) 
3.6 (3.7) 
--- 
 
F=0.8; p=0.4 
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Diagnosis 
         DD 
         SCZ 
         SUD 
 
15SZ:9SA:2SF 
13SZ:5SA:1SF 
--- 
 
χ²=0.5, p=0.8 
Baseline antipsychotic 
(atypical:typical:both:drug-free)+ 
         DD 
         SCZ 
         SUD 
 
 
18:4:3:1 
14:4:0:3 
--- 
 
 
χ²=4, p=0.3 
Alcohol abuse/dependence  
 
         DD 
         SCZ 
         SUD 
 
 
12 YES: 14 NO 
--- 
13 YES: 11 NO 
 
 
χ²=0.3; p=0.6 
Cannabis abuse/dependence  
        DD 
        SCZ 
        SUD 
 
15 YES: 11 NO 
--- 
15 YES: 9 NO 
 
χ²=0.1; p=0.7 
Stimulant abuse/dependence  
        DD 
        SCZ 
        SUD 
 
9 YES: 17 NO 
--- 
10 YES: 14 NO 
 
χ²=0.3; p=0.6 
Multi-substance abuse/dependence   
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        DD 
        SCZ 
        SUD 
10 YES: 16 NO 
--- 
14 YES: 10 NO 
χ²=2; p=0.2 
SZ = schizophrenia; SA = schizoaffective disorder; SF = schizophreniform disorder; + = missing data 
for one subject in SCZ group; DD = dual diagnosis group, SCZ = non-abusing schizophrenia group, 
SUD = non-schizophrenia substance abuser group, *Bonferroni correction.
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Table 2: SUD outcomes 
Variable  Baseline 
(mean, SD) 
Endpoint 
(mean, SD) 
Statistics (multiple comparisons*) 
SUD severity 
DD 
SUD 
 
22.1 (4.4) 
28.3 (7.9) 
 
17.2 (7.7) 
7.1 (10.4) 
Baseline: F=11.3; p=0.002 
Time: F=106.4; p<0.001 
Group x Time: F=41.7; p<0.001 
Endpoint: F=14.7; p<0.001 
Dollars per week 
DD 
SUD 
         
93.4 (65.4) 
467.1 (546.3)   
    
61.8 (60) 
34 (72.7) 
Baseline: F=11.1; p=0.002 
Time: F=21.5; p<0.001 
Group x Time: F=16; p<0.001 
Endpoint: F=2.1; p=0.2 
DD = dual diagnosis group, SCZ = non-abusing schizophrenia group, SUD = non-schizophrenia substance abuser group, 
*Bonferroni correction. 
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Table 3: Neurological symptoms at baseline and endpoint  
Variable Baseline 
(mean, SD) 
Endpoint 
(mean, SD) 
Statistics (multiple comparisons*) 
Parkinsonism 
DD  
SCZ 
SUD 
    
9.7 (14.1) 
2.5 (2.6)  
5.7 (6.9) 
   
4.7 (5.9) 
2.1 (2.4) 
1.5 (3.4) 
Baseline: F=3.6; p=0.03 (DD > SCZ) 
Time: F=9.5; p=0.003  
Group x Time: F=1.8; p=0.2 
Endpoint: F=4.2; p=0.02 (DD > SUD) 
Akathisia 
DD 
SCZ 
SUD 
 
0.7 (0.9) 
0.6 (1.1) 
1.3 (1.2) 
  
0.4 (0.6) 
0.7 (1.2) 
0.3 (0.7) 
Baseline: F=3.1; p=0.05 (SUD > SCZ#) 
Time: F=6.9; p=0.01 
Group x Time: F=5.3; p=0.02 (SUD > SCZ) 
Endpoint: F=1; p=0.4 
Dyskinesia 
DD 
SCZ 
SUD 
 
0.7 (1.8) 
1.9 (3.4) 
0.4 (1.1) 
 
0.2 (0.7) 
1.4 (3.3) 
0.5 (1.3) 
Baseline: F=2.7; p=0.07 
Time: F=1.1; p=0.3 
Group x Time: F=0.4; p=0.7 
Endpoint: F=2.5; p=0.09 
DD = dual diagnosis group, SCZ = non-abusing schizophrenia group, SUD = non-schizophrenia substance abuser group, *Bonferroni 
correction; # = LSD correction. 
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Table 4: Psychiatric symptoms at baseline and endpoint  
Variable Baseline 
(mean, SD) 
Endpoint 
(mean, SD) 
Statistics (multiple comparisons*) 
PANSS positive 
DD  
SCZ  
SUD  
    
18.3 (4.3) 
17.1 (4.3) 
16.2 (5.4) 
   
15.6 (4) 
15.3 (4.3) 
10 (2.7) 
Baseline: F=1.4; p=0.3 
Time: F=38; p<0.001 
Group x Time: F=5.3; p=0.007 (SUD > DD & SCZ) 
Endpoint: F=16.9; p<0.001 (DD & SCZ > SUD) 
PANSS negative 
DD 
SCZ 
SUD 
 
19.5 (4.8) 
17.1 (4.8) 
12.5 (4.8) 
  
16.4 (5) 
16.4 (4.7) 
8.9 (3.2) 
Baseline: F=13.7; p<0.001 (DD & SCZ > SUD) 
Time: F=28.7 p<0.001 
Group x Time: F=2.3; p=0.1 
Endpoint: F=23.6; p<0.001 (DD & SCZ > SUD) 
Depression 
DD 
SCZ 
SUD 
 
6.8 (5) 
3.6 (4.6) 
6 (4.1)            
    
3.9 (3.6) 
1.2 (1.6)  
1.8 (3.1) 
Baseline: F=3.2; p=0.05 (DD > SCZ) 
Time: F=36.6; p<0.001 
Group x Time: F=1.1; p=0.4 
Endpoint: F=5.7; p=0.005; (DD > SCZ & SUD) 
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DD = dual diagnosis group, SCZ = non-abusing schizophrenia group, SUD = non-schizophrenia substance abuser group, PANSS = 
Positive and Negative Syndrome Scale. *Bonferroni correction. 
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4.1 Abstract 
Objective Substance use disorders (SUDs) are associated with a variety of psychiatric 
disorders and mood and behavioural instability. Growing evidence suggests that the atypical 
antipsychotic quetiapine may be useful in the treatment of SUDs. The primary objective of 
the current open-label trial was to examine the effects of quetiapine on SUD outcomes in 
patients entering detoxification. Methods Thirty-three non-psychosis SUD patients 
participated. Patients received quetiapine for a 12-weeks beginning in detoxification. Craving, 
quantities used and psychiatric symptoms were evaluated on baseline and at end-point. 
Results Out of 33 recruited patients, 26 completed more than 9 weeks of treatment. Last 
observation carried forward analyses revealed that craving, SUD severity and quantities used 
improved during the study. Psychiatric and depressive symptoms also improved. Conclusions 
Our results cannot be attributed per se to the pharmacological effects of quetiapine due to the 
open-label design of the study; the small sample size involved and the fact that patients were 
involved in an intensive therapy program. Nevertheless, our results suggest that quetiapine 
may be helpful for the treatment of SUD patients entering detoxification. Controlled studies 
are warranted to determine whether these results are quetiapine-related. 
 
 
Key words quetiapine – substance use disorders – psychiatric symptoms – detoxification – 
atypical antipsychotic 
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4.2 Introduction 
Second-generation antipsychotics (SGAs) are attracting growing interest for the treatment of 
substance use disorders (SUDs). So far, SGAs have shown some benefit over first-generation 
antipsychotics (FGAs) for the treatment of SUDs in patients with schizophrenia or bipolar 
disorder. SGAs have also been tried in non-psychosis substance abusers, with mixed results.1,2 
Preliminary evidence suggests that among SGAs, quetiapine is associated with some of the 
most promising results, particularly during the period of detoxification.3-7 During this period, 
SUD patients often develop psychiatric symptoms, including insomnia, depression, anxiety, 
and psychotic reactions.8-9 Interestingly, in addition to its antipsychotic properties, quetiapine 
has been shown to possess significant sedative, anxiolytic and antidepressant effects.10-11 It is 
perhaps due to these nonspecific effects (rather than owing to a specific mechanism such as 
methadone for heroin dependence) that quetiapine has been shown to be a beneficial treatment 
for withdrawal from a diverse range of addictive substances, such as stimulants, alcohol, and 
opiates.4-6 Nevertheless, only a few retrospective studies have examined the potential efficacy 
of quetiapine in such a context.4-6 
The primary objective of the current open-label, naturalistic trial was to examine the 
effects of quetiapine on SUD outcomes in patients with SUDs entering detoxification. 
Secondary objectives included the examination of clinical and tolerability outcomes. 
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4.3 Methods 
Participants 
Patients with SUD (abuse and/or dependence) (last 3 months) of alcohol, cannabis, cocaine 
and/or amphetamines were diagnosed, based on DSM-IV, by a physician trained in addiction 
medicine (JPC). SUD patients who were using one or multiple substances were included. 
Multiple substance abusers were included for three reasons: (i) abuse of multiple substances is 
very common;12 (ii) its pharmacological treatment is an unmet clinical need raising growing 
concerns;13 and (iii) the potential usefulness of quetiapine during detoxification may be 
attributed to general benefits (antipsychotic, anxiolytic, and antidepressant effects).10-11 All 
patients signed a detailed informed consent form. The study was approved by the local 
scientific and ethics committee. 
 Exclusion criteria were: (1) patients already on quetiapine or clozapine; (2) pregnancy; 
(3) female subjects of childbearing potential without adequate contraception; (4) other axis-I 
psychiatric disorders such as bipolar disorder or schizophrenia spectrum disorders; and (5) 
any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory, cerebrovascular 
disease or other serious, progressive physical disease. Diabetic patients were also excluded 
from the study. Patients were given quetiapine (IR or XR) for a 12-week open-label trial. 
Quetiapine was introduced when patients entered a 2- to 4- week detoxification program.  
Along with their participation in the study, patients were administered one-to-two 
hours a week of individualized inpatient therapy for up to four weeks. Thirty-three patients 
with a diagnosis of SUD were recruited for inclusion in the trial. Out of the 33 recruited 
patients 26 completed more than 9 weeks of treatment.  Seven patients were dropouts, for the 
following reasons: relapse (n=3), lost-to-follow-up without relapse (n=3), and medication not 
well-tolerated (n=1). Twenty-four patients completed the whole trial and two patients 
abandoned the study after 9 weeks. Both 9- and 12-week completers (26 patients) were 
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included in the last observation carried forward (LOCF) analyses. The mean dose of 
quetiapine at endpoint was 150mg ±113.8 [Note: Compliance to quetiapine was assessed via 
pill count and pharmacological records at the clinical setting]. Concomitant medications were 
allowed, except for other antipsychotics. Socio-demographic data, diagnostic data and data 
about medication for these patients are presented in Table 1. 
 
Clinical assessments 
To measure SUDs (all substances), several instruments were administered at baseline (week 
0) and end-point (week 12). The craving of patients for their drug(s) of choice in the last week 
was assessed using a visual analog scale (VAS) (from 0 –no craving– to 100% -most intense 
craving imaginable). Quantities of substances used in the last week were also registered, using 
the TimeLine Follow-Back (TLFB) procedure.14 Quantities used were noted for all 
substances. Amount spent on substances was calculated based on the value market in Quebec 
province (Canada). Apart from craving and substance use, SUD severity was measured with 
the Alcohol, and Drug Use Scales (AUS, and DUS) on baseline and end-point.15 The AUS 
and DUS are five-point scales based on DSM-IV criteria for severity of disorder: 
1=abstinence, 2=use without impairment, 3=abuse, 4=dependence and 5=severe dependence. 
To complement our evaluation of SUDs, urine screenings were performed on weeks 0 and 12, 
for cannabinoids, opiates, phencyclidine, and psychostimulants. In the case of alcohol, plasma 
gamma-glutamyltransferase (GGT) levels were assessed on baseline and at end-point. 
 Psychiatric and depressive symptoms were evaluated, with the Positive and Negative 
Syndrome Scale (PANSS)16 and the Calgary Depression Scale for Schizophrenia (CDSS),17 
respectively, on baseline and at end-point, by a trained physician (TP). The PANSS was 
chosen because it was previously used to measure positive symptoms in SUD patients.8,18 In 
addition, the PANSS is widely considered to be superior to the Brief Psychiatric Rating Scale 
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(BPRS) for measurement of negative symptoms, which are common during withdrawal from 
addictive substances.8-9 Along with the PANSS, the CDSS was used because the present study 
was part of a larger study comparing substance abusers with and without schizophrenia and 
non-abusing schizophrenia patients.19 However, the Beck Depression Inventory Second 
Edition (BDI-II)20 was applied at baseline, and correlated significantly with the CDSS 
(r=0.43; p=0.03), suggesting that the latter scale can be reliably used to measure depressive 
symptoms in SUD patients without comorbid psychosis. 
 
Statistical analyses 
Changes in SUD outcomes, psychiatric symptoms, and medical variables during quetiapine 
treatment were evaluated using repeated-measures analyses of variance (ANOVAs). The level 
of significance was set at p<0.05 for all analyses. 
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4.4 Results 
Substance use disorders 
Of the 26 patients included in the LOCF analyses, alcohol was the drug of choice for 6 
patients, cannabis for 14 patients, and stimulants for 9 patients. Nineteen patients used alcohol 
during the study, 15 patients used cannabis, and 12 used stimulants. 
 Overall, improvements on the AUS and the DUS, as well as a decrease in the weekly 
dollars spent on all substances were observed (Table 2). Craving for alcohol improved 
significantly over time on. Weekly money spent on alcohol significantly decreased from 
baseline to endpoint (84.2 [78.2] vs. 11.1 [25.3]; p=0.0001), but there was no change in 
plasma GGT levels (Table 2). Craving for cannabis (Table 2) and weekly money spent on 
cannabis significantly decreased from baseline to endpoint (178.7 [173.9] vs. 0.4 [1.1]; 
p=0.001). Likewise, craving for stimulants (Table 2) significantly diminished during 
quetiapine therapy from baseline to endpoint as did weekly money spent on stimulants (722.5 
[628.7] vs. 50 [97.8]; p=0.002).  
 Twenty one positive urine screening were detected before treatment with quetiapine, 
such as amphetamine (n=2), cannabis (n=13) and cocaine (n=4). Only two positive screenings 
following treatment with quetiapine were noted: cocaine (n=2). Also noteworthy, before 
quetiapine, 5 patients required treatment with benzodiazepines, whereas only 1 patient still 
received such treatment at study end-point. 
- insert Table 2 here - 
 
Psychiatric symptoms  
There were significant improvements from baseline in PANSS-positive, negative and general 
symptoms during quetiapine therapy. A significant improvement in depressive symptoms was 
also observed on the CDSS (Table 2). 
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Tolerability 
Quetiapine was generally well tolerated and no patients developed cardiometabolic issues. 
The most frequent side-effects reported by the participants during the study were: somnolence 
(n=10), dizziness (n=7), dry mouth (n=5), constipation (n=4), headaches (n=5), fatigue (n=4), 
hypersalivation (n=2), sedation (n=4), palpitations (n=3), blurred vision (n=3) and jointure 
pain (n=2). No patient “misused” quetiapine. 
 Prolactin levels did not increase significantly during quetiapine therapy. No significant 
changes in heart rate were observed. Weight gain was, however, noticed during quetiapine 
therapy (Table 2). 
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4.5 Discussion  
Results from this open-label, naturalistic trial, suggest that quetiapine may be beneficial for 
controlling withdrawal symptoms and promoting abstinence in non-psychosis patients with 
SUDs. During quetiapine therapy, SUD outcomes (quantities used & severity of SUDs and 
craving) significantly improved over time and this was corroborated by urine screenings. 
Although there was no correlation between changes in plasma GGT and reduced alcohol 
consumption, there is evidence that quetiapine may cause asymptomatic increase in liver 
enzymes,21 which could explain this result.  
Our findings are consistent with other reports of quetiapine’s efficacy in the treatment 
of SUDs in psychosis and non-psychosis patients.3-7,22,23 In psychosis patients, quetiapine was 
found to decrease severity of substance abuse and craving.22,23 In non-psychosis patients, 
quetiapine decreased drinking in Type B alcoholics during post-detoxification.3 Moreover, 
quetiapine decreased craving and promoted abstinence in alcohol and psychostimulant 
abusers during withdrawal.5 Overall, the present study adds to the growing literature detailing 
the potential utility of this medication for the treatment of SUDs, especially during the period 
of detoxification. However, we cannot be certain whether the improvements were quetiapine-
related, or whether they were due to the decrease in substance use as well as the 
psychotherapy that patients received.  
The significant decrease in benzodiazepine use during treatment is worthy of mention. 
Although benzodiazepines are considered the drugs of choice for the treatment of acute 
alcohol withdrawal, their use as a long-term treatment of individuals with SUD is generally 
discouraged, because of potential cross-tolerance with alcohol and their potential of misuse.24-
26 Here, the anxiolytic effects of quetiapine may have rendered the use of benzodiazepines 
less necessary use, as previously reported by Pinkofsky et al.6 
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During quetiapine therapy, we observed improvements in positive, negative, general 
and depressive symptoms. Previous research found that quetiapine decreased depression, 
anxiety and agitation in patients undergoing detoxification.6 Moreover, there is evidence that 
two weeks’ quetiapine treatment improved positive, negative and depressive symptoms in 
individuals with cannabis and cocaine-induced psychosis.8 As a whole, findings of the present 
study suggest that quetiapine may be beneficial for the treatment of psychiatric symptoms in 
substance abusers. Alternatively, psychiatric symptoms may have improved during the study 
simply because patients substantially decreased their substance use as well as their 
involvement in intensive therapy. 
Quetiapine was generally well-tolerated among patients. No serious adverse events 
were reported, and only one subject did not tolerate the treatment. Prolactin did not increase 
during treatment. Patients significantly gained weight during the study, which may be 
quetiapine-related or due to an overall diminution of substance abuse. Taken together, these 
results are consistent with data showing that quetiapine is associated with low-to-moderate 
weight gain and little-to-no increase in prolactin.27-29 
 
Conclusion 
Our results cannot be attributed per se to the pharmacological effects of quetiapine, for three 
main reasons: (1) the open-label design of the study; (2) the small sample size involved; and 
(3) the fact that patients were involved in an intensive therapy program. Another limitation of 
the present pilot study is that we did not perform a correction for multiple comparisons, thus 
potentially leading us to commit a Type-I error(s). Finally, although the current study 
administered the CDSS – a scale used to measure depressive symptoms in schizophrenia – it 
correlated significantly with the BDI at baseline, suggesting that it can be used to measure 
depression in non-schizophrenia patients. Nevertheless, despite these limitations, the present 
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study is the first to prospectively administer quetiapine during detoxification, and the first to 
investigate the use of SGAs for cannabis use disorder in non-psychosis patients. Our results 
offer support for the potential benefits of quetiapine in the treatment of psychiatric symptoms 
associated with drug and alcohol withdrawal as well as in helping to maintain abstinence. 
This study encourages further evaluation of quetiapine in non-psychosis SUD patients during 
detoxification.  
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Table 1: Participants’ characteristics (n=26) 
Age, in years  
(mean, SD) 
36.6±11.1 
Sex 17 Males, 9 Females 
Ethnicity 24 Caucasian 
Education level, in years 14.2 ± 2.5 
Duration of SUDs 11.4 ±8.6 
Psychiatric diagnoses Borderline personality disorder (n=2) 
Substance-induced psychotic disorder (n=3) 
SUD diagnoses Alcohol abuse / dependence (n=12) 
Amphetamine abuse / dependence (n=2) 
Cannabis abuse / dependence (n=16) 
Cocaine abuse / dependence (n=9) 
MDMA abuse (n=1) 
Adjuvant medications Anticonvulsants (n=3) 
Antidepressants (n=5) 
Beta-blockers (n=2) 
Benzodiazepines (n=1) 
MDMA= methylene-dioxy-methamphetamine; SUD= substance use disorder 
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Table 2: Substance use, psychiatric and tolerability outcomes during quetiapine therapy 
Variable  Baseline (mean, SD) LOCF* (mean, SD) Statistics 
Craving (visual analog scale) (n=26) 
Alcohol 69.2 (30.7) 21.7 (30.6) F=11.5; p=0.02 
Cannabis 75 (25.3) 15.7 (21.7) F=41.8; p=0.0001 
Stimulants 90.6 (19.4) 31.1 (33) F=33.4; p=0.0001 
Substance use (n=26) 
Mean $ (all substances) 498 (556) 31.4 (70.3) F=22.1; p=0.0001 
AUS 2.8 (1.4) 1.8 (0.9) F=15; p=0.001 
DUS 3.7 (1.5) 1.5 (0.8) F=66.5; p=0.0001 
Psychiatric symptoms (n=24) 
PANSS-positive  16.2 (5.4) 10 (2.7) F=33.4; p= 0.0001 
PANSS-negative 12.5 (4.8) 8.9 (3.2) F=11.7; p= 0.002 
PANSS-general 39.7 (8.9) 26.8 (9.6) F=25; p= 0.0001 
CDSS 6 (4.1) 1.8 (3.1) F=17.2; p= 0.0001 
Tolerability (n=24) 
Prolactin (μg/L)** 11.7 (7.1) 10.3 (10) F=0.3; p=0.6 
Heart rate (beats/min) 82 (15.3) 82.1 (18) F=0.003; p=0.96 
Weight (kg) 76.9 (17.7) 79 (17.4) F=12.3; p=0.002 
GGT (UI/L)** 75.4 (131)  39 (28) F=2.3; p=0.15 
 
**n=22; AUS= Alcohol Use Scale; CDSS= Calgary Depression Scale for Schizophrenia; DUS= 
Drug Use Scale; PANSS= Positive and Negative Syndrome Scale; SUDs= substance use 
disorders; *LOCF= last observation carried forward, $ = dollars spent on alcohol and drugs. 
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5.1 Abstract 
SUDs are associated with poor prognosis in schizophrenia and we do not yet have a good 
explanation for this frequent comorbidity. One hypothesis that has been advanced in the 
literature is that dual diagnosis patients may have a different personality profile than non-
abusing schizophrenia patients. The present case-control study aimed to characterize levels of 
personality traits (sensation-seeking, social anhedonia, and impulsivity) in substance abusers 
with (DD group; n=31) and without schizophrenia (SUD group; n=39), relative to non-
abusing schizophrenia patients (SCZ group; n=23) and healthy controls (n=25). Impulsivity 
was assessed using the Barratt Impulsivity Scale. Sensation-seeking was assessed using the 
Zuckerman Sensation Seeking Scale. Social anhedonia was assessed with the Chapman Social 
Anhedonia Scale. We found that sensation-seeking was significantly higher in DD and SUD, 
relative to SCZ patients. We found that social anhedonia was significantly elevated in DD and 
SCZ, relative to SUD patients and healthy controls. We found that impulsivity was 
significantly higher in DD, SCZ and SUD patients, compared to healthy controls. The results 
suggest that sensation-seeking is prominent in substance abuse (irrespective of 
schizophrenia), social anhedonia is prominent in schizophrenia (irrespective of substance 
abuse), and impulsivity is prominent in all three populations. 
 
Key words: impulsivity, sensation seeking, social anhedonia, personality traits, 
schizophrenia, dual diagnosis, substance abuse 
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5.2 Introduction 
Schizophrenia is a severely disabling psychiatric disease whose treatment is complicated by a 
nearly 50% prevalence of substance use disorder (SUD) in the United States (Regier et al., 
1990). In non-psychosis individuals, SUDs are associated with increased psychiatric 
symptoms (Mauri et al., 2007; Zhornitsky et al., 2010a). In schizophrenia patients, SUDs have 
a negative impact on the course of the pathology. Compared to non-abusing patients, dually 
diagnosed schizophrenia patients are more frequently hospitalized, non-compliant with 
treatment, suicidal, impulsive and violent, homeless and unemployed, and they have more 
legal and health problems (Mueser et al., 1998; Negrete, 2003).  
SUDs are associated with poor prognosis in schizophrenia and we do not have a good 
explanation for this frequent comorbidity. One hypothesis that has been advanced in the 
literature is that dual diagnosis (DD) patients may have a different personality profile than 
non-abusing schizophrenia patients (Gregg et al. 2007). Previous studies have revealed that 
DD patients differ from their non-abusing counterparts on measures of sensation-seeking and 
impulsivity, but not social anhedonia (Kwapil, 1998; Gut-Fayand et al. 2001; Dervaux et al. 
2001). However, these studies suffered from two main limitations: they did not include a 
group of healthy controls and they did not include a group of non-psychosis SUD patients. 
The inclusion of these comparison groups may help us parcel the respective associations 
between schizophrenia, substance abuse and the aforementioned personality traits. This field 
of inquiry is important because personality trait measures may help tailor pharmacological 
and psychosocial intervention in these populations. For instance, there is evidence that 
atypical antipsychotics are beneficial for the treatment of alcoholism among Type B 
alcoholics – characterized by an early onset of drinking, greater severity of dependence and 
more impulsivity and psychiatric symptoms (Babor et al. 1992; for review see Zhornitsky et 
al. 2010b). Similarly, Conrod et al. (2000) found differential improvement in SUD outcomes 
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among non-psychosis female substance abusers who were matched to treatment based on 
levels of impulsivity, hopelessness, sensation-seeking, and anxiety-sensitivity.  
In this context, the present case-control study aimed to characterize levels of 
personality traits (sensation-seeking, social anhedonia, and impulsivity) in substance abusers 
with and without schizophrenia, relative to non-abusing schizophrenia patients and healthy 
controls. Importantly, this is the first study to directly compare these traits in the four groups.  
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5.3 Methods 
Four groups of participants were recruited, namely: (i) substance-abusing patients with 
schizophrenia-spectrum disorders (schizophrenia, schizoaffective disorder, schizophreniform 
disorder; DD group); (ii) non-psychosis substance abusers in detoxification (SUD group); (iii) 
schizophrenia patients with comorbid substance abuse (SCZ group) and; (iv) healthy controls 
(HC group). Psychiatric and substance use disorder diagnoses were by well-trained 
psychiatrists (OL, ES) and physicians (TP; JPC), and were all based on DSM-IV criteria. 
Substance use disorder diagnoses were complemented with urine drug screenings. All 
participants signed a detailed consent form. The study was approved by the local ethics 
committee. 
For all three groups, exclusion criteria were: (i) patients already on clozapine or 
quetiapine; (ii) patients hospitalized in a psychiatric unit; (iii) pregnancy; (iv) female subjects 
of childbearing potential or inadequate contraception; and (v) clinically meaningful unstable, 
renal, hepatic, cardiovascular, respiratory, cerebrovascular or other serious, progressive 
physical disease.  
Psychiatric symptoms (DD, SCZ and SUD groups) were measured using the PANSS 
and the Calgary Depression Scale for Schizophrenia (CDSS; Addington et al. 1994). 
Impulsivity was assessed using the Barratt Impulsiveness Scale (BIS; a 34-item self-report; 
Patton et al. 1995). Sensation-seeking was assessed using the Zuckerman Sensation Seeking 
Scale (form V) (a 40-item self-report; Zuckerman, 1978; Loas et al. 2001). Social anhedonia 
was assessed with the Chapman Social Anhedonia Scale (CSAS; a 40-item self-report; 
Chapman et al. 1976).  
Differences in socio-demographic variables and psychiatric symptoms between the 
DD, SCZ, SUD and HC groups were analyzed using one-way analyses of variance (ANOVA) 
with group as the independent variable. Changes in personality traits were analyzed using 
112 
 
 
 
repeated measures analysis of covariance (ANCOVA) with age as a covariate and group as 
the independent variable. Multiple comparisons were performed using the Bonferroni 
correction. Dichotomous variables were evaluated using Pearson’s Chi-square test. The level 
of significance was set at p<0.05. Statistical analyses were performed using the Predictive 
Analytics SoftWare (PASW; version 18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
 
 
5.4 Results 
Socio-demographic variables 
Analysis of socio-demographic variables showed that individuals in the DD group were 
significantly younger than those in the SCZ and healthy control group (p=0.005); however, 
there were no significant differences in hospitalizations, diagnosis, and antipsychotic or 
substance class (Table 1).  
 
Psychiatric symptoms 
PANSS positive scores were 18.3 (4.6), 16 (4.4), and 15.3 (5.1) in the DD, SCZ and SUD 
groups respectively (p=0.04; DD > SUD); however, the difference did not remain significant 
after controlling for age in the ANCOVA. PANSS negative scores were 19.3 (4.8), 15.6 (4.7), 
13.7 (4.7) in the DD, SCZ and SUD groups respectively (p<0.0001; DD > SUD). CDSS 
scores were 7.3 (4.9), 2.9 (4.4), 6.8 (4.3) in the DD, SCZ and SUD groups respectively 
(p=0.001; DD & SUD > SCZ).  
 
Personality traits 
Sensation-seeking total score was significantly higher in DD and SUD patients, compared to 
schizophrenia patients and significantly higher in SUD patients, compared to healthy controls 
(p<0.0001; Table 1). Social anhedonia score was significantly higher in DD and SCZ patients, 
relative to healthy controls (p=0.005; Table 1). Impulsivity total score was significantly 
elevated in DD, SCZ and SUD patients, relative to healthy controls (p<0.0001; Table 1). The 
results did not change after adding age as a covariate.  
To check whether this confounded our results, we performed a correlation analysis 
(Pearson) on negative symptoms, depression, sensation-seeking, social anhedonia and 
impulsivity. There was only one significant correlation between negative symptoms and 
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social anhedonia (r=0.218; p=0.04). This result is unsurprising since many items on the 
PANSS negative subscale are concepts related to questions on the CSAS.  
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5.5 Discussion 
In the present study, we found that sensation-seeking was significantly higher in DD and 
SUD, relative to SCZ patients. These findings are consistent with previous data showing 
associations between sensation-seeking and substance abuse, regardless of psychosis 
comorbidity (Ersche et al. 2010; Bizzarri et al. 2007, 2009; Dervaux et al. 2001, 2010a,b). 
Most importantly, Bizzarri et al. (2007) showed that sensation-seeking was significantly 
elevated in bipolar patients with substance abuse and in non-psychosis substance abusers, 
relative to healthy controls. Intriguingly, non-abusing bipolar patients exhibited a level of 
sensation-seeking that was higher than healthy controls, but lower than the two substance 
abusing groups. Here, we found that SCZ patients had significantly lower scores in the 
boredom susceptibility subscale of sensation-seeking, relative to healthy controls. These data 
suggest that (i) substance abusers with and without schizophrenia are characterized by 
abnormally high sensation-seeking, and (ii) non-abusing schizophrenia patients are 
characterized by abnormally low sensation-seeking.  
We found that social anhedonia was significantly elevated in DD and SCZ, relative to 
SUD patients and healthy controls. A number of previous studies have established a link 
between social anhedonia and schizotypal personality traits and the development of 
schizophrenia-spectrum disorders. Indeed, there is evidence that subjects with social 
anhedonia exhibited higher schizotypal scores for interpersonal, paranoid, disorganized, and 
cognitive/perceptual dimensions, relative to controls (Rey et al. 2009). Likewise, Kwapil 
(1998) reported that 24% of subjects with high social anhedonia were diagnosed with 
schizophrenia-spectrum disorders at the 10-year follow-up, relative to only 1% of controls. By 
contrast, Dervaux et al. (2001) did not find a difference in physical anhedonia between 
schizophrenia patients with and without substance abuse. Here, the addition of the SUD and 
HC group suggests that anhedonia may actually play a role in dually diagnosed schizophrenia 
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patients, but to do so, it has to be coupled with sensation seeking, whereas anhedonia is not 
required in the SUD group. It may be that sensation-seeking is a way of counteracting 
anhedonia in some schizophrenia patients, may lead them to abuse drugs and/or alcohol. 
Taken together, these data show that social anhedonia is relatively unique to schizophrenia – 
irrespective of SUD comorbidity.  
We found that impulsivity was significantly higher in DD, SCZ and SUD patients, 
compared to healthy controls. As such, our results are in accordance with previous studies that 
found elevated impulsivity in substance abusers without schizophrenia and in non-abusing 
schizophrenia patients, relative to healthy controls (Enticott et al. 2008; Ersche et al. 2010; 
Kaladjian et al. 2011; Duva et al. 2011). However – unlike previous studies – we did not find 
significant differences in impulsivity between substance abusers with and without 
schizophrenia. For example, Dervaux et al. (2010a,b) revealed significantly elevated levels of 
impulsivity in separate cohorts of alcohol and cannabis-abusing schizophrenia patients, 
compared to non-abusing schizophrenia patients. Similarly, Gut-Fayand et al. (2001) found 
significantly elevated levels of impulsivity in mixed substance abusers with schizophrenia, 
relative to non-abusing patients. The inability to find a difference between the groups may 
reflect a type-II error, since our SCZ group evidenced an impulsivity total score which was 
numerically lower than our DD and SUD groups. A larger sample size may have rendered the 
numerical difference statistically significant. Another potential reason is related to the fact 
that the BIS contains numerous cognitive items that may have obscured the results in our 
study. Consequently, experimental measures of impulsivity (e.g. response inhibition) are 
needed to confirm these findings.  
Analysis of socio-demographic variables revealed that these DD patients were more 
likely to be younger, as shown previously in the literature (Wobrock et al. 2007; Koskinen et 
al. 2010). However, controlling for age did not influence our personality traits results. 
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Moreover, analysis of psychiatric symptoms revealed that DD patients had significantly more 
negative symptoms, relative to SUD patients. This is consistent with evidence suggesting that 
negative symptoms are relatively unique to schizophrenia (Zhornitsky et al. 2010a). By 
contrast, we found that depressive symptoms were over two times higher in DD and SUD 
patients, compared to SCZ patients. This finding is in line with research showing that 
substance abuse is a risk factor for the development of depression (Lynskey et al., 2004; Falck 
et al. 2006; Potvin et al., 2007). 
Results of the present study suggest that sensation-seeking is prominent in substance 
abuse (irrespective of schizophrenia), social anhedonia is prominent in schizophrenia 
(irrespective of substance abuse) and impulsivity is prominent in all three populations. These 
results are limited because patients were using mixed substance. However, previous studies in 
the field suggest that personality profiles are not related to a specific substance (Dervaux et al. 
2001, 2010a,b). As a whole, the findings may help tailor pharmacological and psychosocial 
intervention in these populations. Future studies will need to evaluate whether the personality 
profiles reported here reflect state or trait differences. It would also be interesting to verify if 
we can predict the development of substance abuse in schizophrenia based on the personality 
profiles reported here in longitudinal studies initiated during the prodrome of psychosis. 
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Table 1: Personality traits, psychiatric symptoms, and socio-demographic variables  
 
Variable (mean, SD) 
DD 
(n=31) 
SCZ 
(n=23) 
SUD 
(n=39) 
HC 
(n=25) 
Statistics Multiple comparisons* 
Personality traits 
Impulsivity 
    Motor impulsivity     
    Cognitive impulsivity 
    Non-planning impulsivity 
    Total 
 
17.3 (8.2) 
22.5 (5.4) 
22.6 (5.7) 
62.4 (14.8) 
 
16.7 (8) 
19.8 (6.1) 
19 (5.6) 
55.6 (13.7) 
 
19.2 (8) 
21.2 (6.7) 
21.1 (7.5) 
61.3 (19.3)
 
9.9 (5.3) 
14.6 (3.5) 
14.4 (4.8) 
37.9 (8.5) 
 
F=8; p<0.0001 
F=9.8; p<0.0001 
F=11.7; p<0.0001 
F=15.1; p<0.0001 
 
DD, SCZ & SUD > HC 
DD, SCZ & SUD > HC 
DD, SCZ & SUD > HC 
DD, SCZ & SUD > HC 
Sensation-seeking 
    Thrill-seeking 
    Experience-seeking 
 
4.4 (2) 
4.4 (1.8) 
 
2.7 (1.7) 
3.5 (1.3) 
 
4.2 (2) 
5.2 (1.6) 
 
2.6 (2.1) 
4.2 (2.3) 
 
F=6.4; p<0.0001 
F=4.8; p=0.004 
 
DD & SUD > SCZ & HC 
SUD > SCZ 
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    Disinhibition 
    Boredom susceptibility 
    Total 
6.6 (1.8) 
5.3 (2.1) 
20.6 (5.5) 
3.9 (1.2) 
2.9 (1.7) 
13 (5.4) 
6.3 (2.2) 
5.2 (2.2) 
21.1 (6.4) 
4.6 (1.9) 
4.4 (1.9) 
15.9 (6.6) 
F=11.3; p<0.0001 
F=7.9; p<0.0001 
F=11.7; p<0.0001 
DD & SUD > SCZ & HC 
DD & SUD > SCZ ; HC > SCZ 
DD & SUD > SCZ ; SUD > HC 
Social anhedonia 13.8 (7) 12.8 (6.9) 11.6 (5.9) 8 (4.2) F=4.5; p=0.005 DD & SCZ > HC 
Socio-demographic variables 
Age 30 (9.8) 39.9 (12.7) 37.8 (11.9) 40 (12.5) F=4.6; p=0.005 DD > SCZ & HC 
Gender 27M: 4F 14M: 9F 26M: 13F 16M: 9F χ=5.9; p=0.1 --- 
Hospitalisations 2.8 (2.9) 2.8 (2.7) --- --- F=0.5; p=0.9 --- 
Diagnosis 17SCZ:12S
A:2SF 
15SCZ:6S
A:2SF 
--- --- χ=1; p=0.6 --- 
Antipsychotic class 20AP:4TP:5
BT:2DF 
13AP:4TP
:0BT:3DF 
--- --- χ=4.5; p=0.2 --- 
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Substance type 
     Alcohol 
    Cannabis 
    Stimulant 
 
15Y: 16N 
18Y: 13N 
9Y: 22N 
  
25Y: 15N 
20Y: 19N 
16Y: 23N 
  
χ=1.2; p=0.3 
χ=0.3; p=0.6 
χ=1.1; p=0.3 
 
--- 
 
DD = dual-diagnosis schizophrenia; SCZ = schizophrenia only; SUD = non-psychosis patients with substance use disorders; HC = 
healthy controls; SA = schizoaffective disorder; SF = schizophreniform disorder; AP = atypical antipsychotic; TP = typical 
antipsychotic; BT = both; DF = drug-free; Y = yes; N = no; M = male; F = female; * = After Bonferroni correction 
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6.1 Abstract 
Substance dependence has serious negative consequences upon society such as increased health 
care costs, loss of productivity and rising crime rates. While there is some preliminary evidence 
that atypical antipsychotics may be effective in treating substance dependence, results have been 
mixed, with some studies demonstrating positive, and others negative or no effect. The present 
study was aimed at determining whether this disparity originates from the fact that reviewers 
discussed separately trials in patients with (DD) and without (SD) co-morbid psychosis. Using 
electronic databases we screened relevant literature leaving only studies which employed a 
randomized, double-blind, placebo-controlled or case-control design that had a duration of four 
weeks or longer. A total of 43 studies were identified; of these, 23 fell into the category of DD 
and 20 fell into the category of SD. DD studies suggest that atypical antipsychotics – especially 
clozapine – may decrease substance use in individuals with alcohol, and drug use disorders 
(mostly cannabis). SD studies suggest that atypical antipsychotics may be beneficial for the 
treatment of alcohol dependence – at least in some subpopulations of alcoholics. They also 
suggest that these agents are not effective at treating stimulant dependence and may aggravate 
the condition in some cases.  
 
Key words: dual diagnosis, substance dependence, antipsychotic, schizophrenia, alcohol, 
stimulants, cannabis 
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6.2 Introduction 
Abuse of psychoactive substances (PAS) such as stimulants, depressants and hallucinogens is 
currently one of the leading causes of crime, violence, disease, illness and death worldwide, and 
this places considerable burden upon economies via loss in productivity and increases in 
spending on health care and law enforcement.1 For the PAS users, there is a high risk of 
developing psychiatric symptoms such as anhedonia, depression and anxiety during acute and 
protracted withdrawal.2-5 In addition, abuse of some PAS has been shown to produce psychotic 
symptoms requiring treatment – symptoms which are often indistinguishable from those of 
schizophrenia.6 Conversely, individuals with an already present mental illness are at an increased 
risk of developing substance use disorders (SUDs), the lifetime prevalence of which ranges from 
25% in depression and anxiety disorders to 47% in schizophrenia and 56% in bipolar disorder.7 
In these psychosis patients, PAS abuse tends to exacerbate already-present psychiatric symptoms 
and is associated with poorer treatment outcome.8 While psychiatric drugs may be useful in the 
treatment of psychiatric symptoms associated with SUDs, it remains to be seen whether they are 
effective at improving SUD outcomes.   
Antipsychotics, drugs which are normally used to treat psychosis in schizophrenia and 
acute mania in bipolar disorder, have also shown promise in the treatment of SUDs and it has 
been presumed that these benefits are greater in dually diagnosed bipolar and schizophrenia 
patients.12,13 This class of compounds is characterized by antagonism of dopamine (DA), a 
neurotransmitter that is implicated in the rewarding effects of drugs. For instance, animal models 
of reward have demonstrated that antipsychotics reverse cocaine-, amphetamine-, morphine and 
nicotine-induced decreases in threshold for rewarding brain stimulation,14-17 increase responding 
for amphetamine and cocaine in the self-administration paradigm (indicative of decreased 
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rewarding efficacy)18,19 and block the establishment of a conditioned place preference to 
amphetamine, ethanol, and cocaine.20-22 Animal models of relapse have evidenced that 
antipsychotics block drug- and cue-induced reinstatement of responding on the drug-associated 
lever during self-administration of heroin, cocaine and amphetamine23-25 and prevent the ability 
of heroin and amphetamine to reinstate operant runway behavior.26,27  
PET studies show that all PAS increase DA release in the ventral striatum in humans.28 
For their part, all antipsychotics have been evidenced to block D2 receptors in the striatum but 
recent evidence suggests that some newer antipsychotics may be distinguished by faster 
disassociation from D2 receptors and this may be the reason why they are less likely to induce 
anhedonia and extrapyramidal symptoms (EPS).29-31 In addition to dopaminergic antagonism, a 
number of antipsychotics act on other neurotransmitter systems such as serotonin (5-HT), 
norepinephrine (NE).32,33 which may mediate heightened anxiety and depressive symptoms 
during acute and protracted withdrawal from PAS.23,34,35 Such a broad spectrum of action makes 
antipsychotics theoretically useful because they may target a number of psychiatric symptoms 
such as craving, anxiety and depression in addition to blocking the rewarding efficacy of PAS. 
Indeed, some newer (atypical) antipsychotics have shown promise as monotherapies in the 
treatment of mood and anxiety disorders.36-38 However, evidence for the utility of antipsychotics 
for the treatment of SUDs has not been conclusive – with some studies evidencing a decrease 
and others no effect or even an increase in SUD symptomatology. Reasons for these 
discrepancies may include the type of antipsychotic and the type of PAS as well as the presence 
of comorbid psychiatric symptoms.  
Up to this point, the majority of reviews detailing the efficacy of antipsychotics for SUDs 
have only pooled studies of schizophrenia and bipolar patients and have included both controlled 
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as well as uncontrolled, open-label (switch design) trials and case reports.12,39,40 The sole 
comprehensive review of the efficacy of antipsychotics in the non-psychosis population has 
focused on cocaine dependence.41 The present review will examine randomized studies of 
antipsychotics in the treatment of SUDs in non-psychosis substance abusers (SD), as well as 
randomized and case-control studies (including retrospective studies) in psychosis dually-
diagnosed (DD) substance abusers – simultaneously paying attention to antipsychotic and PAS 
type – with the aim of accounting for the aforementioned discrepancies that exist in the literature.  
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6.3 Methods 
A systematic search was performed in the electronic databases PubMed and EMBASE using the 
key words “amisulpride OR antipsychotic OR aripiprazole OR chlorpromazine OR clozapine OR 
flupenthixol OR fluphenazine OR haloperidol OR neuroleptic OR olanzapine OR perphenazine 
OR risperidone OR tiapride OR quetiapine OR ziprazidone” AND “alcohol OR amphetamine 
OR cannabis OR heroin OR marijuana OR methamphetamine OR opiate OR phencyclidine OR 
substance abuse OR substance use disorder OR smoking OR nicotine”. This search identified 
studies published between January 1, 1962 and June 1, 2009. Additionally, studies were 
identified by cross-referencing. 
To be included in the review, studies had to address specifically the treatment of SUDs 
with antipsychotics. All psychosis patients (i.e. schizophrenia, schizoaffective, and bipolar 
disorder) with concomitant SUD were considered for inclusion in the DD group of studies. 
Treatment must have lasted longer than four weeks and outcomes must have been measured by 
craving, alcohol/drug use, and/or relapse. Only randomized studies were included in the SD 
group. In order to increase the number of studies measuring the efficacy of antipsychotics for the 
treatment of SUDs in DD patients, case-control studies comparing two or more antipsychotics 
(retrospective or prospective) with no randomization were also included. Case reports, open-
label (switch design) and cross-sectional studies were excluded from both DD and SD analysis. 
Considering the methodological limitations of DD studies and the heterogeneity of substances 
included in both DD and SD studies, studies included in this review were not amenable to 
quantitative mete-analytic treatment. 
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6.4 Results 
DD and SD study characteristics 
A total of 43 studies were identified; of these, 23 fell into the category of DD and 20 fell into the 
category of SD. The 23 DD studies included 10 case-control and 13 randomized studies (Table 1; 
see Supplemental Table A for full table). Four of the studies in the DD group included primarily 
bipolar patients.42-45 The remaining studies included primarily schizophrenia-spectrum disorders. 
Only two studies in the DD group employed a placebo-controlled design42,43 and two studies had 
an open-label group receiving no medication.44,46 Out of a total of 13 randomized studies in the 
DD group, ten were double-blind and three were open-label.44,47,48 Four studies in the DD group 
were retrospective.49-52 By contrast, 19 out of 20 studies in the SD group were placebo-controlled 
and all were double-blind and randomized (Table 2; see Supplemental Table B for full table). 
 
DD results 
Alcohol and drug use (mostly cannabis) 
Five prospective DD schizophrenia studies investigated alcohol and drug use (mostly cannabis). 
A large 144-week case-control study (N=151) found that clozapine treatment was associated 
with significantly lower drinking severity, fewer days of alcohol use, a marginally significant 
reduction in severity of drug use (a majority of cannabis users) and greater remission.53 Another 
large 144-week case-control study (N=362) found that patients compliant with atypicals 
(clozapine, risperidone and olanzapine) were significantly less likely to use alcohol and drugs 
(unspecified) compared to those compliant with typicals and those receiving no medication for 
90 days.46 Similarly, a large randomized trial (N=115) found that long-acting injectable 
risperidone was associated with significantly less alcohol and drug use (unspecified), lower 
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psychopathology, less EPS and better compliance with a SUD treatment program compared to 
zuclopenthixol depot.48 Moreover, a case-control study found that patients receiving clozapine at 
the first 6-month period of substance abuse remission were significantly less likely to relapse to 
alcohol and drug use (a majority of cannabis users), compared to those receiving olanzapine, 
risperidone and typicals.54 Finally, a case-control study comparing olanzapine to typicals found 
that olanzapine was associated with improvements in symptoms and psychosocial function; 
however, both treatments lead to significant decreases in alcohol use.55 
Three retrospective studies in our sample investigated antipsychotic treatment of alcohol 
and drug use in schizophrenia patients. A retrospective study of clozapine versus risperidone in 
schizophrenia patients with alcohol and cannabis use disorders revealed that clozapine-treatment 
was associated with significantly lower rates of relapse at one year of treatment.49 Another 
retrospective comparison found clozapine to be more effective than olanzapine, and olanzapine 
to be more effective than haloperidol for decreasing relapse in schizophrenia patients with 
alcohol use disorder.51 Moreover, a larger retrospective comparison found that DD patients that 
were switched to or maintained on atypicals (primarily olanzapine and risperidone) evidenced 
significant decreases in alcohol and psychological addiction severity index (ASI) scores, 
compared to those who were treated with typicals.52 However, in this study, multiple regression 
analysis revealed no significantly greater improvement in any ASI scores for those individuals 
who were switched to or maintained on atypicals.  
A study that examined alcoholism in bipolar patients found that quetiapine add-on 
treatment significantly decreased depressive symptoms compared to placebo but was no better at 
reducing drinking variables.42 On the other hand, a more recent pilot study by the same authors 
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found that quetiapine reduced heavy drinking days and increased treatment compliance 
compared to placebo.43 
Two randomized double-blind studies specifically examined cannabis use in 
schizophrenia patients receiving olanzapine compared to risperidone. One found equal 
reductions in cannabis use and craving from baseline56, while the other found equal reductions in 
cannabis craving and a preferential benefit of risperidone on craving.57 
Finally, heroin use was examined in a prospective case-control trial of olanzapine, in 
combination with opioid agonists, in schizophrenia patients. Results demonstrated that 
olanzapine significantly reduced psychopathology and heroin use as well as improved treatment 
retention compared to haloperidol.58 
 
Stimulants 
Seven studies investigated antipsychotics for stimulant dependence in DD patients. One 
randomized, double-blind study failed to find a significant effect of olanzapine and risperidone 
on cocaine use and craving.57 Another randomized double-blind trial found haloperidol to be 
associated with significantly less craving compared to olanzapine in cocaine-dependant 
schizophrenia patients.59 A case-control trial of schizophrenia patients found that risperidone was 
associated with reduced psychopathology, less cue-elicited cocaine craving and lower rates of 
relapse compared to typical agents.60 However, more recent randomized double-blind study by 
the same authors demonstrated olanzapine to significantly reduce cue-elicited craving but not 
cocaine use compared to typical antipsychotics.61  
Two randomized studies found quetiapine treatment to be equally as efficient as 
risperidone45 and more efficient than typicals at reducing stimulant craving in bipolar patients.44 
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On the other hand, a small placebo-controlled trial did not find any difference between 
quetiapine and placebo on cocaine use or craving in bipolar patients.43 
 
Tobacco 
Four studies examined the effects of atypical antipsychotics on cigarette smoking in 
schizophrenia patients. One open-label randomized study found that schizophrenia patients 
treated with atypicals exhibited significantly higher quit rates and lower expired CO than patients 
treated with typicals.47 Additionally, a small double-blind trial, that randomized patients to high, 
medium and low (sub-therapeutic) doses of clozapine, found that those individuals with 
therapeutic plasma levels of clozapine evidenced reductions in cigarettes smoked and expired 
carbon monoxide (CO), compared to their haloperidol baseline.62 A more recent study by the 
same team found that those patients randomized to higher doses of clozapine evidenced a 
significant decrease in the number of cigarettes smoked compared to their haloperidol baseline; 
however, biomarkers such as levels of nicotine, cotinine and expired CO were not significantly 
reduced as a function of clozapine dose.63 On the other hand, a more recent attempt to replicate 
these results using a similar study design, found no significant effect of clozapine treatment on 
plasma cotinine levels (considered to be the most reliable biomarker of smoking decrease and 
abstinence) at any dose.64 Finally, one retrospective study found that olanzapine and typicals 
were associated with a significantly lower completion rate and greater desire to smoke 
immediately after discharge from a SUD treatment program, compared to patients receiving 
risperidone and ziprasidone.50 
 
SD results 
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Alcohol 
Eleven studies investigated the effects of antipsychotics on alcohol use disorder in SD 
individuals. Olanzapine was found to significantly reduce cue-elicited craving and drinking when 
compared with placebo in a subset of individuals with the longer alleles of the DRD4 genotype 
(DRD4 L) but not in those with the shorter alleles (DRD4 S).65 Similarly, quetiapine was found 
to reduce craving and drinking over placebo in Type B alcoholics but not in Type A alcoholics.66 
On the other hand, no difference between olanzapine and placebo was found in a study that did 
not differentiate between subsets of alcoholics.67 Aripiprazole treatment was associated with the 
best outcomes of the atypical antipsychotics in undifferentiated alcoholics. One large placebo-
controlled trial (N=295) found aripiprazole to significantly lower the amount of heavy alcohol 
consumption and alcohol dependence severity.68 Another randomized, double-blind comparison 
of aripiprazole vs. naltrexone found treatment aripiprazole-treatment to be associated with a 
significantly longer abstinence time; however, naltrexone produced larger decreases in craving.69 
The sole study of amisulpride found that the D2/D3 antagonist increased alcohol craving and 
relapse as compared to placebo.70 Tiapride, another substituted benzamide with affinity for 
D2/D3 receptors and atypical properties in preclinical models as well as a very low incidence of 
EPS in humans71,72 was superior to placebo in preventing relapse and decreasing drinking in 
alcoholics with an anxious or depressive temperament73 and in a group of undifferentiated 
alcoholics.74 However, more recent, larger placebo-controlled trials (combined N=360), showed 
tiapride to increase relapse over placebo in undifferentiated alcoholics.75,76 Finally, the only 
study in our sample investigating the use of flupenthixol decanoate for alcoholism found a 
significant increase in relapse in 281 alcoholics compared to placebo.77 
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Stimulants 
A total of nine studies investigated antipsychotic treatment of stimulant dependence in SD 
individuals. One study of flupenthixol decanoate for the treatment of stimulant abuse found the 
antipsychotic to be superior to placebo for reducing crack cocaine use.78 Five other placebo-
controlled studies failed to find any significant differences in cocaine use or craving with either 
risperidone or olanzapine treatment.79-83 However, risperidone increased depressive symptoms in 
one study.80 Additionally, three placebo-controlled studies found atypical antipsychotics to 
significantly increase in stimulant use. In particular, an aggravation of drug use was found for 
olanzapine and cocaine,84 risperidone (8mg/d) and cocaine85 and aripiprazole and intravenous 
amphetamine.86   
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6.5 Discussion  
DD studies 
In DD studies, the biggest improvements in SUD outcome measures were observed for clozapine 
in DD patients with alcohol, and possibly, cannabis use disorders.49,51,53,54 There was also 
evidence that treatment with other atypical antipsychotics such as quetiapine, olanzapine and 
risperidone may lead to improvements in alcohol and drug use (mostly cannabis).43,46,48,51,54,56,57. 
Interestingly, the largest placebo-controlled study in the DD group investigating alcohol use 
found no difference between quetiapine and placebo in bipolar patients.42 However, it must be 
noted that in this study quetiapine was administered as add-on therapy to mood stabilizers, which 
makes it difficult to determine the effects of quetiapine alone on alcohol dependence.   
Findings in DD patients need to be tempered by the fact that many of the studies in this 
group employed a case-control or retrospective design. One limitation of case-control and 
retrospective studies with clozapine may be that this medication is more likely to be tried in 
individuals who are non-responsive to treatment with other antipsychotics.53 Overall, the 
difficulty in maintaining treatment compliance in DD patients renders finding large number of 
patients for randomized studies a hard task and precludes us from drawing causal relationships 
between atypical or typical treatment and SUDs. Nevertheless, of all the DD studies included in 
this review, the studies involving the largest sample sizes and having the longest duration of 
treatment were the clozapine studies. It is therefore difficult to rule out the results from these 
studies when evaluating the potential benefits of clozapine for SUD outcomes in DD patients.  
 The DD studies investigating atypical antipsychotic treatment of stimulant dependence 
showed reductions in craving44,45,57,61 or no effect.43,59 One possibility is that while these studies 
were randomized, many of them contained small sample sizes and may have lacked the power to 
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detect significant differences in stimulant use as a result of antipsychotic treatment. Providing 
support for this possibility, there is evidence that craving predicts relapse to a variety of PAS 
such alcohol, cocaine, tobacco and opiates.88-91 However, despite these putative relationships, the 
effect of antipsychotics on stimulant dependence remains inconclusive.  
Current research suggests that a pharmacokinetic interaction between cigarette smoking 
and specific antipsychotics may lead to increases in antipsychotic plasma levels and 
antipsychotic-induced side-effects, thereby making it difficult for patients to stop smoking. A 
study by Stuyt et al.50 revealed that significantly more patients treated with olanzapine and 
typicals reported a desire to smoke immediately after discharge from a dual diagnosis treatment 
program, compared to those treated with risperidone and ziprazidone. The authors explained 
these data as being due to an induction of the cytochrome P450 isoenzyme 1A2 (CYP1A2) by 
cigarette smoke,50 which has been shown to speed up metabolism of some atypicals such as 
clozapine, olanzapine, and typicals such as haloperidol, chlorpromazine, thiothixene and 
fluphenazine,92,93 leading to as much as a 1.5-fold elevation in plasma clozapine levels when 
patients attempt to quit smoking.94 By contrast, other studies that did not ask smokers to abstain 
from smoking (i.e. provided free unlimited cigarettes to patients) found clozapine to decrease62,63 
or to have no effect64 on smoking. The only other study that we reviewed, which asked patients 
to abstain from smoking, revealed that significantly more patients on atypicals than typicals were 
willing to abstain from smoking for the entire duration of the 12-week trial47. Intriguingly, only 
two out of four of the agents in their atypical group are metabolized by CYP1A2, whereas all of 
the antipsychotics in the typical group are metabolized by CYP1A2.92,93 As a whole, the 
preliminary positive evidence of atypicals for the treatment of tobacco dependence needs to be 
corroborated by future studies with larger sample sizes.  
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SD studies 
Apart from two studies with aripiprazole that found improvements in alcohol dependence,68,69 
the majority of studies – which did not differentiate between subtypes of alcoholics – found both 
typical and atypical antipsychotics to increase relapse in SD individuals.67,70,75-77 By contrast, 
other trials found atypical antipsychotics to be effective – but only in some subtypes of 
alcoholics. In particular, Kampman et al.66 found that quetiapine decreased alcohol craving and 
drinking in Type B alcoholics, but not in Type A alcoholics – the former being characterized by 
an increased presence of psychopathology.95 Another placebo-controlled trial found that tiapride 
decreased drinking and relapse in alcoholics with symptoms of anxiety and depression.73 In 
addition, Hutchinson et al.65 found that olanzapine decreased cue-elicited craving for alcohol and 
drinking over placebo; but only in individuals with the DRD4 L genotype. These results suggest 
that alcoholics with certain phenotypes and genotypes may be more likely to respond to 
treatment with atypical antipsychotics.   
The studies which we reviewed suggest that typical and atypical antipsychotics are not 
effective treatments of stimulant dependence in SD individuals,79-83 and may, in some cases, 
aggravate stimulant use. For example, risperidone was shown to aggravate cocaine use at high 
doses (8mg/day) in SD individuals85 Another study found that olanzapine increased cocaine use 
compared to placebo.84 In addition, aripiprazole was found to aggravate stimulant use in 
intravenous amphetamine users; causing a spike to 100% amphetamine-positive urine screens in 
the last 10 weeks of the study in aripiprazole-treated subjects.86 
Surprisingly, the only study that has found improvements in stimulant use was involving 
flupenthixol decanoate.78 While initial results showed that flupenthixol decreased cocaine use 
over placebo, a later publication revealed that 15% of patients treated with flupenthixol stopped 
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crack use due to the occurrence of severely distressing involuntary muscular restlessness 
(akathisia) after smoking crack-cocaine.96 Similar EPS were found in a study of the effects of 
flupenthixol on subjective responses to intravenous cocaine.97 In this 11-day study (which did 
not meet our inclusion criteria), individuals randomized to the high dose of flupenthixol 
evidenced a high rate of dystonic reactions (29%) and increased desire for the drug. In sum, the 
considerable number of SD studies reporting disturbing EPS and aggravations of stimulant use 
show that typical and atypical antipsychotics are not a clinically useful treatment for stimulant 
dependence in non-psychosis individuals.  
 
Side-effects  
The benefits of antipsychotics for treating SUDs in DD and SD individuals need to be weighed 
against the potential for noncompliance and relapse to substance abuse as a consequence of 
increased side-effects. Regardless of psychiatric comorbidity, antipsychotics may interact with 
PAS to increase EPS.96-98 Moreover, smoking cessation may induce intoxication with clozapine, 
olanzapine and many typical agents, potentially leading to increased adverse effects.94,99 During 
cases of alcohol withdrawal syndrome, treatment with antipsychotics has been found to be 
particularly dangerous because some of these compounds may lower seizure threshold.100 
Importantly, in DD patients, there is evidence that antipsychotic-induced side-effects are 
associated with noncompliance, psychotic relapse and elevated substance abuse.101-104 Similarly, 
in SD individuals, there is evidence that antipsychotic-induced side-effects are associated with 
low treatment retention and elevated substance abuse.85 These data demonstrate that clinicians 
involved in the treatment of DD patients should pay particular attention to interactions between 
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specific antipsychotics and PAS. They also suggest that antipsychotic treatment of SUDs in SD 
individuals may not outweigh the risk for harm.   
 
Conclusion 
DD studies suggest that atypical antipsychotics – especially clozapine – may decrease substance 
use in individuals with alcohol, and drug use disorders (mostly cannabis). SD studies suggest that 
atypical antipsychotics may be beneficial for the treatment of alcohol dependence – at least in 
some subpopulations of alcoholics. They also suggest that these agents are not effective at 
treating stimulant dependence and may aggravate the condition in some cases. Clinicians must 
bear in mind that antipsychotics are useful for the treatment of stimulant-induced psychotic 
disorders, but they must be cautious when using high doses of antipsychotics for the long-term 
treatment of SUD in stimulant abusers.  
Further large-scale studies with long duration of treatment are required to measure the 
efficacy of clozapine on alcohol and cannabis dependence in DD patients. In addition, larger 
randomized trials are needed to determine the precise impact of atypical antipsychotics on 
stimulant dependence in DD patents. Finally, future studies should investigate which subgroups 
of SD alcoholics may benefit most from atypical therapy. 
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Table 1: DD results 
Study N Dx Wks SUD(s) Treatment R D P Outcome(s) 
Swanson et al. 200746 362 SCZ 144 Alcohol + drugs ATP vs. TYP vs. NA N N N ATP ↓ substance use 
Drake et al. 200053 151 SCZ 144 Alcohol + drugs  CLO vs. TYP N N N CLO ↓ substance use ↓ 
relapse 
Brunette et al. 200654 95 SCZ 96 Alcohol + drugs  CLO vs. ATP vs. TYP N N N CLO ↓ relapse 
Petrakis et al. 200652 249 SCZ 48  Alcohol + drugs ATP vs. TYP N N N No difference 
Rubio et al. 200648 115 SCZ 24 Alcohol + drugs RIS (inj) vs. ZUC (inj) Y N N RIS ↓ substance use 
Green et al. 200349 41 SCZ 48  Alcohol + cannabis CLO vs. RIS N N N CLO ↓ relapse  
Brunette et al. 200851 86 SCZ 24 Alcohol CLO vs. OLA vs. TYP N N N CLO ↓ relapse 
Noordsy et al. 200155 38 SCZ 24 Alcohol  OLA vs. TYP N N N Equal ↓ alcohol use 
Brown et al. 200842 102 BD 12 Alcohol QTP Y Y Y No difference 
Brown et al. 201043 12 BD 12 Stimulants + alcohol QTP Y Y Y QTP ↓ alcohol use 
Brown et al. 200344 24 BD 12 Stimulants QTP vs. TYP vs. NA  Y N N QTP ↓ craving 
Nejtek et al. 200845 94 BD 20 Stimulants  QTP vs. RIS Y Y N Equal ↓ craving  
Smelson et al. 200260 18 SCZ 6 Stimulants RIS vs. TYP N N N RIS ↓ relapse ↓ craving 
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Smelson et al. 200661 31 SCZ 6 Stimulants OLA vs. HAL Y Y N OLA ↓ craving 
Sayers et al. 200559 24 SCZ 26 Stimulants  OLA vs. HAL Y Y N HAL ↓ craving 
Akerele & Levin,  
200757 
28 SCZ 14 Stimulants + cannabis OLA vs. RIS  Y Y N Equal ↓ cannabis use; 
RIS ↓ cannabis craving 
van Nimwegen et al. 
200856 
42 SCZ 6 Cannabis OLA vs. RIS Y Y N Equal ↓ use ↓ craving 
Gerra et al. 200758 61 SCZ 12 Heroin OLA vs. HAL N N N OLA ↓ use  
Stuyt et al. 200650 55 SCZ 144 Tobacco OLA vs. RIS vs. ZIP vs. TYP N N N OLA + TYP ↑ craving  
George et al. 200047 44 SCZ 10 Tobacco ATP vs. TYP Y N N ATP ↓ relapse ↓ use 
McEvoy et al. 199562 12 SCZ 12 Tobacco CLO  vs. HAL Y Y N Med + Hi CLO ↓ use 
McEvoy et al. 199963 55 SCZ 12 Tobacco CLO vs. HAL Y Y N Med + Hi CLO ↓ use 
de Leon et al. 200564 38 SCZ 16 Tobacco CLO vs. HAL Y Y N No difference 
 
Table legend: ↑ = increase, ↓ = decrease, N = sample size (intent-to-treat population), dx = diagnosis (majority), wks = weeks, stimulants = 
amphetamines and/or cocaine, inj = injectable, SCZ = schizophrenia, BD = bipolar disorder, R = randomized, D = double-blind, P = placebo-
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controlled, Med = medium dose, Hi = high dose, ATP = mixed atypicals, TYP = mixed typicals, CLO = clozapine, OLA = olanzapine, RIS = 
risperidone, QTP = quetiapine, ZIP = ziprasidone, ZUC = zuclopenthixol, HAL = haloperidol, NA = no medication.  
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Table 2: SD results  
Study N Wks SUD(s) Treatment R D P Outcome(s) 
Wiesbeck et al. 200177 281 48 Alcohol FLU (inj) Y Y Y FLU ↑ relapse  
Shaw et al. 198773 20 24 Alcohol TIA Y Y Y TIA ↓ use ↓ relapse (anxio-depressive 
alcoholics)  
Shaw et al. 199474 54 24 Alcohol TIA Y Y Y TIA ↓ use ↓ relapse 
Gual et al. 200275 81 24 Alcohol TIA Y Y Y TIA ↑ relapse  
Bender et al. 200676 299 24 Alcohol TIA Y Y Y TIA ↑ relapse  
Marra et al. 200270 71 24 Alcohol AMI Y Y Y AMI ↑ relapse ↑ craving 
Guardia et al. 200467 60 12 Alcohol OLA Y Y Y No difference 
Hutchinson et al. 200665 64 12 Alcohol OLA Y Y Y OLA ↓ use ↓ craving (DRD4 L gene) 
Kampman et al. 200766 61 12 Alcohol QTP Y Y Y QTP ↓ use ↓ craving (Type B subtype) 
Anton et al. 200868 295 12 Alcohol APZ Y Y Y APZ ↓ use 
Martionotti et al. 200969 57 16 Alcohol APZ vs. NAL Y Y N APZ ↓ relapse; NAL ↓ craving 
Kampman et al. 200384 30 12 Stimulants OLA Y Y Y OLA ↑ relapse 
Reid et al. 200583 63 8 Stimulants OLA Y Y Y No difference 
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Hamilton et al. 200981 48 16 Stimulants OLA Y Y Y No difference 
Levin et al. 199979 14 24 Stimulants RIS Y Y Y No difference 
Grabowski et al. 200085 125 12 Stimulants RIS Y Y Y Hi RIS ↑ use 
Grabowski et al. 200482 96 26 Stimulants  RIS Y Y Y No difference 
Loebl et al. 200880 31 12 Stimulants RIS (inj) Y Y Y RIS ↑ depressive symptoms 
Tiihonen et al. 200786 36 20 Stimulants APZ Y Y Y APZ ↑ use 
Gawin et al. 199678 54 6 Stimulants FLU (inj) Y Y Y FLU ↓ use 
 
Table legend: ↑ = increase, ↓ = decrease, N = sample size (intent-to-treat population), wks = weeks, stimulants = amphetamine and/or cocaine, inj = 
injectable, R = randomized, D = double-blind, P = placebo-controlled, Hi = high dose, OLA = olanzapine, RIS = risperidone, TIA = tiapride, APZ = 
aripiprazole, QTP = quetiapine, AMI = amisulpride, FLU = flupenthixol, NAL = naltrexone. 
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Supplemental Table A: DD results 
Study N Dx Wks SUD(s) Treatment (dose) R D P Outcome 
Swanson et 
al. 200746 
362 SCZ 144 Alcohol + 
drugs 
Atypicals (clozapine, 
olanzapine, risperidone) 
vs. typicals (NR) vs. no 
medication 
N N N Patients compliant with atypicals exhibited less 
substance use than those receiving no 
medication or those compliant with typicals or 
those noncompliant with antipsychotic 
medication. 
Drake et al. 
200053 
151 SCZ 144 Alcohol + 
drugs  
Clozapine (NR) vs. 
typicals (NR) 
N N N Clozapine associated with significantly lower 
drinking severity, fewer days of alcohol use, 
reduction in severity of drug use and greater 
remission. 
Brunette et 
al. 200654 
95 SCZ 96 Alcohol + 
drugs  
Clozapine (484mg) vs. 
olanzapine or 
risperidone (NR) vs. 
typicals (NR) 
N N N Clozapine associated with significantly lower 
relapse rates than reference antipsychotics. 
Petrakis et 249 SCZ 48  Alcohol + Atypicals (olanzapine, N N N Those switched to or maintained on atypicals 
160 
 
 
 
al. 200652 drugs risperidone, quetiapine) 
vs. typicals (NR) 
exhibited significant reductions in alcohol and 
psychological ASI scores; however, differences 
disappeared after controlling for potential 
confounding factors. 
Rubio et al. 
200648 
115 SCZ 24 Alcohol + 
drugs 
Long-acting risperidone 
(47.2mg/15d) vs. 
zuclopenthixol depot 
(200mg/21d) 
Y N N Risperidone associated with significantly less 
alcohol and drug use and increased compliance 
with a SUD treatment program. 
Green et al. 
200349 
41 SCZ 48  Alcohol + 
cannabis 
Clozapine (439mg) vs. 
risperidone (3.9mg) 
N N N Clozapine associated with significantly lower 
rates of relapse. 
Brunette et 
al. 200851 
86 SCZ 24 Alcohol Clozapine (488mg) vs. 
olanzapine (18mg) vs. 
typicals (405mg*) 
N N N Clozapine associated with significantly lower 
relapse rates than olanzapine and olanzapine 
associated with significantly lower relapse than 
typicals. 
Noordsy et 
al. 200155 
38 SCZ 24 Alcohol  Olanzapine (15mg) vs. 
typicals (393mg*) 
N  N N Equally significant reductions in drinking. 
Sample size of drug users too small to run a 
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statistical analysis. 
Brown et al. 
200842 
102 BD 12 Alcohol Quetiapine (300-
600mg) vs. placebo 
Y Y Y No significant differences in drinking outcomes 
between groups. 
Brown et al. 
201043 
12 BD 12 Stimulants 
+ alcohol 
Quetiapine (429mg) vs. 
placebo  
Y Y Y No significant differences in cocaine use or 
craving. Quetiapine associated with 
significantly fewer heavy drinking days and 
longer time in treatment.  
Brown et al. 
200344 
24 BD 12 Stimulants Quetiapine (394mg) vs. 
typicals (471mg*) vs. 
no medication 
Y N N No significant difference in cocaine and 
amphetamine use between groups. Quetiapine 
associated with significant reductions in 
craving. 
Nejtek et al. 
200845 
94 BD 20 Stimulants Quetiapine (304mg) vs. 
risperidone (3mg) 
Y Y N Equally significant reductions cocaine and 
methamphetamine craving across groups.  
Smelson et 
al. 200260 
18 SCZ 6 Stimulants Risperidone (6mg) vs. 
typicals (522mg*) 
N N N Risperidone associated with significantly lower 
rates of relapse and less cue-elicited cocaine 
craving. 
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Smelson et 
al. 200661 
31 SCZ 6 Stimulants Olanzapine (10mg) vs. 
haloperidol (10mg) 
Y Y N No significant difference in cocaine use 
between groups. Olanzapine associated with 
significantly less cue-elicited cocaine craving. 
Sayers et al. 
200559 
24 SCZ 26 Stimulants Olanzapine (10-20mg) 
vs. haloperidol (10-
20mg) 
Y Y N No significant difference in cocaine use 
between groups. Haloperidol associated with 
significantly less cocaine craving. 
Akerele & 
Levin,  
200757 
28 SCZ 14 Stimulants 
+ cannabis 
Olanzapine (20mg) vs. 
risperidone (9mg) 
Y Y N No significant reductions in cocaine use or 
craving. Risperidone associated with 
significantly less cannabis craving; equally 
significant reductions in cannabis use between 
groups. 
van 
Nimwegen 
et al. 200856 
42 SCZ 6 Cannabis Olanzapine (11mg) vs. 
risperidone (3mg) 
Y Y N Equally significant reduction in cannabis 
craving and use between groups.  
Gerra et al. 
200758 
61 SCZ 12 Heroin Olanzapine (13mg) vs. 
haloperidol (9mg) 
N N N Olanzapine associated with significantly less 
heroin use and longer time in treatment. 
163 
 
 
 
Stuyt et al. 
200650 
55 SCZ 144 Tobacco Olanzapine (19mg) vs. 
risperidone (4mg) vs. 
ziprasidone (133mg) vs. 
typicals (NR) 
N N N Olanzapine and typicals associated with 
significantly more craving and lower 
completion rate of a SUD treatment program. 
George et al. 
200047 
44 SCZ 10 Tobacco Atypicals (600mg*) vs. 
typicals (625mg*) 
Y N N Atypical antipsychotics associated with 
significantly higher quit rates and lower 
expired CO. 
McEvoy et 
al. 199562 
12 SCZ 12 Tobacco Clozapine (see McEvoy 
et al. 1999) vs. 
haloperidol (20mg) 
Y Y N Two highest clozapine plasma levels associated 
with significant reductions in number of 
cigarettes smoked and expired CO. 
McEvoy et 
al. 199963 
55 SCZ 12 Tobacco Clozapine (171mg, 
414mg, or 551mg) vs. 
haloperidol (20mg) 
Y Y N Two highest clozapine plasma levels associated 
with significant reductions in cigarettes 
smoked. 
de Leon et 
al. 200564 
38 SCZ 16 Tobacco Clozapine (100mg, 
300mg, or 600mg) vs. 
haloperidol (NR) 
Y Y N No significant effect of clozapine treatment on 
plasma cotinine levels. 
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Table legend: N = sample size (intent-to-treat population), dx = diagnosis (majority), dose = mean or fixed exit dose, wks = weeks, 
stimulants = amphetamines and/or cocaine, SCZ = schizophrenia, BD = bipolar disorder, R = randomized, D = double-blind, P = placebo-
controlled, * = chlorpromazine equivalents, NR = not reported, CO = carbon monoxide.  
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Supplemental Table B: SD results  
Study N Wks SUD(s) Treatment (dose) R D P Outcome 
Wiesbeck et al. 
200177 
281 48 Alcohol Flupenthixol decanoate 
(10mg/14d) vs. placebo 
Y Y Y Flupenthixol associated with significantly higher 
relapse rates. 
Shaw et al. 
198773 
20 24 Alcohol Tiapride (100mg) vs. 
placebo 
Y Y Y Tiapride associated with significantly lower drinking 
and relapse in alcoholics with symptoms of depression 
and anxiety. 
Shaw et al. 
199474 
54 24 Alcohol Tiapride (100mg) vs. 
placebo 
Y Y Y Tiapride associated with significantly lower drinking 
and relapse.  
Gual et al. 
200275 
81 24 Alcohol Tiapride (100mg) vs. 
placebo 
Y Y Y Tiapride associated with significantly higher relapse 
rates. 
Bender et al. 
200676 
299 24 Alcohol Tiapride (100mg) vs. 
placebo 
Y Y Y Tiapride associated with significantly higher relapse 
rates. 
Marra et al. 
200270 
71 24 Alcohol Amisulpride (50mg) vs. 
placebo 
Y Y Y Amisulpride associated with significantly higher 
relapse rates and craving. 
Guardia et al. 60 12 Alcohol Olanzapine (8mg) vs. Y Y Y No differences in drinking variables between groups. 
166 
 
 
 
200467 placebo 
Hutchinson et 
al. 200665 
64 12 Alcohol Olanzapine (5mg) vs. 
placebo 
Y Y Y Olanzapine associated with significantly less drinking 
and cue-elicited craving and in individuals with the 
DRD4 L genotype, but not in those with D4D4 S. 
Kampman et 
al. 200766 
61 12 Alcohol Quetiapine (400mg) vs. 
placebo 
Y Y Y Quetiapine associated with significantly less drinking 
and craving in Type B but not in Type A alcoholics. 
Anton et al. 
200868 
295 12 Alcohol Aripiprazole (23mg) vs. 
placebo 
Y Y Y Aripiprazole associated with a significantly lower 
amount of heavy alcohol consumption and alcohol 
dependence severity. 
Martionotti et 
al. 200969 
57 16 Alcohol Aripiprazole (8mg) vs. 
naltrexone (50mg) 
Y Y N Aripiprazole associated with a significantly longer 
abstinence time; naltrexone associated with greater 
reductions in craving. 
Kampman et 
al. 200384 
30 12 Stimulants Olanzapine (10mg) vs. 
placebo  
Y Y Y Olanzapine associated with significantly more cocaine 
use and relapse. 
Reid et al. 
200583 
63 8 Stimulants Olanzapine (10mg) vs. 
placebo 
Y Y Y No differences in cocaine use and craving between 
groups. 
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Hamilton et al. 
200981 
48 16 Stimulants Olanzapine (7mg) vs. 
placebo 
Y Y Y No differences in cocaine use and craving between 
groups. 
Levin et al. 
199979 
14 24 Stimulants Risperidone (2mg) vs. 
placebo 
Y Y Y No differences in cocaine use and craving between 
groups. 
Grabowski et 
al. 200085 
125 12 Stimulants Risperidone (2mg vs. 
4mg vs. 8mg) vs. 
placebo 
Y Y Y High dose of risperidone associated with more cocaine 
use and a 100% dropout rate; no differences between 
the moderate and low doses of risperidone and 
placebo. 
Grabowski et 
al. 200482 
96 26 Stimulants Risperidone (2mg vs. 
4mg) vs. placebo 
Y Y Y No significant effect of risperidone, at any dose, on 
cocaine use. 
Loebl et al. 
200880 
31 12 Stimulants Long-acting risperidone 
(25mg/14d) vs. placebo 
Y Y Y No significant effect of risperidone on cocaine use and 
craving. Significantly greater depression in the 
risperidone group.  
Tiihonen et al. 
200786 
36 20 Stimulants Aripiprazole (15mg) vs. 
placebo 
Y Y Y Aripiprazole associated with significantly more 
intravenous amphetamine use than placebo. 
Gawin et al. 54 6 Stimulants Flupenthixol decanoate Y Y Y Flupenthixol associated with a reduction in crack 
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199678 (10-20mg/14d) vs. 
placebo 
cocaine use over placebo. 
 
Table legend: N = sample size (intent-to-treat population), wks = weeks, stimulants = amphetamine and/or cocaine, dose = mean or fixed 
exit dose, R = randomized, D = double-blind, P = placebo-controlled.  
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7.1 Abstract  
The atypical antipsychotic, quetiapine, is frequently prescribed on-and off-label for the 
treatment of a variety of psychiatric disorders. Since quetiapine has variable affinity for 
dozens of receptors, its clinical effects should also show large variation as a function of dose 
and diagnostic category. The present review will attempt to elucidate the dose-response and 
comparative efficacy and tolerability (metabolic data) of quetiapine across psychiatric 
disorders. A systematic search was performed in the electronic databases PubMed and 
EMBASE using the key words "quetiapine" AND "placebo". Both monotherapy and add-on 
studies were included. A total of forty-one studies were identified. In unipolar and bipolar 
depression, studies found quetiapine to be consistently effective versus placebo, at doses of 
around 150¬300mg/d and 300-600mg/d, respectively. In bipolar mania, they found quetiapine 
to be consistently effective at doses of around 600mg/d. In acute exacerbation of 
schizophrenia, the majority of studies found quetiapine to be consistently effective at doses of 
around 600mg/d, however, a few large studies found no difference versus placebo. By 
contrast, quetiapine was found to be more consistently effective for stable schizophrenia. In 
obsessive-compulsive disorder (OCD), studies found quetiapine to be inconsistently effective 
doses of around 300mg/d. However, studies may have underestimated quetiapine`s efficacy 
for OCD due to concomitant administration of antidepressants and the utilization of 
treatment-refractory patients. In generalized-anxiety disorder, studies suggest that quetiapine 
is consistently effective at doses of around 150mg/d. Finally, analysis of metabolic tolerability 
data suggests that even low doses of quetiapine may lead to increases in weight gain and 
triglycerides across psychiatric disorders. Interestingly, however, quetiapine-induced 
elevations in LDL and total cholesterol seem to be restricted to schizophrenia patients.  
Key words: quetiapine, schizophrenia, bipolar disorder, dose-response, depression, anxiety, 
cholesterol  
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7.2 Introduction  
In recent years, atypical antipsychotics have been increasingly tried for the treatment of 
numerous psychiatric conditions such as schizophrenia, bipolar disorder, major depressive 
disorder and anxiety disorders. Among atypical antipsychotics, quetiapine is perhaps the most 
frequently used in the treatment of psychiatric disorders other than schizophrenia. Indeed, 
placebo-controlled studies have shown that quetiapine may be an effective monotherapy in 
bipolar mania and depression (Bowden et al. 2005; Calabrese et al. 2005), major depressive 
disorder (MDD; Weisler et al. 2009; Bortnick et al. 2010) and generalized anxiety disorder 
(GAD; Bandelow et al. 2010; Katzman et al. 2010). In addition, quetiapine was shown to be 
superior to placebo as augmentation therapy for obsessive-compulsive disorder (OCD; Vulink 
et al. 2009; Denys et al. 2004). Finally, uncontrolled studies have found quetiapine to be 
effective for borderline personality disorder (Adityanjee et al. 2008; Perrella et al. 2007).  
With such a range of potential uses, quetiapine may very well be the “aspirin of 
psychiatry” (Stip, 2009). However, the mechanisms of action of quetiapine in the treatment of 
most of the aforementioned psychiatric disorders remain unclear. Quetiapine has affinity for 
dozens of receptors including histaminergic, noradrenergic, dopaminergic, serotonergic and 
cholinergic receptors (Bymaster et al. 1996; Schotte et al. 1996) – a characteristic that may be 
beneficial due to the high rate of comorbidity in psychiatry (Regier et al. 1990; Andrews et al. 
2002). Since the affinity of quetiapine varies greatly from receptor to receptor, its clinical 
effects should also show large variation as a function of dose. Consequently, understanding 
the dose-response and comparative efficacy and tolerability of this medication across 
diagnostic categories is essential for optimally treating each disorder.  
Interestingly, some recent reviews have questioned whether there are real therapeutic 
differences between high and low doses of quetiapine for schizophrenia (Sparshatt et al. 2008; 
Painuly, 2010). In addition, reviews on quetiapine`s dose-response have tended to focus on 
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the treatment of single psychiatric disorders; thus, not being able to compare its efficacy 
across diagnostic categories (Keating et al. 2007; McIntyre et al. 2009). The present review 
will examine placebo-controlled trials of quetiapine in order to elucidate the dose-response 
and comparative efficacy of this medication across psychiatric disorders. Dose- and 
diagnosis-related metabolic tolerability data will also be analyzed.  
 
7.3 Methods  
A systematic search was performed in the electronic databases PubMed and EMBASE using 
the key words "quetiapine" AND "placebo". Both monotherapy and add-on studies were 
included. This search looked for studies published between January 1, 1990 and October 1, 
2010. Additionally, studies were identified by cross-referencing of review articles. Published 
abstracts were not included in the analysis. Moreover, both monotherapy and add-on studies 
were included due to the lack of monotherapy studies for some psychiatric disorders.  
To be included in the review, studies must have contained a placebo-control group and 
addressed the treatment of adult psychiatric disorders with quetiapine. Fixed-and flexible-
dose studies with a duration of three weeks or longer were included. Studies of quetiapine for 
psychosis/delirium/agitation in geriatric patients were excluded due to the inability of 
investigators to use higher than minimal doses when searching for efficacy. Similarly, the 
number of placebo-controlled studies of quetiapine for bipolar-spectrum disorder, social 
anxiety disorder and substance use disorders was too low to establish a dose-response, and 
consequently, they were also excluded from the present review.  
Tolerability dose-responses were calculated by pooling fixed-dose studies of 
quetiapine monotherapy into three dose ranges (50-150mg, 300-400mg, 600-800mg). For 
each dose range, a weighted average of each tolerability mean value (e.g. weight gain, LDL 
cholesterol) was calculated for all relevant studies and adjusted for sample size. Tolerability 
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outcomes were separately calculated for schizophrenia and non-schizophrenia patients, since 
the former group may have poorer overall health (Druss and Rosenheck, 1997; Cradock-
O'Leary et al., 2002). Immediate-and extended-release formulations (IR and XR) were pooled 
for the same dose. Maintenance trials were excluded from tolerability analyses to minimize 
variation in study length. Non-metabolic data were not analyzed because these results have 
recently been published by another group (Wang et al. 2010). Quetiapine was judged to be 
consistently effective when an overwhelming number of studies with large sample sizes 
attested to its efficacy, relative to placebo. Quetiapine was judged to be inconsistently 
effective when some large trials attested to its efficacy, but other important trials found no 
difference compared to placebo. Considering the heterogeneity of conditions (e.g. acute 
exacerbation vs. stable schizophrenia, refractory vs. non-refractory, augmentation vs. 
monotherapy), studies included in this review were not amenable to quantitative meta-analytic 
treatment.  
 
7.4 Results  
Description of studies  
Forty-one studies were identified. Nine trials examined the treatment of unipolar depression 
with quetiapine (Table 1). Five trials examined the treatment of bipolar depression with 
quetiapine (Table 2). Three trials examined the treatment of GAD with quetiapine (Table 3). 
Eight trials examined the treatment of bipolar mania with quetiapine (Table 4). Ten trials 
examined the treatment of schizophrenia with quetiapine (Table 5). Finally, six trials 
examined quetiapine treatment of OCD (Table 6).  
 
Quetiapine for unipolar depression  
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Four studies investigated quetiapine augmentation of unipolar depression. One eight-week 
trial of quetiapine IR (mean dose = 182mg/d) augmentation of SRIs for treatment-refractory 
major depressive disorder (MDD), with comorbid anxiety, found significantly greater 
reductions in Hamilton Depression Scale (HAM-D) and Hamilton Anxiety Scale (HAM-A) 
total scores in the quetiapine group, compared to the placebo group (McIntyre et al. 2007). 
Another 8-week study of quetiapine IR (mean dose = 47mg/d) of fluoxetine for MDD found 
that quetiapine was not superior at improving Montgomery-Åsberg Depression Rating Scale 
(MADRS) response and remission (however, it did improve sleep and anxiety subset over 
placebo; Garakani et al. 2008). Furthermore, a 10-week trial of quetiapine IR (mean dose = 
148mg/d) augmentation of cognitive-behavioural therapy in treatment-refractory MDD found 
that quetiapine was superior to placebo at decreasing MADRS and HAM-D total scores at 
endpoint (Chaput et al. 2008). Additionally, a six-week study compared two doses of 
quetiapine XR (150 or 300mg/d) as adjuncts to SRIs. The authors found that 300mg was 
superior to placebo at decreasing MADRS total scores all time points, whereas 150mg was 
superior to placebo only in the first two weeks of the study. Finally, a six-week trial of 
quetiapine XR (150mg or 300mg/d) as augmentation to SRIs for MDD found both dose 
groups to improve in MADRS total scores at endpoint, relative to placebo (Bauer et al. 2009).  
Five studies investigated quetiapine as monotherapy for MDD. An eight-week study 
found that quetiapine XR (mean dose = 162mg/d) significantly decreased MADRS and HAM-
D total score versus placebo (Bortnick et al. 2010). Moreover, a six-week trial that compared 
monotherapy of MDD with three doses of quetiapine XR (50 or 150 or 300mg/d) 
demonstrated that all doses significantly decreased MADRS total scores at endpoint, relative 
to placebo (Weisler et al. 2009). However, only the 150mg and 300mg doses significantly 
decreased HAM-D total scores at endpoint. In addition, a six-week trial that compared 
quetiapine XR (150mg or 300mg/d) with duloxetine found that all active treatments reduced 
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MADRS total scores versus placebo (Cutler et al. 2009). However, differences between 
quetiapine and placebo were evident as early as week one, whereas the same could be said for 
duloxetine at week two. Additionally, the 300mg dose was superior to the 150mg dose in the 
proportion of MADRS remitters at week six and on some secondary efficacy measures 
(Cutler et al. 2009). Finally, a recent trial investigated quetiapine XR (mean dose = 177mg/d) 
as 52-week maintenance treatment in MDD patients (Liebowitz et al. 2010). The authors 
found that quetiapine significantly reduced the risk of recurrent depressive events and 
MADRS total scores at endpoint, compared to placebo.  
 
Quetiapine for bipolar depression  
Five large studies examined quetiapine as monotherapy for bipolar depression. One eight-
week study found that quetiapine XR (300mg/d) was significantly better than placebo at 
decreasing MADRS total scores at endpoint (Suppes et al. 2010). In addition, two 
complementary eight-week trials (BOLDER I + II) found that quetiapine IR (300 or 600mg/d) 
was superior to placebo at decreasing MADRS total scores at endpoint. However, there were 
no significant differences between the two doses of quetiapine in either study (Calabrese et al. 
2005; Thase et al. 2006). More recently, two complementary eight-week studies 
(EMBOLDEN I + II) found that quetiapine IR (300 or 600mg/d) was superior to lithium and 
paroxetine and placebo at reducing MADRS total scores at endpoint (Young et al. 2010; 
McElroy et al. 2010).  
 
Quetiapine for bipolar mania  
Five studies examined quetiapine augmentation of lithium or divalproex (Li/DVP) for bipolar 
mania. One three-week study found that augmentation of Li/DVP with quetiapine IR (mean 
dose = 504mg/d) resulted in greater decrease in Young Mania Rating Scale (YMRS) total 
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scores than with placebo (Sachs et al. 2004). In addition, a six-week trial found that 
quetiapine augmentation (mean dose = 492) of Li/DVP was associated with significant 
reduction in YMRS total scores compared to placebo (Yatham et al. 2004). Another six-week 
study by the same team found that augmentation of Li/DVP with quetiapine IR (mean dose = 
455mg/d) resulted in significantly greater YMRS response rate but not change in YMRS total 
scores at endpoint (Yatham et al. 2007). Lastly, two large complementary studies examined 
the augmentation of Li/DVP with quetiapine IR (mean dose = 446mg and 519mg/d, 
respectively) for maintenance of bipolar I disorder (Vieta et al. 2008; Suppes et al. 2009). 
These trials demonstrated that the proportion of patients having a mood event (mania or 
depression) was significantly lower in the quetiapine than in the placebo group.  
Three studies examined the monotherapy of bipolar mania with quetiapine. A 12-week 
study found that quetiapine IR (mean dose in responders = 618mg/d) and lithium equally 
reduced YMRS total scores at endpoint, relative to placebo (Bowden et al. 2005). Another 12-
week study found that quetiapine IR (mean dose in responders = 559mg/d) and haloperidol 
decreased YMRS total scores at endpoint, relative to placebo. However, unlike quetiapine, 
haloperidol was more effective than placebo early in the study (McIntyre et al. 2007). In 
addition, a three-week trial found that quetiapine IR (median mode dose = 600mg/d) and 
paliperidone were equally superior to placebo at reducing YMRS total scores at endpoint 
(Vieta et al. 2010).  
 
Quetiapine for schizophrenia  
Four out of eight studies of quetiapine versus placebo for acute exacerbation of schizophrenia 
employed a fixed-dose design (Fabre et al. 1995; Arvanitis et al. 1997, Kahn et al. 2007; 
Lindenmayer et al. 2008). One small three-week trial of quetiapine IR (250mg/d) for 
schizophrenia found the medication to significantly decrease Brief Psychiatric Rating Scale 
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(BPRS) total scores relative to placebo (Fabre et al. 1995). Another study by the same team 
compared five doses of quetiapine IR (75, 150, 300, 600, or 750mg/d) with haloperidol 
(12mg/d) over six weeks for acute exacerbation of schizophrenia (Arvanitis et al. 1997). The 
authors found that 150, 300, and 600mg doses of quetiapine and haloperidol produced 
similarly significant reductions in BPRS total scores compared to placebo (however, the 
750mg dose fared slightly worse). A larger six-week study compared quetiapine IR 400mg/d 
with quetiapine XR 400, 600 or 800mg/d and placebo for acute schizophrenia (Kahn et al. 
2007). Results showed that all treatment groups evidenced significant reductions in Positive 
and Negative Syndrome Scale (PANSS) total scores compared to placebo. However, the 
largest differences versus placebo were found for the 600mg and 800mg groups, with no 
differences between them. Another six-week study compared quetiapine IR (300 or 600mg/d) 
with quetiapine XR (300, 600 or 800mg/d) for acute schizophrenia. The authors found that 
only those patients randomized to quetiapine XR 600mg evidenced a significant reduction in 
PANSS total scores, relative to placebo (Lindenmayer et al. 2008).  
The remaining four studies investigated quetiapine for acute schizophrenia using a 
flexible-dose design (Borison et al. 1996; Small et al. 1997; Potkin et al. 2006; Canuso et al. 
2009). One six-week study that examined quetiapine IR (mean dose = 307mg/d) for acute 
schizophrenia found a non-significant trend for reductions in BPRS total scores, relative to 
placebo (Borison et al. 1996). Another study by the same team, which compared patients 
treated with low (mean = 209mg/d) or moderate doses (mean = 360mg/d) of quetiapine IR for 
acute schizophrenia, found that only those patients randomized to the latter dosage evidenced 
significant reductions in BPRS total scores, compared to placebo (Small et al. 1997). A more 
recent study compared quetiapine IR (mean dose = 556mg/d) with risperidone (mean dose = 
4.4mg/d) for acute exacerbation of schizophrenia (Potkin et al. 2006). The study included a 
two-week monotherapy phase followed by a four-week additive therapy phase. At the end of 
179 
 
 
 
the monotherapy phase, risperidone, but not quetiapine, was superior to placebo in decreasing 
PANSS total scores. Additionally, at the end of the additive therapy phase, a significantly 
lower percentage of risperidone-treated patients required the prescribing of additional 
antipsychotics (33%), compared to patients treated with quetiapine (53%) and placebo (59%). 
A similar trial that compared quetiapine IR (mean dose = 599mg/d) with paliperidone XR 
(mean dose = 9.8mg/d) for acute schizophrenia found that paliperidone, but not quetiapine, 
was superior to placebo at decreasing PANSS total scores at the end of the monotherapy 
phase (Canuso et al. 2009). At the end of the additive therapy phase, 42% of paliperidone, 
51% of quetiapine and 62% of placebo-treated patients required additional antipsychotic 
treatment; a difference that emerged significant only for paliperidone relative to placebo.  
Two studies examined quetiapine as treatment for clinically stable schizophrenia 
(Peuskens et al. 2007; Chen et al. 2010). In the first study, patients who were clinically stable 
on quetiapine XR for four months were randomized to receive quetiapine XR (mean dose = 
669mg/d) or placebo for an additional 10 months. The authors found that quetiapine was 
associated with significantly longer time to relapse and lower relapse rates, relative to placebo 
(Peuskens et al. 2007). These findings were replicated by a more recent trial that switched 
positive symptom-free first-episode patients from their baseline antipsychotic to treatment 
with quetiapine IR (400mg/d) or placebo. The authors found that quetiapine was associated 
with a significantly lower rate of relapse after one year of treatment (Chen et al. 2010).  
 
Quetiapine for OCD  
All of the studies of quetiapine for OCD administered the medication as add-on therapy. 
Moreover, five out of six of these studies included patients who did not respond to previous 
treatment with SRIs. One group administered a fixed-dose of quetiapine IR (300mg/d) in an 
eight-week add-on therapy to SRIs (Denys et al. 2004). Their results showed a significantly 
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greater decrease in Yale-Brown Obsessive Compulsive Scale (YBOCS) total scores in the 
quetiapine group, relative to the placebo group. Similarly, a smaller, eight-week, single-blind 
trial of quetiapine IR (mean dose = 91mg/d) add-on to SRIs for refractory OCD found a 
significantly greater decrease in YBOCS total scores in the quetiapine group (Atmaca et al. 
2002). On the other hand, a six-week trial failed to demonstrate an advantage for quetiapine 
IR (mean dose = 169mg/d) in decreasing YBOCS total scores, when administered as add-on 
to SRIs for refractory OCD (Carey et al. 2005). Another 16-week, add-on trial to selective 
serotonin reuptake inhibitors (SSRIs), did not show any benefits of quetiapine IR (mean dose 
= 215mg) versus placebo in the treatment of refractory OCD (Fineberg et al. 2005). Likewise, 
a 12-week trial of high-dose quetiapine (dose range = 400-600mg/d) as augmentation of SRIs 
did not find a significant difference between the treatment and placebo groups for refractory 
OCD (Kordon et al. 2008).  
One study of quetiapine for OCD utilized non-treatment refractory patients. This 10-
week trial found that quetiapine (dose range = 300-450mg/d) augmentation of citalopram was 
superior to placebo in decreasing YBOCS total scores at endpoint (Vulink et al. 2009).  
 
Quetiapine for GAD  
Two studies of quetiapine for GAD administered the medication as monotherapy. One of 
these was an eight-week study that investigated two fixed-doses of quetiapine XR (50mg or 
150mg/d) versus paroxetine (20mg/d) (Bandelow et al. 2010). All active-treatments produced 
significant reductions in Hamilton Rating Scale for Anxiety (HAM-A) total scores at 
endpoint; however, the 150mg dose was associated with the largest and fastest improvement 
relative to placebo. Another study that evaluated quetiapine XR (mean dose = 163mg/d) as 
52-week maintenance treatment for GAD demonstrated that quetiapine-treated patients had 
significantly reduced risk of anxiety symptom recurrence and a lower HAM-A total score 
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prior to the last anxiety event, relative to placebo (Katzman et al. 2010). On the other hand, a 
small study which administered quetiapine (mean dose = 121mg/d) as eight-week add-on 
therapy to paroxetine for treatment-refractory GAD found no difference between quetiapine 
and placebo in reduction of HAM-A scores at endpoint (Simon et al. 2008).  
 
Tolerability  
The mean duration of fixed-dose studies that were used to calculate the effect of dose and 
psychiatric diagnosis on metabolic tolerability outcomes was 7.3 (1.3) weeks. The pooled 
mean change (schizophrenia versus other diagnoses) in weight, triglycerides, LDL and total 
cholesterol for the fixed-dose studies is shown in Figures 1a-d. In general, a dose-dependent 
elevation was observed for weight and triglycerides in both schizophrenia and non-
schizophrenia patients. By contrast, elevations of LDL and total cholesterol were observed 
uniquely for schizophrenia patients.  
 
7.5 Discussion  
The present review was aimed to elucidate the dose-response and comparative efficacy and 
tolerability of quetiapine across psychiatric disorders. In unipolar and bipolar depression, 
studies consistently found quetiapine to effective versus placebo, at doses of around 150-
300mg/d and 300-600mg/d, respectively. In bipolar mania, they consistently found quetiapine 
to be effective at doses of around 600mg/d. In acute exacerbation of schizophrenia, the 
majority of studies consistently found quetiapine to be effective at doses of around 600mg/d, 
however, a few large studies found no differences versus placebo. By contrast, they 
consistently found quetiapine to be effective for stable schizophrenia. In OCD, studies did not 
consistently quetiapine to be effective doses of around 300mg/d. However, studies may have 
underestimated quetiapine`s efficacy for OCD due to concomitant administration of 
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antidepressants and the utilization of treatment-refractory patients. In GAD, studies 
consistently found quetiapine to be effective at doses of around 150mg/d, and while the 
number of studies is low, these results have been supported by as of yet unpublished studies 
(Atkinson et al 2008; Merideth et al 2008; Mezhebovsky et al. 2009). Finally, analysis of 
metabolic tolerability data suggests that even low doses of quetiapine may lead to increases in 
weight gain and triglycerides across psychiatric disorders. Interestingly, however, quetiapine-
induced elevations in LDL and total cholesterol seem to be restricted to schizophrenia 
patients.  
The efficacy of quetiapine in the treatment of depression has been a mystery for some 
time. Classically, drugs which have antidepressant properties are inhibitors of serotonergic 
(SERT) and/or noradrenergic (NET) transporters. Quetiapine has no affinity for SERT or 
NET but its principle active metabolite, N-desalkylquetiapine (norquetiapine), is a potent 
antagonist of NET (Jensen et al. 2008). In fact, the amount of NET occupancy in patients that 
are treated with quetiapine (150 or 300mg/d) is similar to that measured in patients that are 
treated with the TCA nortriptyline (Nyberg et al. 2007, 2008; Sekine et al. 2010). Whether or 
not NET inhibition can fully explain quetiapine`s antidepressant efficacy is unclear since 
norquetiapine also has high affinity for a number of serotonergic receptor subtypes such as 5-
HT1A, 5-HT2A, 5-HT2C and 5HT7 – all of which may have value as potential targets for new 
antidepressant drugs (Adell et al. 2005; Mnie-Filali et al. 2007). The fact that quetiapine 
significantly decreased MADRS scores a full one to two weeks before the dual SERT and 
NET inhibitor, duloxetine, may point to the presence of other antidepressant mechanisms 
(Cutler et al. 2009). Alternatively, in the Cutler et al. (2009) study, the main advantage of 
quetiapine over duloxetine and placebo was via an improvement in sleep, suggesting that 
histaminergic and/or adrenergic antagonism may be sufficient for observation of an early-
onset anti-depressant effect.  
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Quetiapine`s efficacy for GAD at low doses is unsurprising since it is a potent 
antagonist of α-1 receptors, which regulate the response of the sympathetic nervous system 
and are a target of many TCAs (Stahl, 2008). In addition, norquetiapine is a potent partial 
agonist of 5HT1A receptors, which are also activated by azapirones – a class of drugs with 
established efficacy for GAD (Chessick et al. 2006; Jensen et al. 2008). It is perhaps because 
of these mechanisms, in addition to NET antagonism, that quetiapine XR (150mg) was shown 
to significantly decrease HAM-A total scores a full one to two weeks before the SSRI, 
paroxetine (Bandelow et al. 2010). While quetiapine seems to have promise as a treatment for 
GAD, the overlap in receptor activity between quetiapine and many antidepressants may 
account for why studies of quetiapine augmentation of antidepressants for OCD have been 
mixed (Atmaca et al. 2002; Denys et al, 2004; Carey et al. 2005; Vulink et al, 2009). 
Likewise, the utilization of treatment-resistant patients may preclude the observation of a 
positive effect, due to the fact that these patients have already undergone numerous trials with 
other antidepressant drugs.  
One possibility for why a few large studies did not find quetiapine to be superior to 
placebo for acute schizophrenia may be that studies used conventional titration (5-8 days), 
thereby underestimating quetiapine`s efficacy, especially in the first weeks of administration. 
However, although a preliminary study found rapid titration (3-4 days) to be superior in 
reducing PANSS total scores in schizophrenia patients (Pae et al. 2005), these findings were 
not replicated by a more recent and larger trial (Boidi and Ferro, 2007). Instead, it is more 
likely that quetiapine is a less effective antipsychotic overall, due to its low affinity and loose 
binding to dopamine D2 receptors (Kapur and Seeman, 2001), which may result in inadequate 
blockade of endogenous dopamine hyperactivity, which is believed to play an important role 
in the pathophysiology of positive symptoms in schizophrenia and mania in bipolar disorder 
(Cousins et al. 2009; Howes and Kapur, 2009). In the case of bipolar mania, quetiapine`s 
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loose binding to D2 receptors may be sufficient to achieve consistent efficacy versus placebo, 
since even bipolar mania with psychotic features is associated with a lower mean severity of 
hallucinations and delusions compared to schizophrenia (Baethge et al. 2005). Like bipolar 
mania, stable schizophrenia should respond better to quetiapine treatment, compared acute 
schizophrenia, because it presumably requires less dopaminergic inhibition to attenuate 
positive symptoms. Indeed, two trials of stable schizophrenia did attest to the superiority of 
quetiapine in decreasing relapse rates, relative to placebo (Peuskens et al. 2007; Chen et al. 
2010). Taken together, this evidence suggests that quetiapine may be more effective for 
stable, as opposed to acute schizophrenia.  
A recent study by our group supports the interpretation that quetiapine may produce 
inadequate D2 blockade for the treatment of severe psychoses, even at high doses (Gallo et al. 
2010). In that study, rats received three doses of quetiapine (i.p; 5mg, 10mg and 20mg/kg) 
before being tested in the intracranial self-stimulation paradigm – a powerful and validated 
model of mesolimbic dopaminergic activity (Wise and Rompre, 1989). Surprisingly, all doses 
of quetiapine produced an equally weak attenuation of reward (~20%; Gallo et al. 2010). On 
the other hand, there is evidence that mesolimbic reward attenuation by clozapine and 
haloperidol is dose-dependent and can reach ~45% and ~65%, respectively (Benaliouad et al. 
2007). Supporting the finding that above-maximal doses of quetiapine are not more 
beneficial, a randomized, double-blind, eight-week trial by our group found no difference in 
reduction of PANSS total scores between patients treated with 800mg and 1200mg/d (Honer 
et al. in press) Taken together, our analyses suggest that quetiapine`s antipsychotic efficacy 
may be somewhat of an `all-or-nothing` response and is inconsistently efficacious for acute 
schizophrenia. 
Analysis of tolerability outcomes suggests that quetiapine may produce elevations in 
body weight and triglycerides, even at minimal doses. Elevations in LDL and total cholesterol 
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were also observed but only in schizophrenia patients. These data are limited by the low 
number of studies using 50-150mg for schizophrenia, thereby preventing any meaningful 
direct comparisons at those doses. Nevertheless, the findings confirm the potential for weight 
gain and metabolic side-effects with quetiapine treatment (Simon et al. 2009). They also 
suggest a possible interaction between schizophrenia genes and quetiapine in increasing 
metabolic risk (Boston et al. 1996; Stahl et al. 2009). Intriguingly, a recent study found that 
antipsychotic-naive schizophrenia patients did not exhibit increased LDL and total 
cholesterol, relative to controls (Kirkpatrick et al. 2010). Unfortunately, however, it is yet 
unclear which mechanisms/genes may be responsible for the quetiapine-induced elevations in 
cholesterol in schizophrenia patients.  
The present review is limited due to the inclusion of studies that administered 
quetiapine as augmentation therapy, rather than monotherapy. Quetiapine augmentation of 
antidepressants, for example, may limit interpretation of results since their mechanisms may 
overlap. Interpretation of studies that utilized patients who were resistant to treatment with 
antidepressants is problematic for the same reason. Similarly, in the treatment of bipolar 
mania, the majority of studies administered quetiapine as augmentation to mood stabilizers, 
which may have overestimated the efficacy of the medication as monotherapy for bipolar 
mania (especially in the case of bipolar mania with psychotic features). However, we chose to 
include augmentation studies because of the low number of monotherapy trials with 
quetiapine for certain psychiatric conditions. Additionally, monotherapy and add-on studies 
generally came to the same conclusions.  
Overall, our review highlights the need for more monotherapy trials to be conducted in 
order to better elucidate the efficacy of quetiapine, especially in the case of severe psychoses 
and anxiety disorders. Moreover, the efficacy of quetiapine for both mania and depression 
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makes it an interesting treatment option for mood swings and behavioral instability in 
borderline personality disorder. Randomized controlled trials are warranted in the future. 
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8. General Discussion
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Nearly half of all schizophrenia patients have had a substance use problem during their lifetime 
(Regier et al. 1990). Substance abuse/dependence in schizophrenia is associated with negative 
consequences for the patient and society as a whole. Studies have often found that DD patients 
exhibit more delusions, hallucinations and mood symptoms and they have higher rates of 
rehospitalisation, homelessness, medical problems and infectious diseases, violence, crime, and 
suicide (Negrete et al. 1986; Lysaker et al. 1994). Moreover, DD patients are significantly more 
likely to be noncompliant with antipsychotic treatment, leading to further deterioration in clinical 
and functional outcomes (Drake et al. 1989). 
 
8.1 Extrapyramidal symptoms in substance abusers with and without schizophrenia and in 
non-abusing patients with schizophrenia (baseline analysis) 
In order to understand what impact quetiapine may have on changes in psychiatric and 
extrapyramidal side-effects and substance abuse outcomes across the three groups, we must first 
examine their presence at baseline. In our baseline analyses of psychiatric symptoms, we found 
significantly elevated positive symptoms in DD patients, compared to SUD patients (Zhornitsky 
et al. 2010c). However, positive symptoms were still clinically elevated in our SUD group (mean 
= 15.4 on the PANSS). These results are in accordance with studies showing that substance 
abuse/dependence is associated with increased positive symptoms in schizophrenia patients and 
‘positive-like’ (e.g. paranoia, excitement) symptoms in non-psychosis substance abusers (Serper 
et al. 1999; Mauri et al. 2007; Lapworth et al. 2009).  
We also found elevated negative symptoms in DD and SCZ, compared to SUD patients. 
The results suggest that negative symptoms are relatively unique to schizophrenia, rather than 
arising due to substance abuse. Additionally, while we did not find a significant difference 
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between negative symptoms in DD and SCZ patients in the present study, a previous meta-
analysis revealed that the former group may experience less negative symptoms (groups did not 
differ in age, sex, and positive/general psychopathology)(Potvin et al. 2006b). The differences in 
outcome between the two studies may reflect a type-II error due to the heterogeneous nature of 
substance(s) abused and low sample sizes involved. 
Moreover, we found that depressive symptoms were nearly twice as high in DD patients 
and over one and a half times higher in SUD, relative in SCZ patients. This finding is in line with 
research showing that substance abuse is a risk factor for the development of depression 
(Lynskey et al. 2004; Falck et al. 2006). On the other hand, there is evidence that depressive 
symptoms may lead an individual to abuse substances in order to relieve the symptoms via 
negative reinforcement (Koob and Le Moal, 2008).  
Our analyses of parkinsonism between the three groups revealed that SUD patients had 
(numerically) elevated scores at baseline (mean [SD] = 6.1 [6.2] on ESRS parkinsonism 
subscore), suggesting that substance abuse may produce parkinsonism independently of 
antipsychotics (at least transiently). Moreover, we found that DD patients evidenced increased 
parkinsonism scores at baseline, relative to SCZ patients (mean [SD] = 9.2 [13.5] vs. 3.2, 
respectively). In support, our previous meta-analysis (n=3479) showed that substance abuse is 
associated with augmented parkinsonism in DD patients, versus SCZ patients (Potvin et al. 
2009). Further, we conducted a sub-analysis to see which substance(s) were responsible for this 
result. The sub-analysis showed that parkinsonism was significantly correlated with abuse of 
alcohol and psychostimulants, which is in accordance with previous studies showing that these 
substances elicit deleterious effects on the basal ganglia (discussed in the introduction).  These 
data show that antipsychotics may interact with alcohol and psychostimulants to increase 
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parkinsonism in DD patients. We suspect that abuse of these substances also contributed to 
parkinsonism in SUD patients; however, we did not perform a sub-analysis in this group because 
they were not statistically different from DD or SCZ patients.  
Unexpectedly, we found elevated akathisia at baseline in SUD patients, relative to the 
other two groups. This result is surprising because akathisia is a symptom that is classically 
associated with antipsychotic treatment. Importantly, our measure of akathisia included both 
subjective and objective components, which suggests the presence of ‘true’ akathisia (and not 
merely restlessness) in our SUD group. Moreover, a sub-analysis revealed that akathisia was 
related to alcohol and cannabis abuse which is consistent with reports of restlessness and 
physical tension/agitation during alcohol and cannabis withdrawal (West and Gossop, 1994; 
Kouri and Pope, 2000; Budney et al. 2003).  
There were baseline differences in dyskinesia in our larger sample (SCZ > DD & SUD). 
They disappeared after entering hospitalizations into the ANCOVA. This may be explained by 
the fact that dyskinesia is a symptom that appears after prolonged antipsychotic treatment and 
our SCZ group was significantly older, relative to DD patients. Dystonia was not present in 
significant amounts in this study. 
Altogether, the elevated positive and depressive symptoms and parkinsonism in DD 
patients is significant because DD patients were using significantly lower quantities of 
substances, compared to SUD patients (mean [SD] = 82.3 [62.3] vs. 795.6 [1748.6] dollars per 
week). Significantly, these findings support the notion that abuse of alcohol and drugs may 
induce clinically relevant aggravations in symptomatology in DD patients, even if they use small 
amounts, infrequently (Ziedonis et al. 2005). They also show that substances of abuse may 
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induce psychiatric and extrapyramidal symptoms in non-psychosis individuals, independently of 
schizophrenia diagnosis or antipsychotic treatment.  
 
8.2. Evolution of substance use, neurological and psychiatric symptoms in schizophrenia 
and substance use disorder patients: a 12-week, pilot, case-control trial with quetiapine 
We conducted our case-control trial for three main reasons. First, we asked whether differences 
in improvement would allow us to better understand the trajectory of symptoms in the ‘real 
world setting’. Previous research among non-psychosis substance abusers revealed that they 
exhibited greater improvement in psychopathology following 2-week quetiapine treatment 
compared to non-abusing schizophrenia patients (Mauri et al. 2007). Second, we asked whether 
our analyses would allow us to divulge differences in the nature of the groups themselves. That 
is, are there differences that are innate to DD, SCZ and SUD patients, regardless of comorbid 
substance abuse/dependence (state vs. trait)? Previous research has shown that DD patients may 
have more depressive and less negative symptoms at baseline, compared to SCZ patients; 
however, follow-up studies of the groups undergoing a homogenous antipsychotic treatment are 
lacking (Conley et al. 1998; Potvin et al. 2007). Finally, we aimed to examine the impact of 
quetiapine on changes in substance abuse/dependence outcomes and psychiatric and 
extrapyramidal symptoms across the groups. This is an important question because (as discussed 
previously) quetiapine may have different levels of benefits for different groups of patients, 
depending on the level of comorbid psychiatric symptoms, as well as the dose prescribed. Our 
hypothesis was that quetiapine treatment would result in improvements in substance abuse and 
clinical variables (psychiatric and neurological symptoms) across the groups. We also expected 
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that improvements in substance abuse would be less pronounced in DD patients, relative to non-
psychosis substance abusers. 
In accordance with our hypothesis, we found that all three groups evidenced significant 
improvements in clinical and neurological variables with time, which is consistent with the 
existence of a placebo/practice effect in naturalistic studies of this kind (Goodwin, 2002). 
Likewise, we found that SUD patients had a higher mean SUD severity, spent significantly more 
dollars weekly on alcohol and drugs at baseline and showed greater improvement in these 
variables, compared to DD patients. At endpoint, there was no significant difference in dollars 
spent, but DD patients had a higher mean SUD severity. One explanation for the result that SUD 
patients improved more in substance abuse outcomes than DD patients may be that SUD patients 
had a significantly higher SUD severity at baseline, leading to the greater improvement. In 
support of this explanation, SUD severity was the only significant factor when entered in the 
ANCOVA model.  The results could also be explained by the fact that our SUD group began the 
study in detoxification, whereas our DD group were active users, suggesting that it was easier for 
the former patients to quit alcohol and/or drugs. Alternatively, the results could suggest that it 
may be more difficult for schizophrenia patients to reduce or quit their substance use (Ziedonis et 
al. 2005). In addition, we found that DD patients had a higher mean SUD severity than SUD 
patients at endpoint, despite spending similar amounts on alcohol and drugs. These data are 
supported by evidence that substances of abuse can have deleterious consequences on 
schizophrenia patients, even when they use small amounts (Ziedonis et al. 2005) and evidence of 
increased D2/D3 occupancy in PET studies of schizophrenia patients in response to amphetamine 
challenge, relative to healthy controls (Laruelle, 2000). Together, these data support the 
dopaminergic supersensitivity model of schizophrenia. 
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We also found that SUD patients exhibited elevated PANSS positive symptoms at 
baseline and they improved more than the other two groups. This finding is consistent with 
results of Mauri et al. (2007). In that study, patients with schizophrenia, drug-induced psychosis, 
and borderline personality disorder were treated for two weeks with quetiapine. Their results 
revealed that positive symptoms in drug-induced psychosis individuals were similar to those seen 
in schizophrenia patients at baseline and they exhibited significantly more improvement by 
endpoint. However, in the present study, only two non-psychosis patients were diagnosed with 
substance-induced psychotic disorder (DSM-IV criteria). In order to receive this diagnosis, the 
DSM-IV requires the individual to present with persistent delusions or hallucinations and a lack 
of insight into the nature of these symptoms that cannot be accounted for by organic or 
functional psychosis. Consequently, we examined in more detail which PANSS positive items 
were most elevated at baseline in our SUD group and we found that the most elevated items 
(mean score ≈3) were hostility, excitement and paranoia/suspiciousness. The lack of substance-
induced psychotic disorder diagnosis may be explained by the fact that insight was still present 
in most SUD subjects, even when experiencing symptoms such as paranoia as well as the lack of 
hallucinations and delusions (excluding paranoid delusions). Moreover, the finding that positive 
symptoms showed greater improvement in SUD patients, relative to DD and SCZ patients, is 
likely linked to their greater improvement in substance abuse outcomes. Taken together, our 
findings suggest that paranoia is not a symptom that reliably distinguishes between schizophrenia 
and SUD patients undergoing detoxification. 
Analysis of PANSS negative symptoms revealed that they were significantly more 
elevated in DD and SCZ patients, relative to SUD individuals, and there was no significant 
difference in their improvement across the groups. Again, these results suggest that negative 
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symptoms are relatively unique to schizophrenia. However, non-psychosis individuals presenting 
with substance-induced psychosis may still exhibit significant levels of negative or ‘negative-
like’ symptoms, which tend to return to baseline following cessation of substance use (Mauri et 
al. 2007). 
CDSS scores were significantly elevated in DD and SUD patients at baseline, compared 
to SCZ patients; however, there was no difference in improvement between the groups. This 
latter finding is interesting because it suggests that some DD and SUD patients still had residual 
depressive symptoms, although they both significantly reduced their substance use over time. 
Furthermore, at study endpoint, CDSS scores (mean [SD] = 3.9 [3.6]) were persistently elevated 
in DD patients, despite being prescribed quetiapine – a clinically effective antidepressant. This 
finding may be explained by the fact that DD patients still had a significantly higher SUD 
severity at the end of the study. In addition, CDSS scores were (numerically) elevated in SUD 
patients versus SCZ patients (mean [SD] = 1.8 [3.1] vs. 1.2 [1.6], respectively). Taken together, 
these data suggest that depression is more strongly associated with substance abuse than 
schizophrenia – at least transiently – and should be considered a key target for the treatment of 
SUDs in psychosis and non-psychosis patients.  
Parkinsonism was increased at baseline in DD, relative to SCZ patients and there was no 
significant difference in improvement between the groups. The lack of difference in 
improvement in parkinsonism may be attributed to the fact that all three groups were prescribed 
quetiapine. It may also be attributed to a type-II error because parkinsonism scores were lower in 
this SUD sample and variability was higher (mean [SD] = 5.7 [6.9]), relative to our larger 
baseline sample of SUD patients (described previously). Additionally, at endpoint, DD patients 
still had elevated parkinsonism, relative to the other two groups, although they were taking 
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similar amounts of substances, compared to SUD patients. As a whole, these data show that 
antipsychotics and substances of abuse may independently produce parkinsonism, but co-
administration of the two may act in synergy to further elevate parkinsonism. Interestingly, a 
sub-analysis in DD patients revealed that improvements in parkinsonism were only significant in 
abusers of psychostimulants. This is unsurprising because cocaine abuse is associated with 
significant reduction in dopamine D2 receptor availability in the striatum that may last for 
months after detoxification, similar to the striatal dopaminergic deficit observed in Parkinson's 
disease (Volkow et al. 2004). Moreover, this finding suggests that parkinsonism is more strongly 
associated with cocaine abuse than alcohol abuse, since our baseline sample found both to be 
associated with this symptom. Indeed, previous studies found high levels of Parkinsonian resting 
tremor in non-psychosis cocaine abusers, which contrasts with the (non-parkinsonian) active 
tremor found in alcoholics (Bauer et al. 1993, 1996).  
Akathisia was significantly elevated in SUD patients and they improved significantly 
more, compared to the other two groups. Moreover, our sub-analysis showed that the 
improvement was correlated with the presence of cannabis use disorder, thus excluding the 
effects of alcohol, which were correlated with akathisia in our baseline sample. Consequently, 
we confirm the presence of ‘true’ akathisia during cannabis detoxification – a result that 
coincides with previous studies that evidenced objective restlessness as a consequence of 
cannabis withdrawal (Kouri and Pope, 2000; Budney et al. 2003). Although speculative, these 
results imply that the endogenous cannabinoid system is involved in the manifestation of 
akathisia, which may be associated with its role in motor behaviour (El Manira and Kyriakatos, 
2010). 
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There were no significant differences at baseline or in terms of improvement in 
dyskinesia between the groups. Moreover, there were not a significant number of cases of 
dystonia observed in this study. 
Overall, our results suggest that schizophrenia patients may be supersensitive to the 
effects of alcohol and drugs of abuse, as evidenced by the high SUD severity at endpoint in DD 
patients, despite spending similar amounts of money to obtain the substances. They also suggest 
that antipsychotics and substances of abuse interact in DD patients to increase parkinsonism, 
although they may both produce these symptoms independently of each other. In addition, they 
indicate that substance abuse/dependence is associated with increased depression in psychosis 
and non-psychosis substance abusers. Finally, our results suggest that substances of abuse may 
induce ‘positive-like’ symptoms and akathisia in non-psychosis SUD patients, independent of 
antipsychotic treatment or schizophrenia diagnosis. Unfortunately, we were not able to clarify 
the role of quetiapine in our results and quetiapine dose did not significantly affect any of our 
outcomes when entered as a covariate in the ANCOVA model.  
 
8.3. Clinical evolution of substance use disorder patients during treatment with quetiapine: 
a 12-week, open-label, naturalistic trial  
Before we can describe the impact of quetiapine on psychiatric and extrapyramidal symptoms in 
the three groups, we need to examine its impact on substance abuse as well as safety and 
tolerability outcomes. Analysis of safety/tolerability is crucial because these patients were 
undergoing detoxification and antipsychotic treatment may have potential health implications 
such as increased risk for seizures (Gillman and Lichtigfeld, 1990) and extrapyramidal reactions 
due to dopaminergic supersensitivity (Evans et al. 2001). In addition, we examined the effects of 
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quetiapine on substance use, and craving. Furthermore, although we did not include specific 
scales for the measurement of withdrawal symptoms, we recorded benzodiazepine use for each 
patient (prescribed for withdrawal).   
Analysis of results of our SUD arm revealed that, during quetiapine therapy, substance 
use outcomes (quantities used and severity of SUDs and craving) significantly improved over 
time and this was corroborated by urine screenings. In addition, the present study was 
complementary to a study by Potvin et al. (2006b), which reports the results of our DD group. In 
that study, we found that the decreases in substance use were less prominent than reported here. 
This is important because it may explain why psychiatric and extrapyramidal symptom 
improvements differ between the DD and SUD groups. Furthermore, quetiapine was generally 
well tolerated and there were no new safety concerns that arose during either study and no 
interactions with substances of abuse were noted. 
 
8.4. Sensation-seeking, social anhedonia and impulsivity in schizophrenia and substance 
use disorder patients   
When investigating whether there are innate differences between substance abusers with and 
without schizophrenia, some authors have put forth the hypothesis that they may differ in terms 
of personality profile. Previous research has shown that DD patients may have more sensation-
seeking and impulsivity (but not social anhedonia), compared to their non-abusing counterparts 
(Kwapil, 1998; Gut-Fayand et al. 2001; Dervaux et al. 2001). However, these studies suffered 
from two main limitations: they did not include a group of healthy controls and they did not 
include a group of non-psychosis SUD patients. The inclusion of these comparison groups may 
help us parcel the respective associations between schizophrenia, substance abuse and the 
220 
 
 
aforementioned personality traits. This field of inquiry is important because it may help tailor 
pharmacological and psychosocial intervention in these populations. For instance, there is 
evidence that quetiapine may be beneficial for the treatment of alcoholism among Type B (but 
not Type A) alcoholics – characterized by an early onset of drinking, greater severity of 
dependence and more antisocial traits and psychiatric symptoms (Babor et al. 1992). Similarly, 
among non-psychosis alcoholics with high levels of depression and anxiety, tiapride was 
effective at reducing alcohol use; however, other studies found tiapride to worsen outcomes in 
the general population of alcoholics (Shaw et al. 1987, Gual et al. 2002; Bender et al. 2007).  
In this context, our baseline analysis revealed that sensation-seeking was significantly 
higher in DD and SUD, relative to SCZ patients. This finding is consistent with previous 
associations between sensation-seeking and SUDs (Dervaux et al. 2001, 2010a,b). In addition, 
we found that SCZ patients had significantly lower scores in the boredom susceptibility subscale 
of sensation-seeking, relative to healthy controls. These data suggest that substance abusers with 
and without schizophrenia are characterized by abnormally high sensation-seeking, and/or that 
non-abusing schizophrenia patients are characterized by abnormally low sensation-seeking.  
We also found that social anhedonia was significantly elevated in DD and SCZ, relative 
to SUD patients and healthy controls. This finding is in accordance with previous studies that 
found a link between social anhedonia and schizotypal personality traits (Kwapil, 1998, Rey et 
al. 2009). Little data exists on social anhedonia in DD patients, but previous studies did not find 
elevated physical anhedonia in these individuals (Dervaux et al. 2001, 2010a,b). Together, the 
data show that social anhedonia is relatively unique to schizophrenia – irrespective of SUD 
comorbidity. 
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We found that impulsivity was significantly higher in DD, SCZ and SUD patients, 
compared to healthy controls. This finding is in accordance with studies showing elevated 
impulsivity in schizophrenia and SUD patients, relative to healthy controls (Enticott et al. 2008; 
Ersche et al. 2010; Kaladjian et al. 2011; Duva et al. 2011). However – unlike previous studies – 
we did not find significant differences in impulsivity between substance abusers with and 
without schizophrenia. The inability to find a difference in impulsivity between the groups may 
reflect a type-II error, since our SCZ group evidenced an impulsivity total score, which was 
numerically lower than our DD and SUD groups (mean [SD] = 55.6 [13.7], 62.4 [14.8], 61.3 
[19.3], respectively). A larger per group sample size may have rendered the numerical difference 
statistically significant.  
As a whole, the results suggest that sensation-seeking is prominent in substance abuse 
(irrespective of schizophrenia), social anhedonia is prominent in schizophrenia (irrespective of 
substance abuse) and impulsivity is prominent in all three populations. The findings may help 
tailor pharmacological and psychosocial intervention in these populations. Unfortunately, we 
were not able to answer the question whether these are state or trait differences because a low 
sample size prevented us from analyzing our follow-up data. Similarly, we were not able to 
perform analyses to determine if quetiapine had an effect on alcohol use as a function of 
personality traits (as suggested by Kampman et al. [2007]) because patients in the DD and SUD 
groups were using multiple substances, thereby rendering this type of analysis unfeasible.  
 
8.5. Systematic review on antipsychotics for the treatment of SUDs in psychosis and non-
psychosis patients 
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Due to the potential for serious consequences resulting from alcohol and drug abuse/dependence 
in schizophrenia, clinicians must carefully consider which antipsychotics are optimal for 
decreasing substance abuse among DD patients. Interestingly, although there is some evidence 
from randomized and case-control studies that atypical antipsychotic agents may be effective in 
treating substance dependence, results have been mixed, with some studies demonstrating 
positive and others negative or no effect. Previous reviews on the topic of antipsychotics for 
SUDs considered psychosis and non-psychosis patients separately or have included uncontrolled, 
open-label (switch design) trials and case reports (Wobrock and Soyka, 2009; Green et al. 2008). 
Consequently, we conducted a systematic review to determine whether the disparity originated 
from the fact that reviewers separately discussed trials in psychosis and non-psychosis patients 
(Zhornitsky et al. 2010a). In the context of our case-control trial with quetiapine, we aimed to 
better understand the effects of atypical antipsychotics in general, and quetiapine specifically, on 
substance use outcomes in psychosis and non-psychosis patients.  
In the present systematic review, we examined both psychosis and non-psychosis patients 
and included only the best controlled studies (we included both randomized and case-control 
studies in the DD group in order to increase the number of studies), while simultaneously paying 
attention to the type of antipsychotic and substance of abuse.  
A total of 43 studies were identified; of these, 23 fell into the category of DD (13 
randomized and 10 case-control) and 20 into the category of SUD (all randomized). Studies in 
the DD category revealed atypical antipsychotics to generally be superior to (older) typicals for 
decreasing substance abuse and side-effects. The studies also indicated that atypical 
antipsychotics may improve alcohol and cannabis abuse/dependence use and craving and 
psychostimulant craving (but not use). Studies of atypical antipsychotics for tobacco dependence 
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were mixed and suggested the possibility of a pharmacokinetic interaction that may raise plasma 
levels (and side-effects) of antipsychotics when patients attempt to quit smoking. Studies of 
atypical antipsychotics for alcoholism in the SUD category were equally mixed, with some trials 
reporting that atypical antipsychotics aggravated alcohol abuse/dependence and others reporting 
that they may improve outcomes in the general population or particular subpopulations (e.g. 
individuals with higher baseline psychiatric symptoms and antisocial personality traits). As for 
psychostimulant abuse/dependence, studies either found no effect or they found that 
antipsychotics aggravated outcomes and/or produced disturbing extrapyramidal reactions (e.g. 
akathisia, dystonia, dyskinesia). Finally, specific antipsychotics were found to be more useful 
than others for reducing substance abuse – as was in the case of clozapine for alcohol and 
cannabis abuse/dependence (DD group). Similarly, aripiprazole, olanzapine and quetiapine 
showed promise over other antipsychotics (e.g. amisupride, tiapride, flupenthixol) in the 
treatment of alcoholism.  
In the context of our case-control trial with quetiapine, these results suggest that we may 
expect more favorable outcomes for abusers of alcohol and cannabis in psychosis and non-
psychosis groups, relative to abusers of psychostimulants. They also suggest that individuals 
with certain personality characteristics (e.g. impulsivity, sensation-seeking, anxiety/depression) 
may respond more favourably to quetiapine treatment in our study, relative to those without 
these characteristics (Carlsson and Gullberg, 1978; Shaw et al. 1987; Kampan et al. 2007). 
Finally, the results suggest that there is a potential for extrapyramidal reactions and increased 
substance use during antipsychotic treatment of psychostimulant abusers.  
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8.6 Systematic review on dose-response and comparative efficacy and tolerability of 
quetiapine across psychiatric disorders 
Substance use disorders are often comorbid with psychiatric disorders such as depression, 
anxiety, and psychosis (Regier et al. 1990). Quetiapine itself is frequently prescribed on-label 
and off-label for the treatment of a variety of psychiatric disorders. As quetiapine has variable 
affinity for dozens of receptors, its clinical effects should also show a large variation as a 
function of dose and diagnostic category. This is an important topic of research since 
understanding the comparative efficacy of quetiapine across psychiatric disorders is crucial to 
properly treating DD patients who typically exhibit comorbid mood and anxiety disorders in 
addition to substance abuse/dependence. Previous reviews on quetiapine in psychiatry focused 
on the treatment of single disorders, and thus, were not able to compare the dose-response, 
efficacy and tolerability of this medication across psychiatric disorders (Keating and Robinson, 
2007; McIntyre et al. 2009). Consequently, the present systematic review included placebo-
controlled monotherapy and add-on trials in order to elucidate the dose-response and efficacy of 
quetiapine across psychiatric disorders (excluding substance abuse/dependence due to a lack of 
controlled trials) (Zhornitsky et al. 2011a).  
A total of 41 studies were identified. Psychiatric disorders included schizophrenia (10 
studies), unipolar depression (9 studies), bipolar mania (8 studies), obsessive-compulsive 
disorder (6 studies), bipolar depression (5 studies), and generalized anxiety disorder (3 studies). 
Studies revealed that quetiapine was most effective for generalized anxiety disorder (~150mg), 
unipolar (~150mg) and bipolar depression (~300-600mg), and bipolar mania (~600mg). 
However, studies of quetiapine for schizophrenia and obsessive-compulsive disorder produced 
inconsistent findings – with the most effective doses being ~600mg and ~300mg, respectively. 
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Additionally, by further subdividing studies of schizophrenia by psychosis severity, we found 
that quetiapine was most effective for stable, relative to acute schizophrenia.  
In the context of our case-control trial with quetiapine, these data suggest a number of 
things. First, we may expect DD patients to exhibit less improvement in positive symptoms, 
relative to SCZ patients. This is because animal and human studies have demonstrated that 
quetiapine is a weak antipsychotic (Zhornitsky et al. 2010b, 2011a) and that substance 
abuse/dependence is associated with aggravations of positive symptoms in schizophrenia (Mauri 
et al. 2006; Swofford et al. 2000; Serper et al. 1999). Second, we may expect DD patients to 
exhibit more improvement in depression, compared to SCZ patients. This is because quetiapine 
is an efficient antidepressant for bipolar depression at similar doses which were prescribed in our 
study (DD and SCZ groups were given 554mg and 478mg of quetiapine, respectively), and 
because our meta-analysis revealed that DD patients have more depressive symptoms (Potvin et 
al. 2007), relative to non-abusing patients. Finally, dose-response analysis suggest that any 
improvements in positive symptoms in the SUD group may not be due to quetiapine because 
many patients were administered sub-antipsychotic doses (mean = 150mg [118]). On the other 
hand, quetiapine would still be expected to lead to improvement in depressive symptoms among 
SUD patients, since it may act as an antidepressant at doses as low as 50mg (although 150mg is 
optimal) (Zhornitsky et al. 2011a).  
 
8.7 Strengths of studies 
• These are the first studies of their kind to examine baseline difference and trace the 
evolution of substance abuse, psychiatric and extrapyramidal symptoms in DD, SCZ, and 
SUD patients undergoing a homogenous antipsychotic treatment (quetiapine in this case). 
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This is important because it allows us to parcel out the effects of substance abuse, 
antipsychotics and schizophrenia in DD patients.  
• The studies are the first of their kind to measure and document both subjective and 
objective restlessness as a result of cannabis withdrawal. 
• The inclusion of abusers of multiple substances (e.g. alcohol, cannabis, cocaine) may 
better reflect the ‘real-world’ setting. 
• Our trial in non-psychosis SUD patients was the first study of its kind to prospectively 
administer quetiapine during detoxification.  
• A large portion of our subjects were diagnosed with cannabis abuse disorder (alone or in 
conjunction with other substances; 16 out of 26 patients), making it the first trial to 
investigate the use of atypical antipsychotics for cannabis abuse/dependence in non-
psychosis patients.  
• Our study of personality traits is the first trial of its kind to compare sensation-seeking, 
impulsivity, and anhedonia in substance abusers with and without schizophrenia, in non-
abusing schizophrenia patients and in healthy controls.  
 
8.8 Limitations 
• Our baseline and follow-up studies between the groups were not powered to detect 
complex interactions between socio-demographic, psychiatric, extrapyramidal, and SUD 
variables.   
• Patients in the DD group were active users, while patients in the SUD group were 
undergoing detoxification. However, we were forced to do this due to the fact that acutely 
detoxifying schizophrenia patients may lead to clinical relapse and rehospitalisation.  
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• The inclusion of abusers of multiple substances may confound results and makes difficult 
for us to deduce respective the contribution of each substance.  This is important because 
each substance has its own psychiatric effects and may be abused for different reasons, 
thereby potentially reflecting different subgroups of patients. However, while the overall 
sample size was adequate for a pilot trial (n=26), it was not large enough to separate out 
the effects of specific substances of abuse (e.g. alcohol, cannabis, cocaine). Because of 
the pilot nature of the trial, we did not correct for multiple comparisons, which may have 
led us to commit type I error(s).  
• There were baseline differences in variables such as quetiapine dose, age, and gender 
between the three groups. However, we entered these variables into the ANCOVA model 
and they did not affect our results.  
•  Our results in non-psychosis SUD patients cannot be solely attributed to the 
pharmacological effects of quetiapine because of the study’s open-label, switch design. 
That is, patients were aware of the medication they were taking and there was no control 
group of SUD individuals who were not treated by quetiapine. These confounds make it 
impossible to tell whether the improvements were simply due to participant bias and/or 
the passage of time.  
• Patients were also involved in an intensive individual and group psychotherapy program, 
which may explain the improvements observed in the study.  
• Our trial of quetiapine in non-psychosis patients used psychiatric and extrapyramidal 
scales for schizophrenia and did not include special scales to measure withdrawal from 
substances of abuse. This may limit the generalizability of the present findings to 
quetiapine treatment of other SUD populations undergoing withdrawal. However, it may 
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not have been a problem for depression because our sub-analysis found that CDSS scores 
correlated significantly with Beck Depression Inventory scores at baseline, suggesting 
that the former scale provides a valid measure of depression in non-psychosis patients. 
• In our personality traits study, the lack of difference in impulsivity between the three 
groups may be related to the fact that the BIS contains numerous cognitive items that 
may have obscured the results in our study.  
 
8.9 Epistemological coda 
In the literature, a myriad of studies have compared schizophrenia patients with and without 
substance abuse/dependence. This has helped researchers to better understand the consequences 
of substance abuse in schizophrenia. However, to fully understand the schizophrenia-substance 
abuse comorbidity, studies must also compare dually diagnosed schizophrenia patients to non-
psychosis substance abusers. This part is crucial because it allows researchers to parcel out the 
effects of psychosis and antipsychotics on DD outcomes and to answer questions such as, for 
example, Do schizophrenia patients become addicted quicker? Do they have a harder time to 
quit? Unfortunately, in the current literature, there are few studies which compared DD with 
SUD patients. This may be a challenging (but not impossible) task because the two groups might 
not use the same quantities or the same types of substances, which render the comparison 
difficult, despite its critical importance. Moreover, putting DD patients through detoxification 
may potentially have negative consequences on clinical relapse and rehospitalisation. 
Consequently, future studies should compare active users with active users, thereby avoiding the 
need to put DD patients through detoxification. Another challenge to comparing DD and SUD is 
the difficulty in choosing the scales that are equally valid in both groups. For example, does one 
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administer the PANSS (a schizophrenia scale) to non-psychosis SUD patients? Or does one use 
psychotomimetic scales, which are typically employed in studies with non-psychosis SUD 
patients? In order to overcome this issue, it is important to use a variety of scales (both psychosis 
and non-psychosis) in both groups. However, this may be a difficult task due to time/funding 
limitations. An alternative option may be to use scales that have been validated in both groups; 
however, up to this point, such scales are lacking. Clearly, more research is required to resolve 
these issues.  
 
8.10 Implications for the pharmacotherapy of schizophrenia and SUDs  
The results described herein have a number of implications for the treatment of schizophrenia 
and SUDs. In SUD patients, we found high levels of positive and depressive symptoms, and 
akathisia and parkinsonism at baseline, and these symptoms tended to return to normal after 
patients ceased their substance use. These data indicate that the clinical symptoms observed 
among SUD patients were mostly associated with symptoms of acute and protracted withdrawal 
from substances of abuse. They also suggest that substance abuse/dependence should be the 
primary target of treatment for these patients; however, because our SUD patients were receiving 
concomitant psychosocial therapy, we cannot attribute these benefits solely to quetiapine.  
Our non-psychosis, SUD arm also provided preliminary information on the safety and 
efficacy of quetiapine in patients undergoing detoxification. While our study did not include 
specific alcohol and drug withdrawal scales, we did observe a decrease in the need for 
benzodiazepine prescriptions, which is important because benzodiazepines have a high abuse 
potential themselves and carry many of the same risks as alcohol such as withdrawal-induced 
delirium tremens, convulsions, and death (Albiero et al. 2012). In addition, we did not observe 
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any new safety or tolerability issues, apart from an asymptomatic increase in gamma-glutamyl 
transpeptidase. Elevation of this enzyme is considered to be a biomarker for alcohol 
abuse/dependence and liver disease. Previous research found that atypical antipsychotics 
produced an asymptomatic increase (27%) in gamma-glutamyl transpeptidase in the first month 
and after 6-months of treatment (23%), but significant elevations were rare (Atasoy et al. 2007). 
Consequently, in order to minimize safety risks, these results suggest the need to obtain baseline 
liver enzyme tests before administration of atypical antipsychotics to alcohol use disorder 
patients.  
The relatively low number of side-effects and complications associated with quetiapine 
makes it an attractive candidate for the treatment of alcohol withdrawal at low doses. In animals, 
a review of the literature revealed that quetiapine and risperidone were most efficient among 
atypical antipsychotics at reducing signs of ethanol withdrawal such as locomotor hyperactivity, 
stereotyped behaviour, tremor, wet dog shakes, tail-stiffness, abnormal posture and gait, agitation 
and audiogenic seizures (Uzbay et al. 2011). In humans, there is a rich literature detailing the 
utility of atypical antipsychotics for the treatment of alcohol withdrawal syndrome (i.e. 
hallucinations, paranoia, agitation, anxiety, insomnia), which dates back to at least 1968 with 
thioridazine (Ehik, 1968). Atypical antipsychotics are usually administered in combination with 
anticonvulsants in this context to prevent the emergence of alcohol withdrawal-induced seizures 
(Croissant et al. 2009). Less evidence exists on atypical antipsychotics for withdrawal from 
drugs; however, a few retrospective studies found quetiapine to attenuate symptoms of opiate 
and amphetamine withdrawal in non-psychosis substance abusers (Pinkofsky et al. 2005; Sattar 
et al. 2004).  
231 
 
 
The benefits of antipsychotics for acute alcohol withdrawal may also theoretically extend 
to active alcoholics, since they should consistently re-experience symptoms of craving and 
withdrawal (Koob and LeMoal, 2008). Early studies in chronic alcoholics found that 2-week 
treatment with melperone (an atypical antipsychotic with a similar binding profile to quetiapine) 
improved muscular and nervous tension, depression, craving, emotional lability, somatization, 
ability to sleep, anxiety, paranoid ideation and presumed ability to work, relative to placebo 
(Carlsson  and Gullberg, 1978; Carlsson et al. 1979). This was followed up by evidence that low-
dose tiapride (100mg t.i.d for 6 months) reduced drinking, and neurotic symptoms, and produced 
gains in self-esteem, levels of expressed satisfaction with life situation, and use of health services 
(Shaw et al. 1987, 1994). By contrast, larger studies recently showed that treatment with low-
dose tiapride or amisulpride over 6-months aggravated alcohol abuse/dependence in active 
alcoholics, and these findings could not be accounted for by differences in tolerability (Gual et 
al. 2002; Marra et al. 2002; Bender et al. 2007). It is unclear what may explain the aggravations, 
but one possibility is that substituted benzamides may lead to relapse because they induce 
dopamine release/exert a stimulatory effect at low doses due to their preferential blockade of 
presynaptic D2 receptors (Schoemaker et al. 1997). However, quetiapine does not share a similar 
preference for pre- versus, post-synaptic D2 receptors, and it possesses significant anxiolytic 
activity at low doses via antagonism of α-1 adrenergic receptors, which may have added benefit 
for alleviation of craving, and may explain why quetiapine has never been found to aggravate 
substance use disorder outcomes.   
In DD patients, we observed comparatively high levels depression and parkinsonism at 
baseline, suggesting that an antipsychotic with significant antidepressant properties (or in 
conjunction with an antidepressant) and with a low tendency to produce extrapyramidal 
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symptoms should be ideal for be these patients. Quetiapine closely fits this profile. Quetiapine is 
not associated with large amounts of extrapyramidal symptoms due to its low affinity for D2 
receptors (Weiden, 2007), which should also minimize the possibility of extrapyramidal 
reactions when combined with substances of abuse such as psychostimulants (Evans et al. 2001). 
Moreover, quetiapine possesses significant antidepressant efficacy at low doses, possibly due to 
antagonism of multiple serotoninergic receptor subtypes (e.g. 5-HT2A, 5-HT2C, 5-HT7) and 
antagonism of the norepinephrine transporter by its primary metabolite, norquetiapine (Jensen et 
al. 2008; for review, see Zhornitsky et al. 2011a).     
On the other hand, while all groups showed improvement in parkinsonism and depression 
from baseline to endpoint in our study, DD patients still had significantly higher SUD severity, 
depression and parkinsonism scores at endpoint, which suggests that quetiapine may have 
helped, but that other (perhaps psychosocial) interventions are needed to wean the patients off 
alcohol and drugs and treat their residual psychiatric symptoms. Indeed, a systematic review of 
45 experimental and quasi-experimental studies among DD patients showed that three types of 
interventions (group counselling, contingency management, and residential dual diagnosis 
treatment) exhibited consistent positive effects on SUD outcomes, whereas other interventions 
exhibited consistent positive effects on other areas of adjustment (e.g. case management 
enhanced community tenure and legal interventions increased treatment participation; Drake et 
al. 2008). In addition, a recent qualitative review revealed that psychosocial interventions (e.g. 
contingency management, modified 12-step programs, cognitive behavioural therapy and relapse 
prevention) are promising interventions for DD patients when they are well-coordinated, take a 
multidisciplinary and team approach, have specialist-trained personnel with accessible, 24-hour 
contact, and offer a variety of program types with long-term follow-up (Horsfall et al. 2009). 
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Taken together, these data suggest the possibility that the effects of pharmacotherapy in dual 
diagnosis schizophrenia are increased when combined with quality psychosocial interventions.  
In DD and SUD patients, we found high levels of sensation-seeking and impulsivity at 
baseline, suggesting that these traits may be targets for psychosocial treatment. For example, 
Conrod et al. (2011b) randomized 364 alcohol drinking adolescents with elevated scores of 
impulsivity, sensation-seeking, anxiety-sensitivity and hopelessness to a control no-intervention 
condition or a two-session group coping skills intervention targeting one of the four personality 
risk factors.  Their results showed short-term benefits (6-months) of the targeted interventions for 
quantity/frequency of drinking, and long-term benefits for problem drinking symptoms and 
alcohol-coping motives. The same authors also found benefits of targeted personality 
interventions for decreasing drug use (cannabis and cocaine) over a 24-month period in a 
randomized sample of 732 adolescents (Conrod et al. 2010). These studies offer support for the 
use of psychosocial interventions which target personality traits to decrease substance use in 
non-psychosis individuals. It would be interesting to see if the same would be true for DD 
patients.  
In addition, our other systematic review of antipsychotics for SUDs in patients with and 
without comorbid psychosis revealed that quetiapine may be effective for treating Type-B 
alcoholics – characterized by earlier onset of drinking, more severe dependence and higher 
baseline antisocial traits and psychiatric symptoms (Kampman et al. 2007). However, here we 
did not subtype alcoholics because our subjects were abusers of multiple substances, not just 
alcohol, and consequently, this will be an important measure to include for future studies.  
In DD and SCZ patients, we found high levels of social anhedonia, which is likely related 
to their negative symptoms. Indeed, the PANSS negative contains many items that are based on a 
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similar concept as social anhedonia (e.g. emotional and social withdrawal and poor rapport). It is 
unclear whether psychosocial interventions could be targets for treating social anhedonia since 
negative symptoms, in general, are considered refractory to treatment (Leucht et al. 2009).  
 
8.11 Future directions 
Future studies should include abusers of a single substance (e.g. alcohol only); however, in 
practice, we realize that it may be difficult to recruit patients with such strict criteria. Moreover, 
future studies should take more frequent measurements (e.g., every 3 weeks) of psychiatric and 
extrapyramidal symptoms, in order to better elucidate the temporal relationship in improvements 
of these variables. Nonetheless, regarding psychiatric symptoms, our results are consistent with 
those of Mauri et al. (2007), which showed that SUD individuals improved significantly more 
than schizophrenia patients after two weeks of treatment with quetiapine. In addition, future 
studies should compare improvements in DD and SUD patients who maintain their substance use 
and should include cue-elicited craving in order to have a more precise measurement of SUD 
outcomes. Finally, the contribution of quetiapine to changes in psychiatric and extrapyramidal 
symptoms reported here will need to be elucidated in randomized trials. 
Our non-psychosis SUD arm encourages controlled evaluation of the safety and 
tolerability of quetiapine in non-psychosis SUD patients during detoxification, using specific 
withdrawal scales. Future studies with larger sample sizes may also want to separate alcoholics 
according to personality subtype as reported previously (Carlsson and Gullberg, 1978; Shaw et 
al. 1987; Kampman et al. 2007).  
Future studies on personality traits between the three groups will need to evaluate 
whether the personality profiles reported here reflect state or trait differences. It would also be 
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interesting to verify if we can predict the development of substance abuse in schizophrenia based 
on the personality profiles reported here in longitudinal studies initiated during the prodrome of 
psychosis. Furthermore, future studies should include more measures of personality traits (e.g. 
anxiety-sensitivity, hopelessness), which have shown promise as targets for psychosocial 
interventions (Conrod et al. 2011a,b). Experimental measures (e.g. response inhibition) are 
needed to confirm impulsivity levels reported in this study. 
 
8.12 Conclusion 
In the present trial, we compared SUD outcomes as well as psychiatric and extrapyramidal 
(neurological) symptoms in substance abusers with and without schizophrenia, and in non-
abusing schizophrenia patients at baseline, and after 12-weeks of treatment with quetiapine. In 
order to contextualize the present study, we presented supplementary data on our SUD arm-alone 
and on baseline personality traits between the groups. In addition, we conducted two systematic 
reviews of the literature: the first was on the effects of atypical antipsychotics on 
substance/dependence in patients with and without comorbid psychosis, and the second was on 
the dose-response and efficacy/tolerability of quetiapine across psychiatric disorders. The goal of 
this project was improve our understanding of the complex relationships between substance 
abuse and schizophrenia. It was also expected to help elucidate the clinical consequences of 
substance abuse in schizophrenia patients as well as their potential treatment by pharmacological 
means.  
 In the main trial, we found that SUD patients showed greater improvement in weekly 
dollars spent on alcohol and drugs and SUD severity, compared to DD patients. However, at 
endpoint, there was no significant difference in dollars spent, but DD patients still had a higher 
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mean SUD severity. Interestingly, DD patients also had significantly higher parkinsonism and 
depression than SCZ patients at baseline and endpoint. On the other hand, we found that SUD 
patients had significantly more akathisia at baseline, improved more than SCZ patients, and this 
was related to the presence of cannabis abuse/dependence. Finally, we found that SUD patients 
improved more in PANSS positive scores, relative to DD and SCZ patients.  
Our supplementary data on the non-psychosis (SUD) arm contributed to preliminary 
evidence that quetiapine may be beneficial for the treatment of acute and protracted withdrawal 
from substances of abuse. Additionally, our baseline analysis of personality traits between the 
three groups and healthy controls revealed that sensation-seeking was associated with substance 
abusers, regardless of schizophrenia diagnosis, and social anhedonia was associated with 
schizophrenia, regardless of substance abuse/dependence diagnosis. In our first systematic 
review, we found a preferential benefit of atypical antipsychotics on alcohol vs. psychostimulant 
abuse/dependence. In our second systematic review, we found that quetiapine was an extremely 
effective antidepressant and anxiolytic at low doses, and a mild-to-moderate potency 
antipsychotic at high doses.  
Altogether, our data provide evidence for increased vulnerability to the adverse effects of 
alcohol and drugs in schizophrenia patients, and they indicate that substance abuse/withdrawal 
may mimic some symptoms of schizophrenia. Moreover, the data suggest that quetiapine may 
have benefits for the treatment substance abuse/dependence and schizophrenia due to its 
significant anxiolytic and antidepressant and antipsychotic properties. Nonetheless, clinicians 
must be careful when prescribing antipsychotics for long periods of time to active substance 
abusers because there remains a possibility for these agents to cause harm. Lastly, our data 
suggest that psychosocial treatments (e.g. such as those targeting personality traits) may have 
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added benefit when combined with pharmacotherapy for the treatment of schizophrenia and 
SUDs.  
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